

CURRICULUM VITAE
University of North Carolina at Chapel Hill
Eshelman School of Pharmacy

BIOGRAPHICAL

Name:	Leaf Huang	Birth Date:	September 23, 1946
		Birth Place:	China
		Citizenship:	Naturalized citizen of U.S.A.
Business Address:	Division of Pharmacoengineering and Molecular Pharmaceutics University of North Carolina at Chapel Hill Eshelman School of Pharmacy 1315 Kerr Hall, CB#7571 Chapel Hill, NC 27599	E-Mail Address:	leafh@email.unc.edu
		Web Site:	https://pharmacy.unc.edu/laboratory-of-drug-targeting/
Business Phone:	919-843-0736	Business Fax:	919-966-0197

EDUCATION and TRAINING

UNDERGRADUATE:

1964-1968	National Taiwan University Taipei, Taiwan	B.S. 1968	Physics
-----------	--	--------------	---------

GRADUATE:

1969-1974	Michigan State University East Lansing, MI	Ph.D. 1974	Alfred Haug, Ph.D., Advisor Biophysics
-----------	---	---------------	---

POSTGRADUATE:

1974-1976	Postdoctoral Fellow Department of Embryology Carnegie Institution of Washington Baltimore, MD		Richard E. Pagano, Ph.D., Mentor Cell Biology, Biophysics
-----------	--	--	---

APPOINTMENTS and POSITIONS

ACADEMIC:

2017-2020	Shanghai University of Traditional Chinese Medicine	Adjunct Professor
2016-2017	Shenyang Pharmaceutical University, China	Visiting Professor
2013-2016	Fudan University, China	Advanced Visiting Scholar
2012	Fourth Military Medical University, China	Visiting Professor
2012-present	Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill, NC	Fred Eshelman Distinguished Professor (with tenure)
2010-2017	Chung-Yuan Christian University, Taiwan	Visiting Chair Professor
2010-present	UNC-NCSU Joint Department of Biomedical Engineering University of North Carolina at Chapel Hill Chapel Hill, NC	Professor (joint appointment)
2009	Sichuan University, Chengdu, China	Honorary Professor
2005-2012, 2015	Division of Molecular Pharmaceutics Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill, NC	Fred Eshelman Distinguished Professor (with tenure) and Chair
1999-2005	Department of Pharmaceutical Sciences School of Pharmacy University of Pittsburgh Pittsburgh, PA	The Joseph Koslow Chair Professor of Pharmaceutical Sciences, with tenure
1999-2005	Center for Pharmacogenetics School of Pharmacy University of Pittsburgh Pittsburgh, PA	Director
2001-2005	Department of Bioengineering University of Pittsburgh School of Engineering Pittsburgh, PA	Professor (Secondary Appointment)
1999-2005	Department of Pharmacology	Professor

	University of Pittsburgh School of Medicine Pittsburgh, PA	(Secondary Appointment)
1999-1999	School of Pharmacy University of Pittsburgh Pittsburgh, PA	Associate Dean for Research
1997-1999	Molecular Pharmacology Training Program Interdisciplinary Biomedical Graduate Program School of Medicine University of Pittsburgh Pittsburgh, PA	Director
1993	Liposome Vector Core Pittsburgh Center for Human Gene Therapy University of Pittsburgh Pittsburgh, PA	Director
1992-1999	Department of Pharmaceutical Sciences School of Pharmacy University of Pittsburgh Pittsburgh, PA	Professor (Joint Appointment)
1992	University of Pittsburgh Cancer Institute Pittsburgh, PA	Full Member
1991-1999	Department of Pharmacology University of Pittsburgh School of Medicine Pittsburgh, PA	Professor with tenure and Head, Laboratory of Drug Targeting
1991-	Department of Molecular Genetics and Biochemistry University of Pittsburgh School of Medicine Pittsburgh, PA	Professor (Secondary Appointment)
1985-1991	Department of Biochemistry University of Tennessee Knoxville, TN	Professor with tenure
1978-1991	University of Tennessee Cell, Molecular and Developmental Biology Program University of Tennessee, Knoxville	Faculty Member
1987-1991	Comparative and Experimental Medicine	Faculty Member

	Program University of Tennessee	
1985-1991	Biotechnology Program University of Tennessee, Knoxville	Faculty Member
1987-1988	Research and Development LipoGen, Inc.	Vice President
1985-1986	Cell, Molecular and Developmental Biology Program University of Tennessee, Knoxville	Acting Director
1986	Department of Biology Lanzhou University Lanzhou, China	Visiting Professor (Honorary Appointment)
1980-1985	Department of Biochemistry University of Tennessee, Knoxville	Associate Professor with tenure
1982-1985	Department of Biochemistry University of Tennessee, Knoxville	Associate Head
1985	Department of Biological Sciences and Biotechnology Tsinghua University Beijing, China	Visiting Professor (Honorary Appointment)
1983-summer	Institute of Zoology Academia Sinica Beijing, China	Research Scholar
1982-summer	Department of Chemistry Stanford University	Visiting Research Scholar
1980	Department of Biology Beijing University Beijing, China	Visiting Professor (Honorary Appointment)
1976-1980	Department of Biochemistry University of Tennessee, Knoxville	Assistant Professor
1974-1976	Department of Embryology Carnegie Institution of Washington Baltimore, MD	Postdoctoral Fellow
1969-1974	Department of Biophysics and MSU/DOE Plant Research Laboratory Michigan State University	Research Assistant

HONORS

Title of Award	Year
Matthey-Bishop Pre-doctoral Fellowship	1970-1971
Carnegie Institution of Washington Fellowship	1974-1975
U.S. Public Health Service Research Fellowship	1975-1976
Chancellor's Research Scholar, University of Tennessee, Knoxville	1983
Research Career Development Award, NIH	1981-1986
Member, Science Alliance Center of Excellence, University of Tennessee, Knoxville	1984-1991
Distinguished Speaker, National Science Commission, Republic of China	1993
Distinguished Lecturer, Chinese Pharmaceutical Society, Republic of China	1996
Controlled Release Society Outstanding Pharmaceutical Paper from the 24 th International Symposium on Controlled Release of Bioactive Materials	1997
Fellow, American Association of Pharmaceutical Scientists	1997
Heward Visiting Scientist to the Montreal General Hospital/McGill University	1998
Chairman, Non-viral Gene Therapy Committee, American Society for Gene Therapy	1998 – 1999
Research Grand Round, Moffitt Cancer Center, Tampa, FL	1999
Plenary Speaker, Japanese Society of Pharmaceutical Sciences, Tokushima, Japan	1999
The Joseph Koslow Endowed Chair, University of Pittsburgh	1999 - 2005
“Meet The Professor”, American Society of Gene Therapy Annual Meeting	1999, 2000, 2001
Plenary Speaker, 22 nd Annual Eino Nelson Memorial Conference, Captiva Island, FL	2001
Fellow, American Institute for Medical and Biological Engineering	2003
Distinguished Faculty Committee, University of Pittsburgh	2003 – 2005
Alec D Bangham MD FRS Achievement Award, Liposome Research Days conference, Hsin-Chu, Taiwan. This is the highest honor in liposome research.	2004
Elected member of the Advisory Board, American Society of Gene Therapy	2006 -2011
Plenary speaker, annual meeting of The Pharmaceutical Society of Taiwan, Taiwan	2007
Plenary speaker, The 6 th China-Japan-Korea Foresight Joint Symposium on Gene Delivery and International Symposium on Biomaterials, Sanya, China	2008
Forum speaker, 60 th anniversary of Dalian Institute of Chemistry and Physics, Chinese Academy of Sciences, Dalian, China	2009
Plenary speaker, 4 th International Conference in Advanced Drug Delivery, Shanghai, China	2009

Honorary Professor, Sichuan University, China	2009
Distinguished speaker, Japan Association for The Advancement of Medical Equipment	2010
Distinguished speaker, Global Center of Excellence, University of Shizuoka, Japan	2010
Distinguished speaker, The Academy of Pharmaceutical Science and Technology, Japan	2010
T. Nagai Postdoc Research Achievement Award, Controlled Release Society. Award was presented to both Dr. Sang Kyoon Kim (postdoc) and Professor Leaf Huang (mentor)	2010
Visiting Chair Professor, Chung-Yuan Christian University, Taiwan	2010
Elected Vice Chair, Gordon Research Conference on “Cancer Nanotechnology”	2011
Elected member, Board of Scientific Advisors, Controlled Release Society.	2012-15
Keynote speaker, Symposium of Advanced Nanomaterials in Biomedicine, Chung Yuan Christian University, Taiwan.	2012
Visiting Professor, Fourth Military Medical University, Xi’An, China	2012
Qiushi Chair Professor, Zhejiang University, China (declined)	2012
Changjiang Chair Professor, Zhejiang University, China. Selected by the Ministry of Education, People’s Republic of China (declined)	2012
Senior Visiting Scholar, Fudan University, China	2013-16
Keynote speaker, Chinese Pharmaceutical Conference, “Lipidic Nanoprecipitates for Drug and Gene Delivery”, Wuhan, China	2013
Distinguished Pharmaceutical Scientist Award, American Society for Pharmaceutical Scientists. This is the highest scientific recognition of AAPS.	2013
Qiushi Chair Professor, Zhejiang University, China	2014
Keynote speaker, Cross-Strait Biomaterials and Controlled Drug Release Symposium, Hsinchu, Taiwan	2014
Keynote speaker, NanoDDS2014 conference, Chapel Hill, NC	2014
Keynote speaker, Australian Society of Nanomedicine, Sydney, AU	2015
Visiting professor, ARC Center of Excellence in Convergent Bio-Nano Science and Technology. Lecture tour in three Australian universities	2015
Keynote speaker, International Conference on Applied Materials, Chung Yuan Christian University, Taiwan	2015
Honorable speaker for the Applied Chemistry Lecture Series, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China	2016

Keynote speaker, 48 th annual Pharmaceutics Graduate Student Research Meeting, University of Missouri Kansas City	2016
Lifetime Achievement Award, Chinese American Society of Nanomedicine and Nanobiotechnology	2016
Highly Cited Researchers 2016 in “Pharmacology & Toxicology” by Thomson Reuters	2017
Distinguished Alumni Award, Physics department, National Taiwan University.	2017
Highly Cited Researchers 2017 in “Pharmacology & Toxicology” by Thomson Reuters	2018
Member, External Review Team, School of Pharmaceutical Sciences, Peking University	2018
Highly Cited Researchers 2018 in “Pharmacology & Toxicology” by Clarivate Analytics	2019
Keynote speaker, School of Pharmacy, University of Pittsburgh	2019
Keynote speaker, Virginia Nanomedicine Forum, Virginia Commonwealth University	2019
Keynote speaker, AAPS PharmSci360 Symposium	2020
Highly Cited Researchers 2019 in “Cross-Field” by Clarivate Analytics	2020
Highly Cited Researchers 2020 in “Cross-Field” by Clarivate Analytics	2021
Elected to College of Fellows, Controlled Release Society	2022
Highly Cited Researchers 2021 in “Cross-Field” by Clarivate Analytics	2022
Highly Cited Researchers 2022 in “Cross-Field” by Clarivate Analytics	2022

MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES

Society of Chinese Bio-scientists in America
Controlled Release Society
American Association of Pharmaceutical Scientists
American Society of Gene and Cell Therapy
American Association of Colleges of Pharmacy

START-UP COMPANIES CO-FOUNDED

Lipogen, Inc.	Knoxville, TN	1987-1990
Rx Therapeutics, Inc.	Woodland, TX	1992-1996
Lipella, Inc.	Pittsburgh, PA	2005-present
Curriculum Vitae		Leaf Huang, Ph.D.
01/05/2023		Page 7

PDS Biotechnology, Inc.	Princeton, NJ	2006-present
Qualiber, Inc.	Chapel Hill, NC	2010-2017
KRB, Inc.	Taiwan	2013-2014
OncoTrap	Chapel Hill, NC	2016-2019

Teaching Activity:

University of Tennessee:

Taught “Structure and Function of Biological Membranes” to graduate students, (1976, 1978, 1980, 1982)
 Group taught “Introductory Biochemistry” to pre-med and pre-vet students, (1977-81, 1990)
 Taught “Techniques of Biochemistry” to graduate students, (1977) and group taught again, (1978 - 1986)
 Group taught “Biochemistry” to graduate students, (1978-1991)
 Taught “Introductory Biochemistry” to non-majors, (1979-1981)
 Group taught “Advanced Cell Biology,” (1981, 1983, 1985, 1986, 1988, 1989, 1990)
 Taught “Liposome Technology” to graduate students, (1985, 1986, 1987, 1989)

University of Pittsburgh:

Lectured in “Macromolecules and Bioenergetics” (MS Biochemistry 2210), (1992, 1993)
 Lectured in “Cancer Pharmacology” (Pharmacology MS PHL 2563), (1993 to 1997)
 Lectured in “Receptors and Signal Transduction” (Pharmacology MS PHL 3510), (1991, 1994 to 1997)
 Co-director of “Advanced Topics in Drug Delivery and Targeting” (Pharmacy 3008), (1994, 1997)
 Lectured in “Scientific Ethics” (MGB MS MIC 2290), (1995, 1996)
 Lectured in “Principles in Pharmacology” (Pharmacology 2560) (1994 to 2001)
 Supervised Problem Based Learning Session and Conferences of “Medical Pharmacology” (1994 to 2001)
 Lectured in “Molecular Pharmacology” (MSPHL 2340) (1999 to 2002)
 Taught “Methods in Pharmacology” (Pharmacology MS PHL 2555) (1993 to 1996)
 Lectured in “Advanced Topics in Virology” (MGB MS MIC 2030) (1996).
 Lectured in “Cancer Biology and Therapeutics” (MSCMP 3710 and MSPHL 3310), (1999 to 2004)
 Lectured in “Drug Delivery Systems”, (1999)
 Lectured in “Molecular and Medical Genetics”, (2000 to 2003)
 Lectured in “Gene Therapy Vectors”, (2001)
 Course co-director and lectured in “Advanced Topics in Drug Delivery and Targeting” (Pharm 3008), (2001, 2003)

University of North Carolina, Chapel Hill

Lectured in PHCY 61 “Basic Pharmaceutics II” (2006)
 Lectured in MOPH 864 “Advance in Drug Delivery” (2006, 2007)
 Lectured in MOPH 411 “Basic Pharmaceutics II” (2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014)
 Lectured and led lab session in MOPH 850 “Pharmaceutical Analysis” (2007, 2008, 2009)
 Course director and lecturer, MOPH 864 “Advances in Drug Delivery” (2008, 2009, 2011, 2013, 2015)
 Lectured in DPMP 738 “Nanomedicine” (2009), Block leader (2012), course coordinator (2014, 2016), lecturer (2017, 2018, 2019, 2020, 2021, 2022)
 Coordinated MOPH 899 “Seminar” (2012-13)
 Lectured in MOPH 868 “Advances in Drug Delivery and Nanomedicine” (2016-2020)
 Coordinated and Lectured in DPMP 864 “Advances in Drug Delivery” (2021-2022)

Chung Yuan Christian University, Taiwan

“Advances in Drug Delivery”, a one-week intensive course for graduate students (2011)

Graduate Students Supervised and Their Current/Last Known Positions:

University of Tennessee

Siu-Cheong Ho	Characterization of Large Unilamellar Phospholipid Vesicles and Their Interactions with Cultured Chinese Hamster Cells, (M.S. 1977), Retired.
Ruanglakana Vajanabukka	The Nicotinic Acetylcholine Regulator of <i>Torpedo californica</i> : Purification and Reconstitution, (M.S. 1979), Faculty, Chulalongkorn University, Bangkok, Thailand
Garry L. Adrian	Entrapment of Proteins in Phosphatidylcholine Vesicles, (M.S. 1979), Staff Scientist, State Government of Indiana
Benedict Changan Chang	Synthesis and Characterization of a New Fluorescent Phospholipid, (M.S. 1979), Industrial Scientist, Merck, Inc.
James A. Wilkins	Transport of 5-Hydroxytryptamine by Platelet Dense Granules, (Ph.D. 1979), Senior Scientist, Otsuka America Pharmaceuticals, Inc.
Stephen R. Grant	Site Specific Binding of Liposomes, (Ph.D. 1980), Retired
Siu-Cheong Ho	Phospholipid Vesicles as Carriers to Transfer Biological Molecules into Cells, (Ph.D. 1980), Retired.
Paul T. Naylor	Induction of Cytotoxic T-lymphocytes by Liposomes Containing Herpes Simplex Virus and H-2 Antigens, (Ph.D. 1981), Orthopedic Surgeon, Knoxville, TN
Sharon S. Carpenter-Green	Wheat Germ Agglutinin Covalently Coupled to Liposomes, (M.S. 1981), Science Teacher, S.C.
Chen-Yen Wang	Polyhistidine Mediates an Acid Dependent Fusion of Negatively Charged Liposomes, (M.S. 1984), Professor, University of Hawaii, Honolulu
Bruce P. Babbitt	Model System for Studies of Specific Membrane Interactions, (Ph.D. 1985) Vice President, Parexel, Inc.
Yung-Shyeng Tsao	Interactions of Sendai Virus with Model Target Membrane, (Ph.D. 1985), Senior Scientist, Merck, NJ

Sean M. Sullivan	Heat-Sensitive Immunoliposomes, (Ph.D. 1985), Senior Director, Vical Corporation, San Diego, CA
Jerome Connor	pH-sensitive Liposomes: Characterization and Application, (Ph.D. 1986), Director of Development, LifeCell Corporation, Branchburg, NJ
Kelly S. Houck	The Role of Multivalency in Antibody Mediated Liposome Targeting, (M.S. 1987), practicing physician, Johnson City, TN
Chen-Yen Wang	Cytoplasmic Delivery of Macromolecules via pH-Sensitive Liposomes, (Ph.D. 1987), Professor, University of Hawaii, Honolulu, HA
Rodney J.Y. Ho	Target-Sensitive Immunoliposomes: Design and Application, (Ph.D. 1987), Professor, University of Washington, Seattle, WA
Brenda Hughes	Lung Capillary Endothelial Cell Specific Monoclonal Antibodies Target Liposomes to Mouse Lung in vivo, (jointly supervised by Stephen Kennel), (M.S. 1988)
David Collins	Mechanism of Destabilization of pH-Sensitive Liposomes and Implications for Cellular Delivery, (Ph.D. 1989), Corporate Fellow, Eli Lilly, Indianapolis, IN
Ana Tari	Structure and Function of Phosphatidylglycerol in the Stabilization of Phosphatidylethanolamine Bilayer, (M.S. 1989), Research Associate Professor, University of Florida, Division of Hematology-Oncology, Gainesville, Florida
Lori Steiner	Optimization of DNA Entrapment in pH-Sensitive Liposomes, (M.S. 1989), Pre-Clinical Business Development Manager, ClinForce, Research Triangle Park, NC
Dexi Liu	pH-Sensitive Liposomes: From Test Tube to Animal Model, (Ph.D. 1990), Professor and Chair, School of Pharmacy, University of Georgia, Athens, GA
Atsuhide Mori	Role of Glycolipids on Liposome Biodistribution, Tumor Uptake and Immunotargeting, (M.S. 1991), Senior Scientist, Yamanouchi Pharmaceutical Co., Ltd., Japan
Xiaohuai Zhou	Liposome Mediated Gene Transfer in Mammalian Cells, (Ph.D. 1991), Food & Drug Administration, Riverside, CA

Yong-Serk Park	Effect of Glycolipids on Lipid Polymorphism and Liposome Circulation, (Ph.D. 1992), Professor and Vice Dean, Yonsei University, South Korea
Ana M. Tari	Studies on Bilayer Liposomes Composed of 1, 2-Diacyl-3-succinylglycerol, (Ph.D. 1992), Research Associate Professor, University of Florida, Division of Hematology-Oncology, Gainesville, Florida
University of Pittsburgh	
Fan Zhou	MHC Class I Restricted Presentation of Protein Antigen Delivered by Liposomes, (Ph.D. 1992), Pathologist, Portland, Oregon
David Litzinger	<i>In Vivo</i> Investigations Into the Drug Delivery Potential of Liposomes, (Ph.D. 1993), Associate Director, Preclinical Sciences, Ambrex, Inc., San Diego, CA
Hassan Farhood	Delivery of macromolecules by cationic liposomes. (Ph.D. 1994), Software Consultant, New York, NY
Atsuhide Mori	Liposomal Delivery of Lipophilic Antitumor Drugs. (Ph.D. 1994), Senior Scientist, Yamanouchi Pharmaceutical Co., Ltd., Japan
Xiang Gao	Cationic Liposome and Polymer Mediated Gene Transfer (Ph.D. 1995), Director of Formulation, HiSun Pharmaceutical Co., China
Frank Kofi Bedu-Addo	Biophysical Studies of Long Circulating Liposomes (Ph.D. 1995), President & CEO, PDS Biotechnology, Inc. Princeton, NJ
Frank Sorgi	Pharmaceutical Considerations for Cationic Liposome Mediated Gene Delivery Systems. (Ph.D. 1997) President & CEO, Flag Therapeutics, Raleigh, NC
Kirti Goyal	Development of Hammerhead Ribozyme for the Site-Specific Cleavage of c-erbB-2/c-neu Proto-Oncogene (M.S., 1995)
Michalakis Savva	Grafting and Interaction of Water-soluble Synthetic Polymers with Liposomes (Ph.D. 1998)

Mark Whitmore	Antitumor Activity of the LPD Lipoplex Prepared with Immunostimulatory CpG DNA (Ph.D. 2000) Senior Scientist, Genzyme Corporation, Framingham, MA
Marni Brisson Tierno	Development of an Improved Cytoplasmic Expression System for Gene Therapy (Ph.D. 1999) Medical Science Liaison Director – East, Castle Biosciences, Inc.
Wai Yan (Vivian) Lui	Non-Viral Approaches for Cancer Gene Therapy (Ph.D. 2000) Associate Professor, Department of Biomedical Sciences, Chinese University of Hong Kong, Hong Kong
Yadi Tan	Overcoming The Inflammatory Toxicity of Cationic Liposome/DNA complex delivered systemically (Ph.D. 2001), Consultant, Beijing, China
John Dileo	Induction of Anti-Tumor Immunity by Gene Delivery (Ph.D. 2002), Senior Scientist, The MITRE Corporation, McLean, VA
Pradeep Tyagi	Intravesical Therapy of Interstitial Cystitis (Ph.D. 2005), Associate Professor of Urology, University of Pittsburgh, Pittsburgh, PA
Jerome Lemoine	Delivery of Naked DNA to Nasal Epithelium (Ph.D. 2005), Postdoctoral Fellow, University of Pacific, San Francisco, CA
Pui-Yan Lee	Cell and Gene Therapy for Diabetic Wound Healing (Ph.D. 2005).
University of North Carolina	
Claire Wei-Hsu Chen	Development of A Simple But Effective Cancer Vaccine Consisting of An Antigen And A Cationic Lipid (Ph.D. 2007), Senior Scientist, Amgen British Columbia, Vancouver, Canada
Shyh-Dar (Star) Li	Targeted delivery of siRNA to the tumor (Ph.D. 2008), Associate Professor, School of Pharmacy, University of British Columbia, Vancouver, Canada
Hsin-I (Cindy) Hung	Combined gene therapy of RNA polymerase II driven siRNA and apoptosis inducing factor in a melanoma model. PhD student, Medical University of South Carolina, (MS 2008)
Amber Frick	PharmD 2009, PhD 2013, University of North Carolina. Clinical Assistant Professor, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

Lisa McEwen (Shollenberger)	Interaction of cationic lipid vaccines with cells of the adaptive immune system (Ph.D. 2009), Associate Professor, Old Dominion University, Virginia Beach, VA
Yunching (Becky) Chen	Nanoparticle delivery of siRNA for cancer therapy (Ph.D. 2010), Associate Professor, National Tsing Hua University, Taiwan.
Jiexin (Jason) Deng	Understanding paclitaxel /pluronic F127 nanocrystals prepared by the stabilization of nanocrystal (SNC) method. (MS, 2009), Graduate Student, University of Florida.
Elisabeth Vasievich	Lipid-Based Cancer Vaccines. (Ph.D. 2011), Manager, Roche/Genentech.
Yang Liu	Pharmacokinetics and Biodistribution of LCP Nanoparticles. (Ph.D. 2012), Assistant Professor, School of Pharmacy, Chapman University.
Yu-Cheng Tseng	LCP Nanoparticles for Tumor and Lymph Node Metastasis Imaging. (Ph.D. 2013), Senior Scientist, HBT Labs Inc. Brea, CA.
Yuan Zhang	Systemic Delivery of Phosphorylated Nucleoside Analogues and siRNA via LCP Nanoparticles for Cancer Therapy. (Ph.D. 2013) Associate Professor, South China University of Science and Technology, Guangzhou, China.
Andrew Satterlee	Applications for a Radio-Theranostic Nanoparticle with High Specific Drug Loading (Ph.D. 2016) Entrepreneurial Fellow, University of North Carolina at Chapel Hill, Chapel Hill, NC
Lei Miao	The Role of Tumor Desmoplasia in Nanoparticle Delivery of Drugs and Genes (Ph.D. 2016) Professor, Peking University, China.
Matthew Haynes	Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipid for Enhanced Local and Systemic Delivery (Ph.D. 2017) Consultant.
Tyler Goodwin	Treatment of Liver Metastasis via Nanoparticle Delivery of Engineered Gene Immunotherapies Expressed Locally and Transiently by the Liver Hepatocytes (Ph.D. 2017), Head, Tune Therapeutics, Durham, NC
Qi Liu	Immunotherapy for Desmoplastic Melanoma: Nanomedicine Approaches of Vaccination and Immune-Modulation (Ph.D.

	2018) Senior Scientist, NexImmune, Rockville, MD
Mengying Hu	Relaxin Gene Therapy for Advanced Liver Diseases: Fetching an Endogenous Repair Mechanism. (Ph.D. 2019) Postdoc, Weill Medical School, Cornell University.
Manisit Das	Drug Delivery Strategies to Treat Desmoplastic and Immunosuppressive Pancreatic Cancer. (Ph.D. 2020) Science Writer.
Yun Liu	Chemo-immunotherapy for Triple Negative Breast Cancer (Ph.D. 2020), Senior Scientist, Spark Therapeutics, Philadelphia, PA
Sara Musetti	Remodeling the Tumor Microenvironment of Triple Negative Breast Cancer with Novel Nanoformulations (Ph.D. 2021), Staff Editor, RTI, Research Triangle Park, NC
Yu Zhang	Transferred to other PI, 2022

Postdoctoral Fellows Supervised and Their Current/last-known Positions:

Larry West (1978-1980)	Practicing Physician, Memphis, TN
Anthony Huang (1979-1983)	Deceased, 2010
Maria Correa-Freire (1983-1984)	Director of Technology Transfer, National Institutes of Health, Bethesda, MD
Kuixiong Gao (1984-1986)	Research Associate, Institute of Agriculture, University of Tennessee, Knoxville, TN
Susumu Kanda (1984-1986)	Deceased, August 1999
Lanrong Hu (1985-1986)	Senior Scientist, Clontech, Palo Alto, CA
Stephen Wright (1986-1989)	Professor, Carson-Newman College, Jefferson City, TN
Karen Elkins (1987-1988)	Senior Investigator, CBER, FDA, Bethesda, MD
Eric Holmberg (1987-1989)	Professor, Department of Chemistry and Physics, University of Alaska, Fairbank

Shu-Tian Ruan (1987-1989)	Research Scientist, Department of Immunology, Sloan-Kettering Cancer Center. New York, NY
Purnima Pinnaduwege (1986-1990)	Instructor, Department of Biochemistry, University of Tennessee, Knoxville
Kazuo Maruyama (1988-1990)	Professor, Faculty of Pharmaceutical Sciences, Teikyo University, Japan
Vladimir Trubetskoy (1990-1991)	Senior Scientist, Mirus Corporation, Madison, WI
Dexi Liu (1990-1991)	Professor, Department of Pharmaceutical and Biomedical Sciences, School of Pharmacy, University of Georgia, Athens, GA
Aleksander Klibanov (1991-1993)	Professor, University of Virginia, Charlottesville, VA
Arun Singhal (1992-1994)	Marketing manager, Invitrogen, Inc.
Hans Hofland (1992-1994)	GlaxoSmithKline, Research Triangle Park, NC
Kyonghee Son (1992-1995)	
Robert J. Lee (1994-1995)	Professor, College of Pharmacy, Ohio State University, Columbus, OH
Jing-Ping Yang (1993-1997)	Senior Scientist, Thermo Fisher, Inc., Gaithersburg, MD
Song Li (1994-1996)	Professor, Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA
Hemant Deshmukh (1994-1996)	Senior Scientist, Ligand Pharmaceutical, Inc., San Diego, CA
Yukai He (1994-1997)	Professor, Department of Microbiology, Medical University of Georgia, Augusta, GA
Jung Hee Han (1995)	Postdoctoral Fellow, Korean Advanced Institute Science and of Technology, Seoul, Korea
Toshifumi Hara (1995-1997)	Senior Scientist, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
Soumendu Bhattacharya (1996-1998)	Senior Formulation Scientist, Barr Pharmaceuticals, NJ
Kiyoto Yachi (1996-1997)	Manager, Daiichi Pharmaceutical Co., Tokyo, Japan
Wenchi Tseng (1997-1999)	Professor, National Taiwan University of Science and Technology, Taiwan

Sophie Chesnoy Trentesaux (1997-2001)	Global Product Line Manager, Roquette, Paris, France
Kenneth Liang (1998-2001)	Self employed
Ekapop Viroonchatapan (1998-1999)	Assistant Director, Isis Pharmaceuticals, Carlsbad, CA
Xiaofeng Wu (1999-2000)	Scientist, S*BIO Pte Ltd, Singapore
Makiya Nishikawa (1999 – 2001)	Professor, Tokyo Science University, Tokyo, Japan
Zhiyu Li (1999-2000)	Associate Professor, Philadelphia School of Pharmacy and Science, Philadelphia, PA
Feng Liu (1999-2001)	Research Professor, University of North Carolina, Chapel Hill, NC. Deceased in 2014
Takuro Niidome (2001-2002)	Professor, Faculty of Engineering, Kumamoto University, Japan
Zhenhua Li (2000-2003)	Research Associate, Cedar Sinai Medical Center, Los Angeles, CA
Rajkumar Banerjee (2000-2003)	Professor, Indian Institute of Chemical Technology, Hyderabad, India
Etsuko Satoh (2001-2002)	Assistant Professor, Keio University School of Medicine, Tokyo, Japan
Yoichi Negishi (2001-2002)	Associate Professor, Department of Drug Delivery, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Jingshi Zhang (2001-2003)	Pharmacist, Philadelphia, PA
Su-Ji Han (2002- 2003)	South Korea
Bin Sun (2002- 2003)	Research Instructor, Orthopedic Surgery, University of Pittsburgh, Pittsburgh, PA
Zhengrong Cui (2003-2004)	Associate Professor, College of Pharmacy, University of Texas, Austin, TX
Dileep Vangasseri (2003-2005)	Global IP Analyst, GE Global Research, India
Christine Conwell (2004-2007)	Scientific Administrator, Georgia Institute of Technology, Atlanta, GA
Joyeeta Sen (2005- 2007)	Research Chemist, Hyderabad, India

Weili Yan (2006 – 2007)	Senior Scientist, Genentech, Inc. South San Francisco, CA
Ji-Yong Park (2006 – 2008)	Scientist, Food and Drug Administration, Silver Spring, MD
Surendar Reddy (2007 – 2008)	Deceased in 2020 due to COVID.
Wei-Yun Sheng (2008 – 2011)	Consultant.
Jun Li (2008- 2011)	VP of Research, ZY Therapeutics, Research Triangle Park, NC
Sang Kyoong Kim (2008- 2011)	Senior Scientist, Daegu Gyeongbuk Medical Innovation Foundation, Daegu, Korea
Srinivas Ramishetti (2009 – 2013)	Scientist, Tel Aviv University, Israel
Yunxia Hu (2010-2012)	Professor, Tianjin University of Technology, Tianjin, China
Yuhua (Al) Wang (2010-2015)	Principal Scientist, Crispr Therapeutics, Inc., Boston, MA.
Shutao Guo (2011-2014)	Professor, Nankai University, Tianjin, China
Zhenghong Xu (2011-2014)	Scientist, LEAF Pharmaceuticals Inc., Cambridge, MA
Yi Zhao (2013-2016)	Scientist I, Takara Bio USA, Mountain View, CA
Wantong Song (2016-2018)	Professor, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
Sai An (2016-2018)	Senior Scientist, Tune Therapeutics, Durham, NC
Limei Shen (2016-2018)	Research Associate, Eshelman School of Pharmacy, UNC, NC
Nasha Qiu (2017-2019)	Professor, The First People's Hospital, Zhejiang University, Hangzhou, China
Jianfeng Guo (2018-2020)	Professor, Jilin University, Changchun, China
Zhuo Yu (2018-2020)	Associate Professor, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Menglin Wang (2019-2022)	Postdoc, MIT, Boston, MA
Zhenzhen Chen (2022-present)	

***Visiting (Sabbatical)
Faculty/Scientists:***

Position at their home institutions

Marisa Gennari (1989)	Assistant Professor of Immunology, Instituto de Ciencias Biomedicas, University of Sao Paulo, Brazil
You-Zhen Ding (1990)	Associate Professor, Department of Cell Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
Anneke Heeremans (1990)	Graduate Student, Department of Pharmaceutics, University of Utrecht, The Netherlands
Aleksander Klibanov (1987,1988, 1989-90)	Senior Researcher, Laboratory of Enzyme Engineering, Cardiology Research Center, Moscow, USSR
Stephen Sugarman, M.D. (1990)	Fellow - Department of Medicine, M.D. Anderson Hospital and Tumor Institute, Houston, TX
Vladimir Torchilin (1988, 1989, 1991)	Professor and Head, Enzyme Engineering Laboratory, Cardiology Research Center, Moscow, USSR
Akira Wada (1989-1991)	Researcher, Biological Product Development, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan
Annette Buiting (1992)	Graduate Student, Department of Cell Biology. Free University of Amsterdam, Amsterdam, The Netherlands
Tony Yao (1992)	Undergraduate Student, Department of Biochemistry, Brown University, Providence, RI
Francesca Reig (1992)	Senior Scientist, Consejo Superior de Investigaciones Cientificas, Centro de Investigacion Y Desarrollo, Barcelona, Spain
Maria Jose Fonseca-Chacharo (1993)	Graduate Student, Consejo Superior de Investigaciones Cientificas, Centro de Investigacion Y Desarrollo, Barcelona, Spain
Chih-Haw Wallace Lin, Ph.D. (1994)	Research Associate, Carnegie Mellon University, Pittsburgh, PA
Hsiu-Ying Yu Shen, Ph.D. (1994)	Professor, School of Pharmacy, College of Medicine, National Taiwan University, Taiwan.
Fu-Hsiung Chang, Ph.D. (1996) (1998)	Associate Professor, College of Medicine, National Taiwan University, Taipei
Yong-Serk Park, Ph.D. (1997)	Assistant Professor, Yonsei University, South Korea

Sujatha Dokka, (1997)	Graduate Student, School of Pharmacy, West Virginia University., Morgantown, WV
Yon Rojanasakul, (1997)	Associate Professor, School of Pharmacy, West Virginia University, Morgantown, WV
Ya-Wun Yang, Ph.D. (1997)	Associate Professor, School of Pharmacy, National Taiwan University, Taipei.
Lourdes Herrold, Ph.D. (1998)	Assistant Professor, Carlow College, Pittsburgh, PA
Tanya Jaitley (1998)	Medical Student, School of Medicine, University of Pittsburgh, PA
Merce Rodriguez (1999)	Graduate Student, University of Barcelona, Spain
Cynthia Hofmann (2000)	Pharmacy Student, University of Utrecht, The Netherlands
Kazuo Maruyama (2000, 2001)	Associate Professor, Teikyo University, Japan
Hironobu Yanagie (2000, 2001)	Assistant Professor, Tokyo University, Japan
Hirotaaka Sugiyama (2000, 2001)	Assistant Professor, Aichi Medical University, Japan
Lawrence Block (2001)	Professor of Pharmaceutics, Duquesne University, Pittsburgh, PA
Shyh-Dar Li (2001)	Research Associate, Industrial Technology Research Institute, Taiwan
Yong-Serk Park (2002-2003)	Professor, Yonsei University, South Korea
Erin Cobain (2002) (2004)	Intern, Davidson College, NC
Colleen Rock (2002)	Intern, Wilkes School of Pharmacy
Pao-Chu Wu (2005)	Professor, Kaohsiung Medical University, Taiwan
Tomohiro Asai (2005)	Professor, University of Shizuoka, Japan
Chia-Wen Liu (2005)	Assistant Scientist, Industrial Technology Research Institute, Taiwan
Levent Liu (2006)	Senior Scientist, National Health Research Institute, Taiwan
Sumio Chono (2007- 2008)	Professor, Hokkaido Pharmaceutical University, Japan

Kun Gao (2007 – 2008)	Associate Professor, Xian Jiaotong University, China
Subho Mozumdar (2008)	Associate Professor, University of Dehli, India
Chunshun Zhao (2009-2010)	Professor, Sun Yat-Sen University, China
Yeonsu Oh (2010)	Graduate Student, Seoul National University, Korea
Hsing-Hao Su (2010-2011)	Chief Surgeon, Kaohsiung Veterans General Hospital, Taiwan
Taeho Ahn (2010-2011)	Associate Professor, Chonnam National University, Korea
Xia Guo (2010-2011)	Professor, Yangzhou University, China
Yang (Sunny) Yang (2010-2011)	Associate Professor, Sichuan University, China
Dejian Huang (2011-2011)	Associate Professor, National University of Singapore
Chinying (Keen) Chung (2011)	Graduate Student, Pennsylvania State University
Tomohiro Asai (2011-2012)	Professor, Shizuoka University, Japan
Ivy Hsu (2011)	Professor, Chung Yuan Christian University, Taiwan
Grace Yu (2012)	Assistant Investigator, National Health Research Institute, Taiwan
Yun Liu (2012)	Graduate student, Peking University, China
Jing Yao (2012-2013)	Professor, Chinese Pharmaceutical University, Nanjing, China
Shubiao Zhang (2012-2013)	Professor, Dalian Nationality University, Dalian, China
Jing Zhang (2012-2013)	Associate Professor, Jiangxi Traditional Chinese Medical University, Nanchang, China
Guimei Lin (2013-2014)	Associate Professor, Shandong University, Jinan, China
Cheng-An James Lin (2013)	Assistant Professor, Chung Yuan Christian University, Taiwan
Yao Lu (2013-2015)	Associate Professor, Huazhong University of Science and Technology, Wuhan, China
Yan Zhao (2013-2014)	Associate Professor, China Medical University, Shenyang, China
Ali Badiie (2014-2015)	Assistant Professor, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Meirong Huo (2014-2015)	Professor, China Pharmaceutical University, Nanjing, China

Yang Xiong (2014-2015) Professor, Zhejiang Traditional Chinese Medical University, Hangzhou, China.

Qiang Zhao (transferred from Feng Liu group, 2014) Associate Professor, Sichuan University, Chengdu, China

Hongjuan Zhang (transferred from Feng Liu group, 2014) Associate Professor, Nanjing Medical University, Nanjing, China.

Qi Xiang (transferred from Feng Liu group, 2014) Associate Professor, Jinan University, Guangzhou, China.

Lifang Cheng (transferred from Feng Liu group, 2014) Associate professor, Suzhou University, Suzhou, China.

Yinghui Wei (transferred from Feng Liu group, 2014) Associate Professor, Zhejiang Traditional Chinese Medical University, Hangzhou, China.

Wei Wang (transferred from Feng Liu group, 2014) Professor, China Pharmaceutical University, Nanjing, China.

Zahra Daman (2014 – 2015) PhD student, Tehran University of Medical Sciences, Tehran, Iran

Lina Liu (2014-2015) Associate Professor, Guiyang Medical University, Guiyang, China

Nasha Qiu (2014-2015) Professor, First People's Hospital, Hangzhou, China

Cong Luo (2015-2016) Professor, Shenyang Pharmaceutical University, Shenyang, China

Kai Shi (2015-2016) Professor, Nankai University, Tianjin, China

Kaili (Kelly) Hu (2015-2016) Professor, Shanghai Traditional Chinese Medical University, Shanghai, China

Jing Qin (2015-2016) Associate Professor, Fudan University, Shanghai, China

Ying Xu (2015-2016) Associate Professor, Jiangsu University, Zhenjiang, China

Hongda Zhu (2016-2017) Associate Professor, Hubei University of Technology, Wuhan, China

Xiao Xie (2016-2017) Attending Surgeon, Xinhua Hospital, Shanghai, China

Xueqiong Zhang (2016-2017) Associate Professor, Wuhan University of Technology, Wuhan, China

Li Jing (2016-2016) Volunteer scientist

Haiyang Hu (2016-2017) Associate Professor, Shenyang Pharmaceutical University, Shenyang, China

Yanzhi Wang (2016-2017) Associate Professor, Zhengzhou University, Zhengzhou, China

Xiangnan Liu (2016-2017) Graduate student, Fudan University, Shanghai, China

Lin Hou (2017-2018) Associate Professor, Zhengzhou University, Zhengzhou, China

Lucia Salvioni (2017-2017)	Graduate student, University of Milan, Italy
Ying Wang (2017-2017)	Senior Scientist, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Ligeng Xu (2017-2018)	Associate Professor, Jinan University, Guangdong, China
Jing Zhang (2017-2018)	Professor, Jiangxi University of Traditional Chinese Medicine, Nanchang, China
Yang Xiong (2017-2018)	Professor, Zhejiang University of Traditional Chinese Medicine, Hangzhou, China
Huan Xu (2017-2018)	Associate Professor, Liaoning Normal University, Dalian, China
Lei Li (2017-2018)	Professor, Dalian Medical University, Dalian, China
Yanzuo Chen (2017-2018)	Associate Professor, East China University of Science and Technology, Shanghai, China
Mengrui Liu (2017-2018)	Postdoc, NCSU, Raleigh, NC
Menglin Wang (2017-2019)	Postdoc, University of North Carolina at Chapel Hill, NC
Xuefei Zhou (2018-2020)	Associate Researcher, Zhejiang University, Hangzhou, China
Yishun Yang (2019-2020)	Instructor, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Zhengsheng Liu (2019-2020)	PhD student, Tsinghua University, Beijing, China
Yung-Yi Cheng (2021-present)	Postdoc, University of North Carolina at Chapel Hill, NC
Shuo Han (2021-2022)	PhD student, Southern Medical University, China

Advisory Committees:

1982-1986	Member, Cellular Biology and Physiology Study Section II, NIH
1983-1987	Member, Scientific Advisory Committee, China National Center for Biotechnology and Development, People's Republic of China
1991-1994	Member, AIDS Related Research Study Section 4, NIH
1994-1998	Member, Executive Committee, Liposome Research Days, Inc.
1996-2008	Member, Scientific Review Committee, National Health Research Institute, Taiwan, Republic of China
1997-2000, 2004-2007	Member, Non-viral Vector Committee, American Society of Gene Therapy
1998	Member, Abstract Review Committee for Annual Society Meeting, American Society for Gene Therapy

1998-1999 Member, Nomination Committee, American Society of Gene Therapy
1998 Member, National Gene Vector Laboratories Scientific Review Board
1998-1999 Ad Hoc Member, Medical Biochemistry Study Section, NIH
1999-2002 Member, Medical Biochemistry Study Section, NIH
2004-2007 Member, Scientific Advisory Committee, Vaccine Research & Development Center, National Health Research Institute, Taiwan, Republic of China
2005 Ad Hoc member, Neuroscience of Aging Review Committee, NIH
2006 Ad Hoc member, Neuroscience of Aging Review Committee, NIH
2006-2011 Elected member, Advisory Committee, American Society of Gene and Cell Therapy
2006 Ad Hoc member, Study Section on Non-viral Vector Development, NIH
2008 Ad Hoc member, Review Panel G1, National Cancer Institute of Canada
2009 Ad Hoc member, Special Emphasis Panel/Scientific Review Group 2009/05 ZRG1 CB-N (50) R meeting, NIH
2010-2012 Scientific Advisory Board, CoiN - The North Carolina Center of Innovation for Nanobiotechnology
2011-2013 Member, Board of Visitors, School of Pharmacy, University of Pittsburgh
2012-2015 Elected member, Board of Scientific Advisors, Controlled Release Society
2012-2014 Scientific Advisory Board, Institute of Infectious Diseases and Vaccine Development, National Health Research Institute, Taiwan
Member, Study Section on “The Emerging and Re-emerging Infectious Disease Project”, National Science Council, Taiwan
2012-2013 National Science Council, Taiwan
2015-2019 Member, Study Section on “Gene and Drug Delivery Systems”, NIH

EDITORIAL ACTIVITIES

1984-1998 Editorial Board Member, *Chemistry and Physics of Lipids*
1986-1991 Editorial Board Member, *Journal of Liposome Research*
1991-1997 Editor-in-Chief, *Journal of Liposome Research*
1997-present Editor Emeritus, *Journal of Liposome Research*
1992-1999 Editorial Board Member, *Journal of Drug Targeting*
1992-2001 Editor, *BioScience Reports*
1993-1999, 2000- Editorial Board Member, *Gene Therapy*
1994-2000 Editorial Advisory Board, *Bioconjugate Chemistry*
1995-2000 Editorial Board, *Advanced Drug Delivery Reviews*
1999-1999 Associate Editor, *Gene Therapy*
1999-2004 Associate Editor, *Molecular Therapy*
1999-2006 Editorial Board Member, *Journal of Gene Medicine*
2000-2020 Editorial Board Member, *Journal of Controlled Release*
2003-2010 Editorial Board Member, *Molecular Pharmaceutics*
2004-present Editorial Board Member, *Biological and Pharmaceutical Bulletin*
2010-2015 Editorial Board Member, *BBA – Biomembranes*
2011-2021 Editorial Board Member, *Acta Pharmaceutica Sinica B*
2011-present Editorial Board Member, *Molecular Therapy: Nucleic Acids*
2014-present Editorial Board Member, *Journal of Chinese Pharmaceutical Sciences*

Industrial Consultations:

1984-1985	International Minerals and Chemicals Corporation
1986-1987	Proctor and Gamble Company
1985-1990	LipoGen, Inc. (Founder and CSO)
1991-1993	Vestar, Inc.
1991-1993	Ribozyme Pharmaceuticals, Inc.
1992-1995	Argus Pharmaceuticals, Inc.
1992-1995	Life Technologies, Inc.
1993-1994	Genzyme Corporation
1993-1994	Theragen, Inc.
1994-1995	NOF Corporation
1994-1996	RGene Therapeutics, Inc. (Founder)
1994-1996	GenVec, Inc.
1996-2001	Targeted Genetics Corporation
2000	Biogen, Inc.
2001-2003	Conrex Pharmaceutical Company
2002-2003	BioMet Corporation
2003-2004	IC-Vec, Ltd.
2003-2007	Industrial Technology Research Institute, Taiwan, Republic of China
2005-present	Lipella Pharmaceutical, Inc. (co-Founder)
2006-present	PDS Biotechnology, Inc. (co-Founder)
2006	Alnylam Pharmaceuticals, Inc.
2007	Ambria, Inc. Montreal, Canada
2007	Merck, Inc. Philadelphia, PA
2007	Eli Lilly, Indianapolis, IN
2007-2008	Abbott Laboratories, Chicago, IL
2007	GlaxoSmithKline, London, UK
2007	Eisai Pharmaceutical Company, Research Triangle Park, NC
2008	Pfizer, Boston, MA
2008	Roche, Nutley, NJ
2009-2012	Institute of Biomedical Engineering, Industrial Technology Research Institute, Taiwan
2010-2017	Qualiber, Inc., Co-founder and Chief Scientific Officer, Chapel Hill, NC (company shut down in 2017)
2013-2014	KRB, Inc. Co-founder and CEO, Taiwan (company shut down in 2014)
2016-2019	OncoTrap, Inc. Co-founder, Chapel Hill, NC

University Committee Experience:

University of Tennessee:

Departmental Curriculum Committee, (1976-77, 1981-84)
 University Biohazard Planning Committee, (1977-78)
 Department Head Search Committee, (1977-79)
 Liberal Art Dean's Research Advisory Council, (1978-81)
 Departmental Seminar Series, (1978-80, 1985-87, 1990-1991)
 Biomedical Research Support Grant Review Committee, (1978-82)
 Department Student Recruitment Committee, (1979-81)
 Faculty Search Committee, (1979-80, 1984-85)
 Planning Committee for Biotechnology Curriculum, (1983-84)

Curriculum Vitae
 01/05/2023

Leaf Huang, Ph.D.
 Page 24

Cell and Molecular Biology Program Steering Committee, (1979-82)
Biology Curriculum Committee, (1982-84)
UT-ORNL Life Sciences Committee, (1984)
Biotechnology Program Executive Committee, (1984-1987)
Biotechnology Task Force, (1986-1987)
Leadership Assessment Review Committee, (1986)
Comprehensive Examination Committee, (1988-1991)

University of Pittsburgh:

Appointment and Promotion Committee, Department of Pharmacology (1991-1999)
Comprehensive Examination Committee, Department of Pharmacology (1992-1999)
Graduate Curriculum Committee, (1993-1993)
Faculty Search Committee, Department of Pharmacology, (1992-1993)
Faculty Search Committee, Department of Pharmaceutical Sciences, (1992-1993)
Budget Planning Committee, Department of Pharmacology, (1994 - 1995)
Resource Task Force, School of Medicine, (1994)
Ad Hoc Committee for Faculty Promotion (1994, 1995)
Task Force for Integration of Basic Science into 3rd and 4th Year Medical Curriculum (1996)
Committee for Promotion of Tenured Faculty, School of Medicine (1996-1997)
Ad Hoc Committee for Faculty Grievance (1996)
Departmental Seminar Coordinator (1996-1997)
Director, Molecular Pharmacology Graduate Training Program (1997-1999)
Chairman, Faculty Search Committee, Department of Pharmacology (1998-1999)
Chairman, Faculty Search Committee, Center for Pharmacogenetics (1999-2002)
Committee on Awards (1999-2004)
Entrepreneurial Oversight Committee (2000-2004)
Chairman, Brown Bag Discussion Committee, School of Pharmacy (2001-2003)
Distinguished Faculty Committee (2003-2005)

University of North Carolina, Chapel Hill

Graduate Curriculum Review Committee, MOPH (2005-2008)
Professional Education Curriculum Committee, School of Pharmacy (2005-2006)
Dean's Advisory Council, School of Pharmacy (2005-2007)
Full Professor's Committee, Eshelman School of Pharmacy (2005-present)
MOPH Faculty Search Committee, Chair (2005, 2006)
Executive Committee, Eshelman School of Pharmacy (2005-present)
Advisory Committee, Carolina Center of Cancer Nanotechnology Excellence (2006-2010)
Conflict of Interest Committee, Eshelman School of Pharmacy (2007- 2008)
Chair, Faculty Search Committee, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy (2012-13)
Mentoring Committee for Dr. Shawn Hingtgen, MOPH (2012-2018)
CTSA grant renewal planning committee, UNC (2012)
Faculty Co-Advisor, Christian Pharmacist Fellowship, UNC Eshelman School of Pharmacy, UNC (2013, 2014)

Symposium, Courses and Seminar Series Organized:

Membrane Journal Club, University of Tennessee, 1976-1991

Symposium on Frontiers of Biomembrane Research, University of Tennessee, Speakers: G. E. Palade, E. Holtzman, S. Roseman, D. Papahadjopoulos, W.R., Lowenstein, R.G.W. Anderson, and G.D. Fischbach, November, 1977

Grantsmanship Workshop in Biomedical Sciences. University of Tennessee, 1980

“Liposome Technology” course, Jinan University and Tsinghua University, China, summer, 1985

“The Liposome Conference in St. Petersburg - New Concepts, Perspectives and Clinical Applications”, St. Petersburg, Russia, June 1993, member of the Organization Committee “A Liposome Birthday Conference: Back to the Future, Babraham, Cambridge, United Kingdom, March 27-30, 1995.

“Pharmaceutical Approaches of Oligonucleotide and Gene Therapy”, Workshop sponsored by Controlled Release Society, Seattle, WA, August 3-4, 1995.

“Non-viral Vectors for Gene Therapy,” Educational Section 88th Annual Meeting of American Association For Cancer Research, San Diego, CA, April 12, 1997.

“Pharmaceutical Approaches of Oligonucleotide and Gene Therapy”, Workshop sponsored by Controlled Release Society, Stockholm, Sweden, June 15-16, 1997.

“Synthetic Non-viral Vector Systems”, Keystone Symposium, Keystone, CO, Co-organizer with Philip Felgner, Frank Szoka, and Ernest Wagner, Jan 19-25, 1998.

Organized and chaired “Lipid-mediated Gene Therapy”, education sessions. American Society of Gene Therapy annual meeting, Seattle, WA, May 28-31, 1998

“Structure and Design of Synthetic Gene Carriers”, San Francisco, co-organizer with Philip Felgner and Francis Szoka, Feb. 24-26, 1999.

Organized and chaired “Lipid-mediated Gene Therapy”, education sessions, American Society of Gene Therapy annual meeting, Washington, DC, June 9-13, 1999.

Chaired “Delivery or Tumor Targeting” section, Gordon Research Conference on “Chemotherapy of Experimental/Clinical Cancer”, New London, NH, July 11-16, 1999.

Chaired “Nucleic Acid Drugs-Gene Delivery” section, 7th International Liposome Research Days, University of California, San Francisco, San Francisco, California, April 13-15, 2000.

Co-Chaired with Rimona Margalit, “Liposomal Therapeutics: Gene Therapy and More”, Controlled Release of Bioactive Materials, Controlled Release Society, Paris, France, July 7-13, 2000.

Co-Chaired with Philip Felgner, Workshop on “Naked DNA and Physical Methods”, American Society for Gene Therapy annual meeting, Seattle, WA, May 30-June 3, 2001.

Organized and chaired 9th Liposome Research Days Conference, Hsin-Chu, Taiwan, May 11-15, 2004.

Organized and chaired 1st Chapel Hill Drug Conference/10th Liposome Research Days Conference, Chapel Hill, NC. May 19-22, 2006.

Re-established the series “UNC/GSK Distinguished Speakers in Drug Delivery” funded by GlaxoSmithKline, Inc.

Organized “UNC/Duke Drug Delivery Discussion Group”, 2006-present.

Member, Program Committee, 11th Liposome Research Days Conference, Yokohama, Japan, July, 2008.

Member, Program Committee, The 6th China-Japan-Korea Foresight Joint Symposium on Gene Delivery, December 2008, Sanya, China.

Member, Scientific Advisory Committee, 4th Chapel Hill Drug Conference, Chapel Hill, NC, May, 2009.

Member, Scientific Program Committee, 13th Liposome Research Days Conference, Hangzhou, China, October, 2012

Vice Chair, Gordon Research Conference “Cancer Nanotechnology”, July, 2013.

Chair, Gordon Research Conference “Cancer Nanotechnology”, June, 2015.

Clinical Trials Participated:

1. Gene therapy for melanoma, Phase I, 1992, with Dr. Gary Nabel, University of Michigan. Ann Arbor, MI.
2. Gene therapy for gynecological cancers, Phase I, 1994-96, with Dr. Kam Hui, Singapore General Hospital,

Singapore.

3. Gene Therapy for cystic fibrosis, Phase I, 1994, with Drs. Eric Alton, Duncun Geddes and Bob Williamson, National Lung and blood Institute, London, UK.
4. Gene therapy for cystic fibrosis, Phase I, 1995, with Drs. Stephen Hyde, Debra Gill and Chris Higgins, University of Oxford, Oxford, UK.
5. Gene Therapy for Canavan's Disease, Phase I/II, 1996, with Drs. Matthew During and Paula Leone, University of Auckland, New Zealand.
6. Gene Therapy for cystic fibrosis by multiple dosing, Phase I, 1996-1997, with Drs. Debra Gill, Stephen Hyde and Chris Higgins, University of Oxford, Oxford, UK.
7. Gene therapy for c-erbB-2 overexpressing ovarian and breast cancers, Phase I, 1996-1997, with Drs. G. Hortobagyi and Mien-Chie Hung, MD Anderson Cancer Center, Houston, TX.
8. Gene therapy for head/neck carcinoma, Phase I, 1999-2002, with Drs. J. Reubin Grandis and D. Trump, University of Pittsburgh Cancer Institute.
9. Evaluation of Intravesical LP08 (sphingomyelin liposomes) in Patients with Interstitial Cystitis/Painful Bladder Syndrome, Phase II, 2015 ongoing, Lipella Pharmaceuticals, Inc.
10. Therapeutic vaccine for cervical intraepithelial neoplasia (CIN) patients. Phase I, 2014-2015, PDS Biotechnology.

Grant and Manuscript Reviews:

National Institutes of Health (ad hoc reviewer, study section member and site visits)

National Science Foundation (grants)

National Research Council (grants)

Medical Research Council, Canada (grants)

Biochemistry

Journal of Biological Chemistry

Biochimica et Biophysica Acta

Science

Cancer Research

Experimental Cell Research

Proceedings of National Academy of Sciences, USA

Journal of Cell Biology

Journal of Cellular Physiology

Planta

Journal of Membrane Biology

Journal of Membrane Biochemistry

Journal of Immunological Methods

Pharmaceutical Research

Chemistry and Physics of Lipids

Journal of Pharmaceutical Sciences

European Journal of Cell Biology

Journal of Liposome Research

Curriculum Vitae

01/05/2023

Leaf Huang, Ph.D.

Page 27

American Journal of Physiology: Cellular Physiology
Histochemistry and Cytochemistry
Blood
Analytical Biochemistry
Archives of Biochemistry and Biophysics
Journal of Colloidal and Interfacial Chemistry
Gene Therapy
BioScience Reports
Bioconjugate Chemistry
Human Gene Therapy
Journal of American Chemical Society
Nature Biotechnology
Biophysical Journal
Molecular Therapy
Molecular Pharmaceutics
Nature Nanotechnology
Journal of Controlled Release
Nature Medicine

Invited Seminars (since 1995):

Roswell Park Cancer Institute, “Liposome mediated gene transfer: chemistry meets genetics”, Buffalo, NY, (1995)
Seventh International Symposium on Recent Advances in Drug Delivery Systems, “Lipidic systems in gene transfer”, Salt Lake City, Utah, (1995)
Second International Conference on Engineered Vaccines for Cancer and AIDS, “Liposomes”, San Francisco, (1995)
Stanford University, “Liposome mediated gene transfer: chemistry meets genetics”, Stanford, CA, (1995)
A Liposome Birthday Conference: “Back to the Future, Babraham, Cambridge, United Kingdom, (1995)
Conference on “Therapeutic oligonucleotides: From cell to man, cellular & clinical aspects”, Paris, France, (1995)
“5th International Symposium on Delivery and Targeting of Peptides, Proteins & Gene, Leiden, The Netherlands, (1995)
Symposium dedicated to A.I. Virtanen, Kuopio, Finland, (1995)
Gene Therapy Session of the 6th International Symposium of SCBA, “Lipid mediated gene transfer in cancer therapy”, Vancouver, (1995)
22nd International symposium on the Controlled Release of Bioactive Materials, Seattle, WA (1995)
Controlled Release Society Workshop “Pharmaceutical approaches to oligonucleotide and gene therapy”, Seattle, WA (1995)
4th Liposome Research Days Conference, Freiberg, Germany (1995)
NIDDK- Sponsored Conference, “Targeting of novel therapeutics to the liver and GI tract”, NIH Conference Center, Bethesda, MD (1995)
Massachusetts General Hospital, “Gene transfer with non-viral systems”, (1995)
CHI Artificial Self-Assembling Systems for Gene Transfer Conference, “Lipid self-assembly systems for gene transfer”, Wakefield, MA (1995)
Rutgers University Seminar, “Liposomes in gene therapy” Newark, NJ (1995)
6th Princeton Liposome Conference, “Targeted lipid/liposomal delivery of genes” Princeton, NJ (1995)
University of Pennsylvania Medical Center, “Liposomes in gene therapy” Philadelphia, PA (1995)
University of California San Francisco, “Supramolecular assemblies for gene transfer” San Francisco, CA (1996)
Ohio State University, “Supramolecular assemblies for gene transfer”, Columbus, OH (1996)

University of Medicine and Dentistry of New Jersey, "Supramolecular assemblies for gene transfer", Newark, NJ (1996)

Symposium on Biotechnology, "Cancer gene therapy with non-viral vectors", Stockholm, Sweden (1996)

Midwest Regional Meeting -American Association of Pharmaceutical Scientists, "Challenges and opportunities of intercellular delivery of DNA" Chicago, IL (1996)

The Pharmaceutical Society of Republic of China, "Novel supramolecular assemblies for gene transfer", Taipei, Taiwan (1996)

5th Liposome Research Days, "Novel supramolecular assemblies for gene transfer", Shizuoka, Japan (1996)

Second Satellite Symposium of The Joint Section on Tumors of the American Association of Neurological Surgeons, "Novel supramolecular assemblies for gene transfer", Montreal, Canada (1996)

Gene Therapy of Cancer Assembly of Nanostructures, "Novel supramolecular assemblies for gene transfer", San Diego, CA (1996)

University of Uppsala, "Supramolecular assemblies for gene transfer", Sweden, (1996)

Liposome Advances: Progress in Drug and Vaccine Delivery, "Supramolecular assemblies for gene transfer", London (1996)

West Virginia University, "Supramolecular assemblies for gene transfer", West Virginia (1997)

Cold Spring Harbor Laboratory, Vector targeting strategies, "Novel supramolecular assemblies for gene transfer", New York (1997)

University of Texas, Houston "Novel supramolecular assemblies for gene transfer", Texas (1997)

American Association for Cancer Research "Non-viral delivery systems for gene therapy", San Diego, CA (1997)

4th International Symposium on Bio-organic Chemistry, "Supramolecular assemblies for gene transfer", Biarritz, France (1997)

The 24th International Symposium on Controlled Release of Bioactive Materials, "Gene therapy systems for DNA delivery", Stockholm, Sweden (1997)

Cambridge Healthtech Institute's Conference, "Artificial Self-Assembling Systems for Gene Delivery", Coronado, CA (1997)

Heward Visiting Scientist to The Montreal General Hospital/McGill University, Montreal Canada (1998)

Johns Hopkins University, Molecular Pharmacology Department, "Cancer Gene therapy with Therapeutic RNA Expressed in the Tumor Cells", Baltimore, MD. (1998)

Johns Hopkins University, Biomedical Engineering Department, "Novel Non-viral Vectors for Gene Transfer: Liposomes and More", Baltimore, MD (1998)

University of Michigan, "Novel non-viral vectors for cancer gene therapy" (1998)

University of Illinois at Chicago, "Novel non-viral vectors for cancer gene therapy", Chicago, IL (1998)

University of Kentucky, Markey Cancer Center, "Novel Non-viral Vectors for Gene Therapy", Lexington, KY (1998)

The First Annual Meeting of the American Society of Gene Therapy, "Cationic Lipid Mediated Gene Therapy", Seattle, WA, (1998)

Society for Controlled Release, "Novel Non-viral Vectors for Gene Therapy", Las Vegas (1998)

Membrane Fusion: Mechanisms and Applications to Cell Biology, Drug Delivery and Gene Therapy, "Fusion Active Liposomes in Gene Delivery", Salamanca, Spain (1998)

University of Texas MD Anderson Cancer Center, "Novel Non-viral Vectors for Cancer Gene Therapy", Houston, TX (1998)

University of Paris-Sud, "Novel Non-viral Vector for Gene Transfer", Paris, France (1998)

Symposium "From Lipids to Membranes, in Tribute to Vittorio Luzatti", "Lipids in Non-viral Vectors", Paris, France (1998)

National Hemophilia Foundation, "Second Biennial Workshop on Gene Therapies for Hemophilia", "Non-viral Vectors", San Diego, CA (1998)

University of Illinois at Chicago, "Gene Therapy as a Drug Delivery Problem", Chicago, IL (1998)

Moffitt Cancer Center, "Novel Non-viral Vectors for Cancer Therapy", Tampa, FL (1999)

University of Kentucky, College of Pharmacy, “LPD Nanoparticles for Systemic Gene Delivery”, Lexington, KY (1999)

American Society of Gene Therapy, Second Annual Meeting, “LPD nanoparticles as a novel nonviral vector for systemic gene delivery”, Washington, D.C., (1999)

Roswell Park Cancer Institute Seminar, “Cancer therapy with nonviral vectors”, Buffalo, NY (1999)

ASHG Workshop, “Non-Viral Vectors”, San Francisco, CA (1999)

1999 Global Chinese Symposium on Biomaterials and Controlled Release, “Delivery of DNA for Gene Therapy”, Taipei, Taiwan (1999)

Institute for Human Gene Therapy Seminar, “Cancer Gene Therapy with Non-Viral Vectors”, Philadelphia, PA (1999)

Nature Biotechnology, “LPD Nanoparticles for Gene Delivery”, Washington, D.C. (1999)

Temple University, School of Medicine, “Non-Viral Vectors for Gene Therapy: Activity and Toxicity”, Philadelphia, PA (1999)

University of London, School of Pharmacy, Liposome Advances: Progress in Drug and Vaccine Delivery Seminar, “Novel Non-Viral Vectors: Liposomes and More”, London (1999)

University of Florida, Center for the Neurobiology of Aging, “Non-viral vectors for gene therapy: Liposome and Beyond”, Gainesville, FL (2000)

University of Florida, Center for the Neurobiology of Aging, “Cancer gene therapy using non-viral vectors”, Gainesville, FL (2000)

Boston University, Whitaker Cardiovascular Institute, Non-Viral Vectors for Gene Therapy”, Boston, MA (2000)

Duke University Medical Center, Department of Pharmacology and Cancer Biology, “Gene Transfer Mediated by Non-Viral Vectors”, Durham, NC (2000)

National Defense Medical Center, Neural Transplantation Group, “Non-Viral Approaches to Gene Therapy”, Taipei, Taiwan (2000)

National Chung-Hsin University, “Non Viral Approaches to Gene Therapy”, Taichung, Taiwan (2000)

National Tsing-Hua University, Life Science Department and Chemical Engineering Department, “Non Viral Approaches to Gene Therapy”, Hsin-Chu, Taiwan (2000)

National Cheng-Kung University, “Non Viral Approaches to Gene Therapy”, Tainan, Taiwan (2000)

American Society of Gene Therapy Meeting, “LPD Nanoparticles For Systemic Gene Delivery: Activity And Toxicity”, Denver, Colorado (2000)

Controlled Release Society, “Novel Non-Viral Vectors for Gene Therapy”, Paris, France (2000)

International Symposium on DNA Vaccine and Gene Therapy Technology, NHRI, “Novel Non-Viral Vectors for Gene Therapy”, Academia Sinica, Taipei, Taiwan (2000)

American Association of Pharmaceutical Scientists, “Non-Viral Approach to Gene Therapy”, Indianapolis, IN (2000)

Intracellular delivery of DNA by non-viral vectors workshop hosted by AFM and AFLM, “Lipoplexes”, Paris, France (2000)

22nd Annual Eino Nelson Memorial Conference, “Delivering Genes for Therapy”, Captiva Island, FL (2001)

10th International Symposium on Recent Advances in Drug Delivery Systems, “Novel Non-Viral Vectors”, Salt Lake City, UT (2001)

University of North Carolina at Chapel Hill, Department of Pharmacology, “Non-Viral Gene Therapy”, Chapel Hill, NC (2001)

American Association of Pharmaceutical Scientists, Pharmaceutical Congress of the Americas, “Gene Therapy with Lipidic Non-Viral Vectors”, Orlando, FL (2001)

National Institutes of Health, Division of Intramural Research of the National Human Genome Research Institute, “Non-Viral Gene Therapy”, Washington, DC (2001)

Annual Meeting of Taiwan Neurology Society, “Non-Viral Vectors for Gene Therapy”, Taipei, Taiwan (2001)

Tri-Service General Hospital and National Defense Medical Center, Department of Biochemistry, “Progress and

Challenges of Non-Viral Gene Therapy”, Taipei, Taiwan (2001)

University of Nebraska Medical Center, Department of Biochemistry and Molecular Biology, “Recent Progress in Non-Viral Gene Therapy”, Omaha, NE (2001)

American Society of Gene Therapy annual meeting, “Naked DNA for Gene Therapy”, Seattle, Washington (2001)

MD Anderson Cancer Center, University of Texas, Gene Therapy Seminar Series, “Non-Viral Gene Therapy”, Houston, TX (2001)

9th SCBA International Symposium, “Non-Viral Gene Therapy”, Taipei, Taiwan (2001)

AAPS workshop on “Critical Issues in the Design & applications of Polymeric Biomaterials in Drug Delivery”, “Lipid mediated gene delivery”, Arlington, VA (2002).

Magee Woman Research Institute, “Gene Therapy for HPV Positive Cervical Cancer”, Pittsburgh, PA (2002)

Virginia Commonwealth University, “Non-viral Gene Therapy - Challenges Ahead”, Richmond, VA (2002)

8th Liposome Research Days Conference, “Beyond the Impossible”, Berlin-Buch, Germany (2002)

National Gene Therapy Center, “Gene Delivery by LPD Nanoparticles”, London, UK (2002)

American Society of Gene Therapy 5th Annual Meeting, “Non-viral Vectors- Formulations”, Boston, Massachusetts (2002)

Magee Woman Research Institute, “Non-viral gene transfer to mdx mouse diaphragm: a model for Duchenne Muscular Dystrophy gene therapy”, Pittsburgh, PA (2002)

6th New Jersey Symposium on Biomaterial Science, “Recent advances in drug and gene delivery with lipid and polymer”, Piscataway, New Jersey (2002)

2nd International Symposium on DNA Vaccine and Gene Therapy Technology, “DNA vaccines for HPV DNA-positive tumor model”, Taipei, Taiwan (2002)

“Tumor-specific Delivery by Non-viral Systems: Approaching a Reality”, Maui, Hawaii (2003)

2nd International Symposium on Gene Technology and Skin Gene Therapy, “Novel gene transfer techniques using naked DNA”, Düsseldorf, Germany (2003)

“Liposome Advances” conference, London, UK, (2003)

University of California, Davis, “LPD nanoparticles as an efficient cancer vaccine carrier”, Davis, CA (2004)

Louisiana State University Health Science Center, “LPD nanoparticles: a gene vector turned into a potent cancer vaccine carrier”, New Orleans, LA, (2004)

7th Pharmaceutical Science Forum, “LPD nanoparticles as a potent cancer vaccine carrier”, Hokkaido, Japan (2004)

2nd annual meeting of the Japanese Society of Gene Delivery and Expression, “Non-viral vectors for gene delivery”, Kyoto, Japan (2004)

9th Liposome Research Days conference, Bangham Award lecture, “My liposome journey”, Hsin-Chu, Taiwan (2004)

Shanghai Liposome Workshop, “LPD nanoparticles: an efficient carrier for cervical cancer vaccine”, Shanghai, China (2004)

Workshop on Pharmaceutical Perspectives of Nucleic Acid Based Therapeutics, “LPD nanoparticles: a novel cancer vaccine carrier”, Controlled Release Society annual symposium, Honolulu, Hawaii (2004)

Shanghai Jiao Tong University, College of Pharmacy, “Cell and gene therapy for diabetic wound healing”, Shanghai, China (2005)

Royal Society of Medicine, “The future for non-viral vectors”, London, England (2005)

School of Pharmacy, University of London, “Cell and gene therapy for diabetic wound healing”, London, England (2005)

Lineberger Comprehensive Cancer Center, University of North Carolina, “A Novel Therapeutic Vaccine Delivery System for Cervical Cancer.” Chapel Hill, NC (2005)

Department of Chemistry, Purdue University, “LPD Nanoparticle Mediated Delivery of siRNA”, West Lafayette, IN (2006)

Conference on Transposable Elements in Gene Therapy, “Non-Viral Delivery of DNA”, University of Minnesota, St Paul, MN. (2006)

International Conference on Pharmacogenetics, “Gene Therapy in Pharmacogenetics?”, Changsha, China. (2006)

International Conference on Nanotechnology in Drug Delivery, “LPD Nanoparticles for Efficient Delivery of siRNA to Solid Tumor”, Chandigarh, India. (2006)

2nd International Liposome Society conference, “LPD nanoparticles for the delivery of siRNA and cancer vaccines”, London, UK. (2006)

42nd Arden Conference on Pharmaceutical Technology, AAPS. “Advances in Gene Delivery and Nucleic Acid Therapeutics: Formulation and Delivery Strategies”, West Point, NY (2007)

Department of Pharmaceutics, School of Pharmacy, Shanghai Jiaotong University, “LPD nanoparticles for delivery of genes and siRNA”, Shanghai, China. (2007)

Pharmaceutical Sciences World Congress, 3rd. “Intravenous siRNA effectively silences target genes in solid tumor”, Amsterdam, The Nederland. (2007)

Symposium celebrating 20th anniversary of non-viral vectors, annual meeting, American Society of Gene Therapy, “Looking into The Future”. Seattle, WA (2007)

Annual meeting, Controlled Release Society, “Liposomes Live and Kicking: Cancer Vaccine”, Long Beach, CA (2007)

Institute of Nuclear Energy Research, “Targeted Delivery of Genes and Oligonucleotides”, Taiwan (2007)

GTRV Summer Course, “Targeted Delivery of siRNA to Solid Tumor and Metastasis”, La Grande Motte, France (2007)

Brain Cancer Center, Duke University, “Targeted Delivery of siRNA for Tumor Therapy”, Durham, NC (2007)

School of Pharmacy, University of Iowa, “Targeted Delivery of siRNA for Tumor Therapy”, Iowa City, IA (2007)

NCI Nanotechnology Alliance Investigators meeting, “Pharmacokinetics and Nanoparticles”, Friday Center, Chapel Hill, NC (2007)

Symposium on Recent Advances in Vaccinology, National Health Research Institute, “A Simple Vaccine for Cancer Therapy”, Taiwan (2007)

“Targeted Delivery of siRNA for Tumor Therapy”, National Health Research Institute, Taiwan (2007)

“Targeted Delivery of siRNA for Therapy of Solid Tumor and Metastasis”, Carolina Center of Cancer Nanotechnology Excellence, UNC-Chapel Hill (2007)

North Carolina Pharmaceutics Discussion Group, “Delivery of siRNA for Tumor Therapy”, Research Triangle Park, NC (2007)

Pharmaceutical Society of Taiwan, annual meeting, “Targeted Delivery of siRNA for The Therapy of Cancer”, Kao-Hsiung, Taiwan (2007)

Department of Biotechnology, National Kao-Hsiung University, “siRNA: Delivery and Therapy”, Kao-Hsiung, Taiwan (2007)

School of Medicine, National Cheng Kung University, “A Novel Liposomal Cancer Vaccine”, Tainan, Taiwan (2007)

Chang Gung Memorial Hospital, Grand Round, Department of Surgery, “Gene Therapy: Basic Research and Clinical Applications”, Kao-Hsiung, Taiwan (2007)

Chang Gung Memorial Hospital, School of Medicine, “Targeted Delivery of siRNA for Cancer Therapy”, Kao-Hsiung, Taiwan (2007)

Wayne State University School of Medicine, “Targeted Delivery of siRNA for Cancer Therapy”, Detroit, MI (2008)

Korea Conference in Science and Technology, “Designing a Highly Efficient Vector for siRNA Delivery for Cancer Therapy”, Jeju Island, Korea (2008)

Seoul National University, College of Pharmacy, “Delivery of siRNA for Cancer Therapy”, Seoul, Korea (2008)

Cancer Nanotechnology Alliances conference, “LPD Nanoparticles for siRNA Delivery”, Chicago, IL (2008)

Liposome Research Days conference, “A Simple Therapeutic Vaccine for Cervical Cancer”, Yokohama, Japan (2008)

University of Iowa, College of Pharmacy, “Delivery of siRNA for Cancer Therapy”, Iowa City, IA (2008)

Controlled Release Society annual meeting, “siRNA Delivery to Tumor Cells”, NYC, NY (2008)

American Academy of Nanomedicine, “Delivery of siRNA with Nanoparticles”, Potomac, MD (2008)

The Third Oligonucleotide Therapeutics Conference, “Delivery of siRNA”, Boston, MA (2008)

Texas A&M University, “Targeted Delivery of siRNA for Cancer Therapy”, College Station, TX (2008)

The 6th China-Japan-Korea Foresight Joint Symposium on Gene Delivery, “Core/Shell Nanoparticles for siRNA Delivery”, Sanya, China (2008)

Peking University, School of Pharmacy, “Systematic Delivery of siRNA for Cancer Therapy”, Beijing, China (2008)

Peking University, School of Pharmacy, “A Simple Therapeutic Vaccine for Cervical Cancer”, Beijing, China (2008)

National Cancer Institute, “Targeted Delivery of siRNA for Cancer Therapy”, Frederick, MD (2008)

Louisiana State University, “Delivering siRNA for Cancer Therapy”, Baton Rouge, LA (2009)

PittCon annual conference, “Self-assembled Nanoparticles for siRNA Delivery”, Chicago, IL (2009)

American Physical Society annual meeting, “Novel Nanoparticles for siRNA Delivery”, Pittsburgh, PA (2009)

Conference on “Liposomes and Nanotechnology”, Itaparica, Brazil (2009)

Chinese University of Hong Kong, “Non-viral Gene Therapy”, Hong Kong (2009)

Chinese University of Hong Kong, “Deliver siRNA for Cancer Therapy”, Hong Kong (2009)

Shenzhen University, “Deliver siRNA for Cancer Therapy”, Shenzhen, China (2009)

University of Science and Technology of China, “Delivery of siRNA and Peptide for Cancer Therapy”, Hefei, China (2009)

Sichuan University, “Delivery of siRNA and Peptide for Cancer Therapy”, Chengdu, China (2009)

Zhejiang University, “Delivery of siRNA and Peptide for Cancer Therapy”, Hangzhou, China (2009)

Fudan University, “Delivery of siRNA and Peptide for Cancer Therapy”, Shanghai, China (2009)

Dalian Nationalities University, “Deliver siRNA for Cancer Therapy”, Dalian, China (2009)

Dalian Institute of Chemistry and Physics, “Smart Nanoparticles for siRNA delivery”, Dalian, China (2009)

4th International Conference in Advanced Drug Delivery, “Delivery of siRNA for Cancer Therapy”, Shanghai, China (2009)

China Pharmaceutical University, “Nanoparticle Delivery of siRNA”, Nanjing, China (2009)

University of Florida, “Delivery of siRNA for Cancer Therapy”, Gainesville, FL (2009)

National Central University, “Self-Assembled Nanoparticles Evading RES”, Chung-Li, Taiwan (2009)

Chung Yuan Christian University, “Delivering siRNA for Cancer Therapy”, Chung-Li, Taiwan (2009)

National Health Research Institute, “The Challenge of siRNA Delivery”, Zhunan, Taiwan (2009)

University of Washington, “Delivering siRNA for Cancer Therapy”, Seattle, WA (2009)

Gakushuin University, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Tokyo, Japan (2010)

Hoshi University of Pharmaceutical Sciences, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Tokyo, Japan (2010)

Teikyo University, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Tokyo, Japan (2010)

Kyoto University, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Kyoto, Japan (2010)

Shizuoka University, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Shizuoka, Japan (2010)

Dana Farber Cancer Institute, Harvard Medical School, “The Challenge of Delivering siRNA to The Tumor”, Boston, MA (2010)

Yale University, “Nanoparticle Delivery of siRNA to Tumors”, New Haven, CT (2010)

Purdue University, “Delivery of siRNA for Cancer Therapy”, West Lafayette, IN (2010)

Penn State Hershey College of Medicine, “The challenge of delivering siRNA to tumor cells”, Hershey, PA (2010)

Beijing University, School of Pharmacy, “Nanoparticle Delivery of siRNA to Tumors”, Beijing, China (2010)

Third Military Medical University, “Nanoparticle Delivery of siRNA to Tumors”. Chongqing, China (2010)

Sichuan University, Institute of Biomaterials Science, “Novel Membrane/Core Nanostructures for siRNA Delivery”, Chengdu, China (2010)

Sichuan University, School of Pharmacy, “Nanoparticle Delivery of siRNA to Tumors”, Chengdu, China (2010)

Liposome Research Days conference, “A New Endosome Release Mechanism for Nanoparticle Mediated siRNA Delivery”, Vancouver, Canada (2010)

Gordon Conference in “Drug Carriers in Biology and Medicine”, “Escaping RES and Endosome”, Waterville Valley

Resort, NH (2010)

Vanderbilt University, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Nashville, TN (2010)

Rutgers University, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Piscataway, NJ (2010)

International Vaccine Conference, National Health Research Institute, Taiwan, “Delivery of siRNA and Vaccine for Cancer Therapy”, Zhunan, Taiwan (2010)

Keynote speaker, “Nanoparticle Delivery of siRNA for Cancer Therapy“, Symposium on Drug Delivery and Biomedical Sciences, Chung Yuan Christian University, Chung-Li, Taiwan

NanoDDS10 symposium, “Nanoparticles Escaping Reticuloendothelial System and Endosome: A PEG Dilemma?” Omaha, NE (2010)

Focused group discussion on “Image Guided Drug Delivery”, National Cancer Institute, Bethesda, MD (2010)

Short Course on Nanotechnology, “The Challenge of siRNA Delivery”, AAPS/FIP annual meeting, New Orleans, LA (2010)

Round Table Discussion on Targeted Delivery of Theranostics, “Nanoparticles Escaping Reticuloendothelial System and Endosome” AAPS/FIP annual meeting, New Orleans, LA (2010)

National Center for Nanoscience and Technology of China, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Beijing, China (2011)

Sun Yat-Sen University, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Guangzhou, China (2011)

National Taiwan University, “Evading Reticuloendothelial System and Escaping Endosome: Challenges in Nanoparticle Mediated Drug Delivery”, Taipei, Taiwan (2011)

Chang Gung University, “Nanoparticle Delivery of siRNA for Cancer Therapy”, Tao-Yuan, Taiwan (2011)

2011 International Advanced Drug Delivery Symposium, “LCP Nanoparticles for Drug and Gene Delivery”, Hsinchu, Taiwan (2011)

Liposomes Jerusalem 2011, “Lipidic Nanoparticles: Escaping RES and Endosomes for Enhanced siRNA Delivery”, Jerusalem, Israel (2011)

Gordon Research Conference on “Cancer Nanotechnology”, “Nanoparticles Escaping RES and Endosome for Efficient Cytoplasmic Delivery”, Waterville, ME (2011)

Sun Yat-San University, “Nanoparticle Delivery of siRNA to Tumor”, Guangzhou, China, (2011)

Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, “Nanoparticle Delivery of siRNA to Tumor”, Shenzhen, China (2011)

Union Hospital, “Nanoparticle Delivery of Genes and siRNA to Tumor and Liver”, Wuhan, China (2011)

Zhejiang University, “Nanoparticle Delivery of Genes and siRNA to Tumor and Liver”, Hangzhou, China (2011)

University of Georgia, “Delivery of Genes and siRNA to Tumor and Liver”, Athens, GA (2012)

University of Michigan, “Membrane/Core Nanoparticles for Drug/Gene Delivery”, Ann Arbor, MI (2012)

University of Queensland, “Nanoparticle Delivery of Genes and Drugs to Tumor and Liver”, Brisbane, Queensland, Australia (2012)

CSIRO, “Nanoparticle Delivery of Genes and Drugs to Tumor and Liver”, Clayton, Melbourne, Australia (2012)

University of New South Wales, “Nanoparticle Delivery of Genes and Drugs to Tumor and Liver”, Sydney, Australia (2012)

Symposium of Advanced Nanomaterials in Biomedicine, “Nanoparticle Delivery of Genes and Drugs to Tumor and Liver”, Chung Yuan Christian University, Chung-Li, Taiwan (2012)

National Tsing Hua University, “Nanoparticle Delivery of Genes and Drugs to Tumor and Liver”, Hsin-Chu, Taiwan (2012)

Xi’An Jiaotong University, “Nanoparticle Delivery of Genes and Drugs to Tumor and Liver”, Xi’An, China (2012)

Fourth Military Medical University, “Nanoparticle Delivery of Genes and Drugs to Tumor and Liver”, Xi’An, China (2012)

Ninth World Biomaterials Congress, “LCP Nanoparticles Effectively Deliver siRNA and Drugs to Cancer Cells”, Chengdu, China (2012)

Sichuan University, “Nanoparticle Delivery of Plasmid DNA to the Liver”, Chengdu, China (2012)

Southwest Jiaotong University, “Nanoparticle Delivery of Genes and Drugs to Tumor and Liver”, Chengdu, China

(2012)

- Annual meeting, Canadian Society for Pharmaceutical Scientists, “Nanoparticle Delivery of siRNA and Chemotherapy to Tumors”, Toronto, Canada (2012)
- UC Davis Cancer Center, University of California Davis, “Nanoparticle Delivery of Genes and siRNA to Tumor and Liver”, Sacramento, CA (2012)
- University of Sao Paulo, Sinospq conference, “Gene Therapy”, Ribeirao Preto, Brazil (2012)
- University of Toronto, Faculty of Pharmacy, “Calcium Phosphate Nanoparticles Coated with a Single Lipid Bilayer Efficiently Deliver cDNA and siRNA to Hepatocytes”, Toronto, Canada (2012)
- University of Pittsburgh, School of Pharmacy, “Calcium Phosphate Nanoparticles Coated with a Single Lipid Bilayer Efficiently Deliver cDNA and siRNA to Hepatocytes”, Pittsburgh, PA (2012)
- China Bio conference, Shanghai Jiaotong University, “Novel formulations for gemcitabine and cisplatin”, Shanghai, China (2012)
- Shanghai Institute of Materials Medica, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver”, Shanghai, China (2012)
- Liposome Research Days conference, “Intravenous Delivery of Plasmid DNA to Hepatocytes”, Hangzhou, China (2012)
- Zhejiang University, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver”, Hangzhou, China (2012)
- Fudan University, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver”, Shanghai, China (2012)
- Second Military Medical University, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver”, Shanghai, China (2012)
- NCI Cancer Nanotechnology Alliances Conference, “A Novel Cisplatin Nanoformulation with a Bystander Effect”, Houston, TX (2012)
- MD Anderson Cancer Center, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver”, Houston, TX (2012)
- Johns Hopkins University, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver”, Baltimore, MD (2012)
- AAPS Webnar, “Potential of Nanotechnology in Gene Therapy” (2013)
- University of North Carolina at Chapel Hill, Carolina Center for Cancer Nanotechnology Excellence, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver” (2013)
- Chung Yuan Christian University, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver”, Taiwan (2013)
- University of Memphis, “Nanoparticle Delivery of Genes and siRNA to Hepatocytes In Vivo” (2013)
- Stanford University, “Lipid-Calcium-Phosphate (LCP) Nanoparticles for Drug and Gene Delivery” Palo Alto, CA (2013)
- Peking University, School of Chemistry and Chemical Engineering, co-lectured with Professor Michael Jay in “Drug Delivery”, an intensive course for 5 days (2013)
- Peking University, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver” (2013)
- Fudan University, School of Pharmaceutical Sciences, “Liposomes – Anything New?” (2013)
- Fudan University, School of Pharmaceutical Sciences, “LPD Nanoparticles for Cancer Therapy” (2013)
- Fudan University, School of Biology and Biotechnology, “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver” (2013)
- Shanghai Jiaotong University, “Liposomes – Anything New?” (2013)
- Fourth Military Medical University, “Lipid-Calcium-Phosphate (LCP) Nanoparticles for Drug and Gene Delivery” (2013)
- Nanjing University, “Lipid-Calcium-Phosphate (LCP) Nanoparticles for Drug and Gene Delivery” (2013)
- Georgia State University, “LPD Nanoparticles for Drug and Gene Delivery” (2013)
- Harbin Medical University, China, “Lipidic Nanoprecipitates for Drug and Gene Delivery” (2013)

Fudan University, School of Pharmaceutical Sciences, “Cancer Drug Delivery”, a short course for 4 days (2013)

Huazhong University of Science and Technology, School of Biology and Biotechnology, “EPR Effect, Tumor Microenvironment and Stealth Nanoparticles”, Wuhan, China (2013)

Huazhong University of Science and Technology, School of Pharmacy, “Drug Delivery Using Liposomes with a Solid Precipitate Core”, Wuhan, China (2013)

Chinese Pharmaceutical Conference, “Lipidic Nanoprecipitates for Drug and Gene Delivery”, Wuhan, China (2013)

Zhejiang University, Department of Chemical and Biological Engineering, “EPR Effect, Tumor Microenvironment and Stealth Nanoparticles”, Hangzhou, China (2013)

Chung Yuan Christian University, “Cancer Drug Delivery”, a 2-day short course, Taiwan (2013)

Distinguished Pharmaceutical Scientist Award speech “Liposomes Supported by an Inner Nano-Precipitate Encapsulating Drugs and/or Nucleic Acids”, San Antonio, TX (2013)

Mini-Symposium on “Lipid-Based Nanoprecipitates for siRNA Delivery”, American Society of Pharmaceutical Scientists annual meeting, San Antonio, TX (2013)

National Taiwan University, School of Pharmacy, “Lipid-coated Nano-precipitate for Drug and Gene Delivery”, Taipei, Taiwan (2013)

Virginia Tech, “Lipid-Calcium-Phosphate (LCP) Nanoparticles for Drug and Gene Delivery”, Blacksburg, VA (2014)

National Health Research Institute, “Tumor Microenvironment: Opportunities and Challenges for Nanoparticle Mediated Therapy”, Zhunan, Taiwan (2014)

National Tsing Hua University, “Remodeling Tumor Microenvironment by Nanomedicines”, Hsinchu, Taiwan (2014)

University of Texas at Dallas, “Lipid-coated Nano-precipitate for Drug and Gene Delivery”, Dallas, TX (2014)

University of Pennsylvania, “Lipid-coated Nano-precipitate for Drug and Gene Delivery”, Philadelphia, PA (2014)

5th FIP Pharmaceutical Sciences World Congress, Symposium on “Nanotechnologies for drug delivery”, “Remodeling tumor microenvironment to improve therapy”, Melbourne, Australia (2014)

5th FIP Pharmaceutical Sciences World Congress, Symposium on “Gene-based therapeutics: Possibilities and challenges”, “Delivering Plasmid DNA to Hepatocyte Nuclei”, Melbourne, Australia (2014)

Cross-Strait Biomaterials and Controlled Drug Release Symposium, “Remodeling Tumor Microenvironment to Improve Therapy”, Hsinchu, Taiwan (2014)

Peking University, School of Pharmacy, “Remodeling Tumor Microenvironment to Improve Drug Delivery”, Beijing, China (2014)

Suzhou University, School of Pharmacy, “Remodeling Tumor Microenvironment to Improve Drug Delivery”, Suzhou, China (2014)

Liposome Research Days Conference, “Liposomal Cisplatin Precipitate as a Tool to Study Tumor Microenvironment”, Copenhagen, Denmark (2014)

Virginia Commonwealth University, Department of Biomedical Engineering, “Lipid-Calcium-Phosphate (LCP) Nanoparticles for Drug and Gene Delivery”, Richmond, Virginia (2014)

Fudan University, School of Pharmaceutical Sciences, “Remodeling Tumor Microenvironment to Empower Therapy”, Shanghai, China (2014)

Shanghai Institute of Cancer Research, “Remodeling Tumor Microenvironment to Empower Therapy”, Shanghai, China (2014)

China Pharmaceutical Conference, “Liposomal Cisplatin Precipitate as a Tool to Study Tumor Microenvironment”, Changsha, China (2014)

Central China University of Science and Technology, Tongji School of Pharmacy, “Remodeling Tumor Microenvironment to Empower Therapy”, Wuhan, China (2014)

Hubei College of Science and Technology, School of Pharmacy, “Nanoparticle Mediated Cancer Therapy”, Xianning, Hubei, China (2014)

Zhejiang University, Research Retreat, “Remodeling Tumor Microenvironment to Empower Therapy”, Hangzhou, China (2014)

Academia Sinica, Institute of Cellular and Organismic Biology, “Modulating Tumor Microenvironment to Empower Therapy”, Taipei, Taiwan (2014)

NanoDDS2014 conference, Keynote speaker, “Nanoparticle Remodeling of Tumor Microenvironment to Improve Therapy”, Chapel Hill, NC (2014)

Annual symposium, China Nanomedicine Society, Keynote speaker, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Hangzhou, China (2015)

Shenyang Pharmaceutical University, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Shenyang, China (2015)

Institute of Process Engineering, Chinese Academy of Sciences, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Beijing, China (2015)

Peking University, Department of Biomedical Engineering, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Beijing, China (2015)

Sino-German Youth Forum in Inorganic Nano Materials for Drug Delivery, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Shanghai, China (2015)

Boston University, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Boston, MA (2015)

University of North Texas Health Science Center, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Fort Worth, TX (2015)

Australian Society of Nanomedicine, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Sydney, AU (2015)

University of New South Wales, “Lipid-stabilized nano-precipitates for drug and gene delivery”, Sydney, AU (2015)

University of Queensland, “Lipid-stabilized nano-precipitates for drug and gene delivery”, Brisbane, AU (2015)

Monash Institute of Pharmaceutical Sciences, “Lipid-stabilized nano-precipitates for drug and gene delivery”, Melbourne, AU (2015)

Chung Yuan Christian University, “Lipid-stabilized calcium phosphate nanoparticles for drug and gene delivery”, Taiwan (2015)

Chinese University of Hong Kong, “Lipid-stabilized nano-precipitates for drug and gene delivery”, Hong Kong (2015)

Wayne State University, “Lipid-stabilized nano-precipitates for drug and gene delivery”, Detroit (2015)

Vancouver Nanomedicine Day, “Lipid-stabilized nano-precipitates for drug and gene delivery”, Vancouver, Canada (2015)

University of Delaware, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Newark, DE (2016)

Tufts University, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Boston, MA (2016)

North Carolina State University, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Raleigh, NC (2016)

University of Oklahoma, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Oklahoma City, OK (2016)

Asian Symposium of Pharmaceutical Sciences, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Shenyang, China (2016)

Changchun Institute of Applied Chemistry, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Changchun, China (2016)

Jiangxi University of Traditional Chinese Medicine, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Nanchang, China (2016)

Shanghai University of Traditional Chinese Medicine, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Shanghai, China (2016)

Fudan University, School of Pharmaceutical Sciences, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Shanghai, China (2016)

Fudan University, State Key Lab of Molecular Engineering of Polymers, “Nanoparticle delivery of drugs and genes

to desmoplastic tumors”, Shanghai, China (2016)

East China University of Science and Technology, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Shanghai, China (2016)

48th annual Pharmaceuticals Graduate Student Research Meeting, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, University of Missouri at Kansas City, Kansas City, MO (2016)

Keynote speaker, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Chinese American Society of Nanomedicine and Nanobiotechnology, Beijing (2016)

Peking University, School of Pharmacy, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Beijing, China (2016)

Beijing Institute of Pharmacology and Toxicology, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Beijing, China (2016)

Sichuan University, School of Pharmacy, “Cancer Drug Delivery”, a condensed course, Chengdu, China (2016)

University of Nebraska Medical Center, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Omaha, NA (2016)

North Carolina State University, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Raleigh, NC (2016)

Kao-Hsiung Medical University, “Nanoparticle delivery of drugs and genes to desmoplastic tumors”, Kao-Hsiung, Taiwan (2017)

Chung Yuan Christian University, “Targeting neighbors: A new approach in drug delivery”. Chung-Li, Taiwan (2017).

National Tsing Hua University, “Targeting neighbors: A new approach in drug delivery”. Hsin-Chu, Taiwan (2017).

North Carolina State University, “Targeting neighbors: A new approach in drug delivery”. Raleigh, NC (2017).

University of Pennsylvania, “Nanoparticle delivery of drugs and genes to desmoplastic tumors: Targeting neighbors”, Philadelphia, PA (2017)

Washington University at St. Louis, “Nanoparticle delivery of drugs and genes to desmoplastic tumors: Targeting neighbors”, St. Louis, MO (2017)

Gordon Research Conference on Cancer Nanotechnology, “Targeting Tumor Associated Fibroblasts for Therapy”, West Dover, VT (2017)

Fudan University, School of Pharmaceutical Sciences, “Targeting Tumor Associated Fibroblasts for Therapy”, Shanghai, China (2017)

Chinese University of Hong Kong, “Targeting Tumor Associated Fibroblasts for Therapy”, Hong Kong (2017)

Invited speaker, “Translational Research and Entrepreneur Activity: My Personal Experience with Two Start-Ups”, Chinese American Society of Nanomedicine and Nanobiotechnology. Suzhou, China (2017)

National Center for Nano Science & Technology, “Nanoparticle Exploration of Tumor Microenvironment in Desmoplastic Cancer”. Beijing, China (2017)

Tsinghua University, School of Pharmaceutical Sciences, “Nanoparticle Exploration of Tumor Microenvironment in Desmoplastic Cancer”. Beijing, China (2017)

Central South University, Xiangya School of Pharmaceutical Sciences, “Nanoparticle Exploration of Tumor Microenvironment in Desmoplastic Cancer”. Changsha, China (2017)

Nanqiang Forum for Molecular Imaging, Center for Molecular Imaging and Translational Medicine, Xiamen University, “Nanoparticle Exploration of Tumor Microenvironment in Desmoplastic Cancer”. Xiamen, China (2017)

School of Materials Science and Engineering, Xiamen University, “Nanoparticle Exploration of Tumor Microenvironment in Desmoplastic Cancer”. Xiamen, China (2017)

School of Medicine, Shanghai Jiaotong University, “Nanoparticle Exploration of Tumor Microenvironment in Desmoplastic Cancer”. Shanghai, China (2017)

Shanghai University of Traditional Chinese Medicine, “Nanoparticle Exploration of Tumor Microenvironment in Desmoplastic Cancer”. Shanghai, China (2017)

North Carolina State University, “Remodel Tumor Microenvironment for Immunotherapy”. Raleigh, NC (2018)

Nanotechnology workshop, University of North Carolina at Chapel Hill, “Overcoming the Suppressive Immune Microenvironment with Nanoparticles”, Chapel Hill (2018)

Society for Biomaterials annual meeting, “Overcoming the Suppressive Immune Microenvironment with Nanoparticles”, Atlanta, GA (2018)

Shanghai University of Traditional Chinese Medicine, “Overcoming Suppressive Immune Microenvironment of Solid Tumors”, Shanghai, China (2018)

Airforce Medical University, “Overcoming Suppressive Immune Microenvironment of Solid Tumors”, Xian, China (2018)

School of Pharmaceutical Sciences, Peking University, “Nanoparticle Remodeling the Suppressive Tumor Microenvironment for Immunotherapy”. Beijing, China (2018)

School of Pharmaceutical Sciences, Peking University, “The Creative Moments in My Research Career”, Beijing, China (2018)

School of Life Sciences, Dalian Nationality University, “Targeted Delivery of Drugs and Genes for Tumor Immunotherapy”, Dalian, China (2018)

Wuya School of Innovation, Shenyang Pharmaceutical University, “Nanoparticle Remodeling the Suppressive Tumor Microenvironment for Immunotherapy”, Shenyang, China (2018)

Wuya School of Innovation, Shenyang Pharmaceutical University, “The Creative Moments in My Research Career”, Shenyang, China (2018)

The 5th International Biomaterials Symposium, “Targeting Lipopolysaccharide to Promote Checkpoint Blockade Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis”, Changchun, China (2018)

College of Pharmacy, University of Texas Austin, “Nanoparticle Remodeling the Suppressive Tumor Microenvironment for Immunotherapy”, Austin, TX (2018)

College of Pharmacy, Virginia Commonwealth University, “Nanoparticle Remodeling the Suppressive Tumor Microenvironment for Immunotherapy”, Richmond, VA (2018)

Beijing Union Medical University, “Nanoparticle Remodeling the Suppressive Tumor Microenvironment for Immunotherapy”, Beijing, China (2018)

Shanghai University of Traditional Chinese Medicine, “Fetching an Endogenous Fibrosis Resolution Mechanism: Gene therapy for Liver Metastasis”, Shanghai, China (2018)

College of Pharmaceutical Sciences, Zhejiang University, “Nanoparticle Remodeling the Suppressive Tumor Microenvironment for Immunotherapy”, Hangzhou, China (2018)

School of Pharmaceutical Sciences, Suzhou University, “Nano-TCM Mediated Chemo-Immunotherapy for Advanced Desmoplastic Tumors”, Suzhou, China (2019)

School of Pharmaceutical Sciences, China Pharmaceutical University, “Nano-TCM Mediated Chemo-Immunotherapy for Advanced Desmoplastic Tumors”, Nanjing, China (2019)

College of Pharmaceutical Sciences, Zhejiang University, “Nano-TCM Mediated Chemo-Immunotherapy for Advanced Desmoplastic Tumors”, Hangzhou, China (2019)

College of Chemical and Biological Engineering, Zhejiang University, “Fetching an Endogenous Fibrosis Resolution Mechanism: Gene therapy for Liver Metastasis”, Hangzhou, China (2019)

Shanghai University of Traditional Chinese Medicine, “Nano-TCM Mediated Chemo-Immunotherapy for Advanced Desmoplastic Tumors”, Shanghai, China (2019)

School of Pharmaceutical Sciences, Fudan University, “Fetching an Endogenous Fibrosis Resolution Mechanism: Gene therapy for Liver Metastasis”, Shanghai, China (2019)

Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, “Targeting Tumor Microenvironment for Immunotherapy”, Shanghai, China (2019)

Canadian Society of Pharmaceutical Scientists annual symposium, “Gene Delivery to Treat Liver Metastasis of Colorectal Cancer”, Vancouver, Canada (2019)

Gordon Research Conference on Cancer Nanotechnology, “Nanotechnology for Manipulating Microbiome in Cancer”, Mt. Snow, Vermont (2019)

China Nano 2019, “Targeting Tumor Microenvironment for Immunotherapy”, Beijing, China (2019)

CASNN 2019, “Targeting Tumor Microenvironment for Immunotherapy”, Hangzhou, China (2019)
Shanghai Institute of Materia Medica, “Research Career and Life”, Shanghai, China (2019)
Renji Hospital, “Targeting Tumor Microenvironment for Immunotherapy”, Shanghai, China (2019)
Shanghai Jiao Tong University, “Targeting Tumor Microenvironment for Immunotherapy”, Shanghai, China (2019)
China Pharmaceutics Conference, “Relaxin for Liver Fibrosis Therapy”, Yantai, China (2019)
Shandong University, “Targeting Tumor Microenvironment for Immunotherapy”, Jinan, China (2019)
Zhejiang University of Traditional Chinese Medicine, “Targeting Tumor Microenvironment for Immunotherapy”, Hangzhou, China (2019)
Shanghai University of Traditional Chinese Medicine, “Chemo-Immunotherapy for Colorectal Cancer and Liver Metastasis”, Shanghai, China (2019)
Fudan University, School of Basic Medical Sciences, “Chemo-Immunotherapy for Colorectal Cancer and Liver Metastasis”, Shanghai, China (2019)
University of Florida, College of Pharmacy, “Targeting Tumor Microenvironment for Immunotherapy”, Gainesville, FL (2019)
Winter Enrichment Program, King Abdulla University of Science and Technology, “Targeting Tumor Microenvironment for Immunotherapy”, KAUST, Saudi Arabia (2020)
North Carolina State University, “Targeting Tumor Microenvironment for Immunotherapy”, Raleigh, NC (2020)
University of Tennessee Knoxville, “Targeting Tumor Microenvironment for Immunotherapy”, Knoxville, TN (2020)
Shanghai University of Traditional Chinese Medicine, “Vaccine Therapy for Solid Tumors”, via internet, Shanghai, China (2020)
Tongji University, “Targeting Tumor Microenvironment for Immunotherapy”, via internet, Shanghai, China (2020)
Innovations and Transformations in Pharmaceutical Sciences-Virtual 2020, “Targeting Tumor Microenvironment for Immunotherapy”, via Zoom. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC (2020)
Carolina Nanomedicine Workshop, “Nanoparticles for Immunotherapy and TME Modulation”, via Zoom, University of North Carolina at Chapel Hill, NC (2020)
Shanghai University of Traditional Chinese Medicine, “Colorectal Cancer Therapy: Preclinical Studies”, via Zoom, Shanghai, China (2020)
Keynote speaker, Second Annual ADME: Lead Characterization and Optimization Conference, “Chemo-immunotherapy for Colorectal Cancer and Liver Metastasis”, via Zoom, Gulf Coast Consortia, Houston (2020)
Keynote speaker, “Blocking Bacterial Lipopolysaccharide to Relieve Immune Suppression in Colorectal Cancer”, via internet, AAPS PharmSci360 (2020)
Northeastern University, “Nanomedicine Targeting Tumor Microenvironment” via Zoom, Boston (2020)
Keynote speaker, 8th International E-Congress on Nanoscience & Nanotechnology, “Targeting Tumor Microenvironment for Immunotherapy”, via internet. Mashhad University of Medical Sciences, Mashhad, Iran (2021)
Education session, Annual meeting of the American Association for Cancer Research, “Nano-FOLFOX for Cancer Therapy”, via Zoom, (2021)
Pharmaceutics Conference, Shanghai Pharmaceutical Association, “Targeting Tumor Microenvironment for Immunotherapy”, via Zoom, (2021)
Keynote speaker, NanoTME2021 virtual conference, “Nano Intervention of Tumor Microenvironment to Improve Therapy”, via Zoom, (2021)
National Taiwan University, College of Pharmacy, “Nano Intervention of Tumor Microenvironment to Improve Therapy”, via internet, (2021)
Zhejiang University, School of Pharmacy, “Overcoming Tumor Microenvironment for Therapy”, “Cancer Immunotherapy and Vaccine”, via Zoom, (2022)
Shenyang Pharmaceutical University, “Macromolecular Nucleic Acid Drugs”, via internet, (2022)

Liposome Research Days conference, “Liposomal Antibiotics Induces Anticancer Immunity by Killing the Tumor Associated Bacteria”, Vancouver, Canada, (2022)

Xi’An Jiao Tong Liverpool University, “Macromolecular Nucleic Acid Drugs”, via internet, (2022)

Industrial Presentations (since 1995):

Somatix Seminar, Gene Transfer and Gene Therapy, “Nonviral supramolecular assemblies for gene transfer”, Alameda, CA (1995)

Roche Bioscience, “Supramolecular assemblies for gene transfer”, Palo Alto, CA (1995)

Targeted Genetics, Inc., “Supramolecular assemblies for gene transfer”, Seattle, WA (1996)

Introgen Therapeutics, Inc., “Supramolecular assemblies for gene transfer”, Houston, TX (1996)

ASTRA, “Supramolecular assemblies for gene transfer”, Stockholm, Sweden (1996)

Fournier, “Novel lipidic vectors for gene”, France (1997)

Vical, Inc. “Progress in non-viral vector development”, La Jolla, CA (1997)

Genzyme Corporation, “Cationic lipids: advantages and limitations in systemic gene transfer.” Framingham, MA (1998)

RPR Gencell, “Novel Non-Viral Vectors for Gene Therapy”, Hayward, CA (1999)

Pfizer, Inc., “Non-Viral DNA Delivery”, Groton, CT (1999)

Aventis Pharma, “Non viral lipidic systems for gene delivery”, Paris, France (2000)

Abbott Pharmaceutical Co., “Advance in Gene Delivery Using Non-Viral Vectors”, Chicago, IL (2001)

Chicagoland Pharmaceutical Discussion Group (CPDG), Chicago College of Pharmacy, “Advance in Gene Delivery Using Non-Viral Vectors”, Chicago, IL (2001)

Genzyme, “Gene Transfer to Muscles with Naked DNA” Framingham, MA (2001)

Purdue Pharma, “LPD nanoparticles as a potent cancer vaccine carrier”, NJ (2004)

Alnylam Pharmaceuticals, Inc. “Delivery of siRNA to tumor cells”, Boston, MA (2007)

Eisai Pharmaceuticals, Inc. “Targeting drugs and siRNA to tumor cells in animal models”, Research Triangle Park, NC (2007)

Merck, Inc. “Delivery of siRNA to Solid Tumor”, Philadelphia, PA (2007)

Eli Lilly, “Delivery of siRNA with Self-assembled Nanoparticles”, Indianapolis, IN (2007)

GlaxoSmithKline, “Delivery of siRNA with Non-viral Vectors”, London, UK (2007)

Abbott Laboratories, “Delivery of siRNA for Tumor Therapy”, Abbott Park, IL (2008)

Silence Therapeutics, “Systemic Delivery of siRNA for Cancer Therapy”, Berlin, Germany (2008)

Pfizer, “Delivery of siRNA for Cancer Therapy”, Cambridge, MA (2008)

PPD, Inc., “Delivery of siRNA for Cancer Therapy”, Morrisville, NC (2008)

Roche, “Delivery of siRNA for Cancer Therapy”, Nutley, NJ (2008)

Entegron, Inc. “Nanoparticles Evading RES and Delivering siRNA to Tumor Cells”, Durham, NC (2009)

Life Technologies, Inc. “Nanoparticle Delivery of siRNA to Tumor Cells”, Carlsbad, CA (2009)

Life Technologies, Inc. “Nanoparticle Delivery of siRNA to Tumor Cells”, Austin, TX (2009)

Nitto Denko Technology, “Nanoparticles Escaping Reticuloendothelial System and Endosome”, Oceanside, CA (2010)

Dicerna Pharmaceuticals, Inc. “Nanoparticle Delivery of siRNA for Cancer Therapy”, Boston, MA (2010)

Ribo Pharmaceuticals, Inc. “Membrane/Core Nanoparticles for Drug and Gene Delivery to Tumor and Liver”, Kunshan, China (2012)

Novartis, Inc., “Lipid-Calcium-Phosphate (LCP) Nanoparticles for Nucleic Acid Delivery” Boston, MA (2013)

Luye Sike Pharmaceutical Co., “Lipid-Calcium-Phosphate (LCP) Nanoparticles for Drug and Gene Delivery”, Nanjing, China (2013)

Hisun Pharmaceutical Company, “Lipid-Calcium-Phosphate (LCP) Nanoparticles for Drug and Gene Delivery”, Hangzhou, China (2014)

Bristol-Myers Squibb, “Lipid-Stabilized Nanoprecipitates for Gene Delivery”, East Brunswick, NJ (2017)

Wuxi BioPharma Forum, “Drug Delivery Systems: Current Status and Challenges”, Wuxi, China (2018)

Novo Nordisk, “Relaxin Gene Therapy for Liver Fibrosis”, via Team (2021)

Major Research Interest:

Gene therapy; Drug delivery and targeting; Liposome technology; Tumor microenvironment; Cancer vaccine;
Tumor associated bacteria

PUBLICATIONS

H-index: 141 (as of Jan 5, 2023)

Total Citations: 75,570

Google Scholar

Dissertation:

1. Structure and function of *Acholeplasma* membranes - effects of lipid chain length and carotenoid pigments. Ph.D. dissertation, Michigan State University, 1974.

Peer Reviewed Articles:

1. **Huang, L.**, Jaquet, D.D. and Haug, A. The effect of fatty acyl chain length on some structural and functional parameters of *Acholeplasma* membranes. *Canad. J. Biochem.* 52:483-490, 1974.
2. **Huang, L.** and Haug, A. Regulation of membrane lipid fluidity in *Acholeplasma laidlawii*: effect of carotenoid pigment content. *Biochim. Biophys. Acta* 352:361-370, 1974.
3. **Huang, L.**, Lorch, S.K., Smith, G. and Haug, A. Regulation of membrane fluidity in *Acholeplasma laidlawii*. *FEBS Letters* 43:1-5, 1974.
4. Hsung, J.C., **Huang, L.**, Hoy, D. and Haug, A. Lipid and temperature dependence of membrane bound ATPase activity of *Acholeplasma laidlawii*. *Canad. J. Biochem.* 52:974-980, 1974.
5. Pagano, R.E., **Huang, L.** and Wey, C. Interaction of phospholipid vesicles with cultured mammalian cells. *Nature* 252:166, 1974.
6. **Huang, L.** and Pagano, R.E. Interactions of phospholipid vesicles with cultured mammalian cells. I. characteristics of uptake. *J. Cell Biol.* 67:38-48, 1974.
7. Pagano, R.E. and **Huang, L.** Interaction of phospholipid vesicles with cultured mammalian cells. II. studies of mechanism. *J. Cell Biol.* 67:49-60, 1975.
8. Ozato, K., **Huang, L.** and Ebert, J.D. Accelerated calcium ion uptake in murine thymocytes induced by concanavalin A. *J. Cell. Physiol.* 93:153-160, 1977.
9. **Huang, L.**, Ozato, K. and Pagano, R.E. Interactions of phospholipid vesicles with murine lymphocytes. I. vesicle-cell adsorption and fusion as alternate pathways of uptake. *Memb. Biochem.* 1:1-25, 1978.

10. Ozato, K., **Huang, L.** and Pagano, R.E. Interactions of phospholipid vesicles with murine lymphocytes. II. correlation between altered surface properties and enhanced proliferative response. *Memb. Biochem.* 1:27-42, 1978.
11. Wilkins, J.A., Greenawalt, J.W. and **Huang, L.** Transport of 5-hydroxytryptamine by dense granules from porcine platelets. *J. Biol. Chem.* 253:6260-6265, 1978.
12. **Huang, L.** Transmembrane nature of acetylcholine receptor as evidenced by protease sensitivity. *FEBS Letters* 102:9-12, 1979.
13. **Huang, L.** and Kennel, S.J. Binding of immunoglobulin G to phospholipid vesicles by sonication. *Biochemistry* 18:1702-1707, 1979.
14. Chang, B.C. and **Huang, L.** Synthesis and characterization of a new fluorescent phospholipid. *Biochim. Biophys. Acta* 556:52-60, 1979.
15. Adrian, G. and **Huang, L.** Entrapment of proteins in phosphatidylcholine vesicles. *Biochemistry* 18:5610-5614, 1979.
16. West, L.K. and **Huang, L.** Transient permeability changes induced osmotically in membrane vesicles from *Torpedo* electroplax: a mild procedure for trapping small molecules. *Biochemistry* 19:4418-4423, 1980.
17. Lawman, M.J.P., Naylor, P.T., **Huang, L.**, Courtney, R.J. and Rouse, B.T. Cell mediated immunity to Herpes Simplex virus: induction of cytotoxic T lymphocyte responses by viral antigens incorporated into liposomes. *J. Immunol.* 126:304-308, 1980.
18. Huang, A., **Huang, L.** and Kennel, S.J. Monoclonal antibody covalently coupled with fatty acid: a reagent for in vitro liposome targeting. *J. Biol. Chem.* 255:8015-8018, 1980.
19. Huang, A., Kennel, S.J. and **Huang, L.** Immunoliposome labeling: a sensitive and specific method for cell surface labeling. *J. Immunol. Meth.* 46:141-151, 1981.
20. Lee, H.H. and **Huang, L.** Initiation of developmental biology in the People's Republic of China. *J. Tenn. Acad. Sci.* 56:110-111, 1981.
21. Grant, S.R., Babbitt, B.P., West, L. and **Huang, L.** A model system for studies of specific membrane interactions. *Biochemistry* 21:1274-1279, 1982.
22. West, L.K. and **Huang, L.** Acetylcholine receptor-mediated sodium ion efflux after rapid hypo-osmotic loading of radiotracer. *Arch. Biochem. Biophys.* 215:508-513, 1982.
23. Huang, A., Tsao, Y.S., Kennel, S.J. and **Huang, L.** Characterization of antibody covalently coupled to liposomes. *Biochim. Biophys. Acta* 716:140-150, 1982.
24. Ho, S.C. and **Huang, L.** Transfer of *Torpedo* acetylcholine receptors to mouse L-cell surface membranes by liposomes containing Sendai virus envelope proteins. *Eur. J. Cell Biol.* 27:221-229, 1982.

25. Naylor, P.T., Larsen, H.S., **Huang, L.** and B.T. Rouse. *In vivo* induction of anti-Herpes Simplex virus immune response by HSV-1 antigens and lipid A incorporated into liposomes. *Infection and Immunity* 36:1209-1216, 1982.
26. Shen, D.F., Huang, A. and **Huang, L.** An improved method for covalent attachment of antibody to liposomes. *Biochim. Biophys. Acta* 689:31-37, 1982.
27. Pool, G.L., French, M.E., Edwards, R.A., **Huang, L.** and Lumb, R.H. Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. *Lipids* 17:448-452, 1982.
28. Ho, S.C. and **Huang, L.** A novel cytochemical marker for liposome decomposition in lysosomes. *J. Histochem. Cytochem.* 31:404-410, 1983.
29. Carpenter-Green, S. and **Huang, L.** Incorporation of acylated wheat germ agglutinin into liposomes. *Analyt. Biochem.* 135:151-155, 1983.
30. Huang, A., Kennel, S.J. and **Huang, L.** Interactions of immunoliposomes with target cells. *J. Biol. Chem.* 258:14034-14040, 1983.
31. Connor, J., Yatvin, M.B. and **Huang, L.** pH-sensitive liposomes: acid induced liposome fusion. *Proc. Natl. Acad. Sci. U.S.A.* 81:1715-1718, 1984.
32. Babbitt, B.P., **Huang, L.** and Freire, E. Thermotropic and dynamic characterization of interactions of acylated alpha-bungarotoxin with phospholipid bilayer membranes. *Biochemistry* 23:3920-3926, 1984.
33. Wang, C.-Y. and **Huang, L.** Polyhistidine mediates an acid dependent fusion of negatively charged liposomes. *Biochemistry* 23:4409-4416, 1984.
34. Tsao, Y.-S. and **Huang, L.** Sendai virus-induced leakage of liposomes containing gangliosides. *Biochemistry* 24:1092-1098, 1985.
35. **Huang, L.** Incorporation of acylated antibody into planar lipid multilayers: characterization and cell binding. *Biochemistry* 24:29-34, 1985.
36. Babbitt, B.P. and **Huang, L.** α -bungarotoxin attached to and oriented on a lipid bilayer vesicle surface. *Biochemistry* 24:15-21, 1985.
37. Babbitt, B.P. and **Huang, L.** Effects of valency on thermodynamic parameters of specific membrane interaction. *Biochemistry* 24:2186-2194, 1985.
38. Sullivan, S.M. and **Huang, L.** Preparation and characterization of heat-sensitive immunoliposomes. *Biochim. Biophys. Acta* 812:116-126, 1985.
39. Connor, J. and **Huang, L.** Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive immunoliposomes. *J. Cell Biol.* 101:582-589, 1985.
40. Ho, R.J.-Y. and **Huang, L.** Interactions of antigen sensitized liposomes with immobilized antibody: a homogeneous solid-phase immunoliposome assay. *J. Immunol.* 134:4035-4040, 1985.

41. Kabalka, G.W., Varma, R.S., Jinaraj, V.K., **Huang, L.** and Painter, S.K. Synthesis of iodine-125 labeled w-iodoundecyl cholesteryl ether. *J. Labeled Compounds and Radiopharmaceuticals* 22:333-338, 1985.
42. Norley, S.G., **Huang, L.** and Rouse, B.T. Targeting of drug loaded immunoliposomes to Herpes Simplex virus infected corneal cells--an effective means of inhibiting virus replication *in vitro*. *J. Immunol.* 136:681-685, 1986.
43. Tsao, Y.S. and **Huang, L.** Kinetic studies of Sendai virus-target membrane interactions: independent analysis of binding and fusion. *Biochemistry* 25:3971-3976, 1986.
44. Connor, J. and **Huang, L.** pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. *Cancer Res.* 46:3431-3435, 1986.
45. Tsusaki, B.E., Kanda, S. and **Huang, L.** Stimulation of superoxide release in neutrophils by 1-oleoyl-2-acetyl glycerol incorporated into pH-sensitive liposomes. *Biochem. Biophys. Res. Commun.* 136:242-246, 1986.
46. Ho, R.J.Y., Rouse, B. and **Huang, L.** Target-sensitive immunoliposomes: preparation and characterization. *Biochemistry* 25:5500-5506, 1986.
47. Wang, C.-Y., Hughes, K. and **Huang, L.** Improved cytoplasmic delivery to plant protoplasts via pH- sensitive liposomes. *Plant Physiol.* 82:179-184, 1986. PMID 1056086
48. Sullivan, S.M. and **Huang, L.** Enhanced delivery to target cells by heat sensitive immunoliposomes. *Proc. Natl. Acad. Sci. U.S.A.* 83:6117-6121, 1986.
49. Ho, R.J.Y., Rouse, B.T. and **Huang, L.** Destabilization of target-sensitive immunoliposomes by antigen-binding- a rapid assay for virus. *Biochem. Biophys. Res. Commun.* 138:931-937, 1986.
50. Connor, J., Norley, N. and **Huang, L.** Biodistribution of pH-sensitive liposomes. *Biochim. Biophys. Acta* 884:474-481, 1986.
51. Hu, L.R., Ho, R. and **Huang, L.** Trypsin induced destabilization of liposomes composed of dioleoylphosphatidylethanolamine and glycophorin. *Biochem. Biophys. Res. Commun.* 141:973-978, 1986.
52. Kabalka, G., Buonocore, E., Hubner, K., Moss, T., Norley, N. and **Huang, L.** Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. *Radiology* 163:255-258, 1987.
53. Gao, K. and **Huang, L.** Preparation of colloidal gold labeled agarose-gelatin microspherules for electron microscopic studies of phagocytosis in cultured cells. *J. Histochem. Cytochem.* 35:163-173, 1987.
54. Norley, S., Sendele, D., **Huang, L.** and Rouse, B. Inhibition of herpes simplex replication in the mouse cornea by drug containing immunoliposomes. *Invest. Ophthalmol. Vis. Sci.* 28:591-595, 1987.
55. Collins, D. and **Huang, L.** Cytotoxicity of diphtheria toxin A fragment to toxin-resistant murine cells delivered by pH-sensitive immunoliposomes. *Cancer Res.* 47:735-739, 1987.
56. Tsao, Y.-S., Freire, E. and **Huang, L.** Thermodynamic and phase characterizations of phosphatidylethanolamine and ganglioside GD1a mixtures. *Biochim. Biophys. Acta* 900:79-87, 1987.

57. Gao, K. and **Huang, L.** Solid core liposomes with encapsulated colloidal gold particles. *Biochim. Biophys. Acta* 897:377-383, 1987.
58. Houck, K.S. and **Huang, L.** The role of multivalency in antibody mediated liposome targeting. *Biochem. Biophys. Res. Commun.* 145:1205-1210, 1987.
59. Ho, R.J.Y., Rouse, B. and **Huang, L.** Target-sensitive immunoliposomes as an efficient drug carrier for antiviral activity. *J. Biol. Chem.* 262:13973-13978, 1987.
60. Ho, R.J.Y., Rouse, B. and **Huang, L.** Interactions of target-sensitive immunoliposomes with herpes simplex virus: the foundation of a sensitive immunoliposome assay for the virus. *J. Biol. Chem.* 262:13979-13984, 1987.
61. Wang, C.-Y. and **Huang, L.** pH-sensitive immunoliposome mediates a target cell-specific delivery and controlled expression of a foreign gene in mouse. *Proc. Natl. Acad. Sci. USA* 84:7851-7855, 1987.
62. Wang, C.-Y. and **Huang, L.** Plasmid DNA adsorbed to pH-sensitive liposomes efficiently transforms the target cells. *Biochem. Biophys. Res. Commun.* 147:980-985, 1987.
63. Kanda, S. and **Huang, L.** Enhanced neutrophil stimulation by phorbol ester encapsulated in pH-sensitive liposomes. *J. Liposome Res.* 1:63-79, 1988.
64. Pinnaduwege, P. and **Huang, L.** A homogeneous, liposome-based signal amplification for assays involving enzymes. *Clin. Chem.* 34:268-272, 1988.
65. Ho, R.J.Y., Ting-Beall, H.P., Rouse, R. and **Huang, L.** Kinetic and ultrastructural studies of interactions of target sensitive immunoliposomes with herpes simplex virus. *Biochemistry* 27:500-506, 1988.
66. Pinnaduwege, P. and **Huang, L.** Beta-Galactosidase induced destabilization of liposome composed of phosphatidylethanolamine and ganglioside GM₁. *Biochim. Biophys. Acta* 939:375-382, 1988.
67. Kabalka, G., Buonocore, E., Hubner, K., Davis, M. and **Huang, L.** Gadolinium-labeled liposomes containing paramagnetic amphipathic agents: targeted MRI contrast agents for the liver. *Magnetic Resonance in Medicine* 8:89-95, 1988.
68. Klibanov, A., Bogdanov, A., Torchilin, V. and **Huang, L.** Biotin-bearing pH-sensitive liposomes: high-affinity binding to avidin layer. *J. Liposome Res.* 1:233-244, 1989.
69. Liu, D. and **Huang, L.** Role of cholesterol in the stability of pH-sensitive, large unilamellar liposomes prepared by detergent-dialysis method. *Biochim. Biophys. Acta* 981:254-260, 1989.
70. Liu, D. and **Huang, L.** Small, but not large, unilamellar liposomes composed of dioleoylphosphatidylethanolamine and oleic acid can be stabilized by human plasma. *Biochemistry* 28:7700-7707, 1989.
71. Liu, D., Zhou, F. and **Huang, L.** Characterization of plasma-stabilized liposomes composed of dioleoylphosphatidylethanolamine and oleic acid. *Biochem. Biophys. Res. Commun.* 162:326-333, 1989.

72. Tari, A. and **Huang, L.** Structure and function relationship of phosphatidylglycerol in the stabilization of phosphatidylethanolamine bilayer. *Biochemistry* 28:7708-7712, 1989.
73. Pinnaduwege, P., Schmitt, L. and **Huang, L.** Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. *Biochim. Biophys. Acta* 985:33-37, 1989.
74. Wang, C.-Y. and **Huang, L.** Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. *Biochemistry* 28:9508-9514, 1989.
75. Hughes, B.J., Kennel, S., Lee, R. and **Huang, L.** Monoclonal antibody targeting of liposomes to mouse lung *in vivo*. *Cancer Res.* 49:6214-6220, 1989.
76. Pinnaduwege, P. and **Huang, L.** The role of protein-linked oligosaccharide in the bilayer stabilization activity of glycophorin A for dioleoyl phosphatidylethanolamine liposomes. *Biochim. Biophys. Acta* 986:106-114, 1989.
77. Collins, D., Maxfield, F. and **Huang, L.** Immunoliposomes with different acid sensitivities as probes for the cellular endocytic pathway. *Biochim. Biophys. Acta* 987:47-55, 1989.
78. Holmberg, E., Maruyama, K., Litzinger, D.C., Wright, S., Davis, M., Kabalka, G.W., Kennel, S.J. and **Huang, L.** Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions. *Biochem. Biophys. Res. Commun.* 165:1272-1278, 1989.
79. Wright, S.E., White, J.C. and **Huang, L.** Partitioning of teniposide into membranes and the role of lipid composition. *Biochim. Biophys. Acta.* 1021:105-113, 1990.
80. Liu, D. and **Huang, L.** pH-Sensitive, plasma-stable liposomes with relatively prolonged residence in circulation. *Biochim. Biophys. Acta* 1022:348-354, 1990.
81. Brynestad, K., Babbitt, B., **Huang, L.** and Rouse, B.T. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. *J. Virol.* 64:680-685, 1990.
82. Maruyama, K., Holmberg, E., Kennel, S.J., Klivanov, A., Torchilin, V.P. and **Huang, L.** Characterization of *in vivo* immunoliposome targeting to pulmonary endothelium. *J. Pharmaceut. Sci.* 79:978-984, 1990.
83. Liu, D., **Huang, L.**, Moore, M.A., Anantharamaiah, G.M. and Segrest, J.P. Interactions of serum proteins with small unilamellar liposomes composed of dioleoylphosphatidylethanolamine and oleic acid: HDL, apolipoprotein A1 and amphipathic peptides stabilize liposomes. *Biochemistry* 29:3637-3643, 1990.
84. Zhu, Z., Hughes, K.W., **Huang, L.** and Li, X. Cationic liposome-mediated transformation of rice protoplasts. *Focus* 12:41-44, 1990.
85. Zhu, Z., Hughes, K. and **Huang, L.** Transformation of tobacco protoplasts with DNA entrapped in pH-sensitive liposomes. *Plant Cell, Tissue and Organ Culture* 22:135-145, 1990.
86. Collins, D., Litzinger, D.C. and **Huang, L.** Structural and functional comparisons of pH-sensitive liposomes composed of phosphatidylethanolamine and three different diacylsuccinylglycerols. *Biochim. Biophys. Acta* 1025:234-242, 1990.

87. Maruyama, K., Kennel, S.J. and **Huang, L.** Lipid composition is important for highly efficient target binding and retention of immunoliposomes. *Proc. Natl. Acad. Sci. USA*, 87:5744-5748, 1990.
88. Klibanov, A.L., Maruyama, K., Torchilin, V.P. and **Huang, L.** Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. *FEBS Lett.* 268:235-237, 1990.
89. Collins, D., Connor, J., Ting-Beall, H.P. and **Huang, L.** Proton and divalent cations induce synergistic but mechanistically different destabilization of pH-sensitive liposomes composed of phosphatidylethanolamine and oleic acid. *Chem. Phys. Lipids* 55:339-349, 1990.
90. Holmberg, E., Maruyama, K., Kennel, S.J., Klibanov, A., Torchilin, V., Ryan, U. and **Huang, L.** Target-specific binding of immunoliposomes *in vivo*. *J. Liposome Res.* 1:393-406, 1990.
91. Kabalka, G.W., Davis, M.A., Moss, T.H., Buonocore, E., Hubner, K., Holmberg, E. Maruyama, K. and **Huang, L.** Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. *Magn. Reson. Med.* 19:406-415, 1991.
92. Klibanov, A.L., Maruyama, K., Beckerleg, A.M., Torchilin, V.P. and **Huang, L.** Activity of amphipathic polyethyleneglycol 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. *Biochim. Biophys. Acta.* 1062:142-148, 1991.
93. Kabalka, G.W., Davis, M.A., Holmberg, E., Maruyama, K. and **Huang, L.** Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain length: targeted MRI contrast enhancement agents for the liver. *Magn. Reson. Imag.* 9:373-377, 1991.
94. Maruyama, K., Mori, A., Kennel, S.J., Waalkes, M.V.B., Scherphof, G.L. and **Huang, L.** Drug delivery by organ-specific immunoliposomes. In: *Polymeric Drugs and Drug Delivery Systems*, Eds. Dunn, R.L. and Ottenbrite, R.M., A.C.S. Symposium Series 469, Amer. Chem. Soc., Washington, D.C., Chapter 24, pp. 275-284, 1991.
95. Zhou, X., Klibanov, A. and **Huang, L.** Lipophilic polylysines mediate efficient DNA transfection in mammalian cells. *Biochim. Biophys. Acta.* 1065:8-14, 1991.
96. Zhu, Z., Hughes, K.W. and **Huang, L.** Effects of 5'azacytidine on transformation and gene expression in *Nicotiana tabacum*. *In Vitro Cell. Dev. Biol.* 27:77-83, 1991.
97. Reddy, R., Zhou, F., **Huang, L.**, Carbone, F., Bevan, M. and Rouse, B. pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. *J. Immunol. Methods* 141:157-163, 1991.
98. Liu, D., Mori, A. and **Huang, L.** Large liposomes containing ganglioside GM₁ accumulate effectively in spleen. *Biochim. Biophys. Acta.* 1066:159-165, 1991.
99. Klibanov, A.L., Khaw, B.A., Nosiff, N., O'Donnel, S.M., **Huang, L.**, Slinkin, M.A. and Torchilin, V.P. Targeting of macromolecular carriers and liposomes by monoclonal antibodies to myosin heavy chain. *Am. J. Physiol. Suppl.* 261:60-65, 1991.

100. Mori, A., Klivanov, A.L., Torchilin, V.P., and **Huang, L.** Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM₁ on the circulation time of liposomes and on the target binding of immunoliposomes *in vivo*. FEBS Lett. 284:263-266, 1991.
101. Gao, X. and **Huang, L.** A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 179:280-285, 1991.
102. Maruyama, K., Mori, A., Bhadra, S., Subbiah, M.T.R. and **Huang, L.** Proteins and peptides bound to long-circulating liposomes. Biochim. Biophys. Acta. 1070:246-252, 1991.
103. Zhou, F., Rouse, B.T. and **Huang, L.** An improved method of loading pH-sensitive liposomes with soluble proteins for class I restricted antigen presentation. J. Immunol. Methods 145:143-152, 1991.
104. Liu, D., Wada, A and **Huang, L.** Potentiation of the humoral response of intravenous antigen by splenotropic liposomes. Immunol. Lett. 31:177-182, 1992.
105. Liu, D., Mori, A. and **Huang, L.** Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM₁-containing liposomes. Biochim. Biophys. Acta. 1104:95-101, 1992.
106. Wright, S. and **Huang, L.** Bilayer stabilization of phosphatidylethanolamine by N-biotinylphosphatidylethanolamine. Biochim. Biophys. Acta. 1103:172-178, 1992.
107. Nair, S., Zhou, F., Reddy, R., **Huang, L.** and Rouse, B.T. Soluble proteins delivered to dendritic cell via pH sensitive liposomes induce primary CTL responses *in vitro*, J. Exp. Med. 175:609-612, 1992.
108. Reddy, R., Zhou, F., Nair, S., **Huang, L.** and Rouse, B.T. *In vivo* cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol. 148:1585-1589, 1992.
109. Litzinger, D.C. and **Huang, L.** Biodistribution and immunotargetability of ganglioside stabilized dioleoylphosphatidylethanolamine liposomes. Biochim. Biophys. Acta. 1124:179-187, 1992.
110. Park, Y.S. and **Huang, L.** Cryoprotective activity of synthetic glycopospholipids and their interactions with trehalose. Biochim. Biophys. Acta. 1124:241-248, 1992.
111. Liu, D. and **Huang, L.** Trypsin induced lysis of lipid vesicles: effect of surface charge and lipid composition. Anal. Biochem. 202:1-5, 1992.
112. Pinnaduwege, P. and **Huang, L.** Stable target-sensitive immunoliposomes. Biochemistry 31:2850-2855, 1992.
113. Liu, D. and **Huang, L.** Size homogeneity of a liposome preparation is crucial for liposome biodistribution *in vivo*. J. Liposome Res. 2:57-66, 1992.
114. Zhou, X., Klivanov, A. and **Huang, L.** Improved encapsulation of DNA in pH-sensitive liposomes for transfection. J. Liposome Res. 2:125-139, 1992.
115. Torchilin, V.P., Klivanov, A.L., **Huang, L.**, O'Donnell, S., Nossiff, N.D. and Khaw, B.A. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 6:2716-2719, 1992.

116. Steward, M.J., Plautz, G.E., Del Buono, L., Yang, Z.Y., Xu, L., Gao, X., **Huang, L.**, Nabel, E.G. and Nabel, G.J. Gene transfer *in vivo* with DNA liposome complexes: safety and toxicity in mice. *Human Gene Therapy* 3:267-275, 1992.
117. Wright, S.E. and **Huang, L.** Immunomagnetic particle induced lysis of antibody-conjugated liposomes. *J. Liposome Res.* 2:257-273, 1992.
118. Nair, S., Zhou, X., **Huang, L.** and Rouse, B.T. Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. *J. Immunol. Methods.* 152:237-243, 1992.
119. Trubetskoy, V.S., Torchilin, V.P., Kennel, S.J. and **Huang, L.** Use of N-terminal modified poly-L-lysine-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells. *Bioconjug. Chem.* 3:323-327, 1992.
120. **Huang, L.**, Reddy, R., Nair, SK, Zhou, F., Rouse, BT. Liposomal delivery of soluble-protein antigens for class-I MHC-mediated antigen presentation. *Research in Immunology*, 143: (2) 192-196, 1992
121. Trubetskoy, V.S., Torchilin, V.P., Kennel, S. and **Huang, L.** Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly-L-lysine-antibody conjugate in mouse lung endothelial cells. *Biochim. Biophys. Acta.* 1131:311-313, 1992.
122. Park, Y.S., Maruyama, K. and **Huang, L.** Some negatively charged phospholipid derivatives prolong the liposome circulation *in vivo*. *Biochim. Biophys. Acta.* 1108:257-260, 1992.
123. Litzinger, D.C. and **Huang, L.** Amphipathic poly(ethyleneglycol) 5000-stabilized dioleoyl-phosphatidylethanolamine liposomes accumulate in spleen. *Biochim. Biophys. Acta.* 1127:249-254, 1992.
124. Zhou, F., Rouse, B.T. and **Huang, L.** Induction of cytotoxic T lymphocytes *in vivo* with protein antigen entrapped in membranous vehicles. *J. Immunol.* 149:1599-1604, 1992.
125. Farhood, H., Bottega, R., Epand, R.M. and **Huang, L.** Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. *Biochim. Biophys. Acta.* 1111:239-246, 1992.
126. Park, Y.S. and **Huang, L.** Interaction of synthetic glycopospholipids with phospholipid bilayer membranes. *Biochim. Biophys. Acta.* 1112:251-258, 1992.
127. Zhou, F., Rouse, B.T. and **Huang, L.** Prolonged survival of thymoma bearing mice by vaccination with a soluble protein antigen entrapped in liposomes: a model study. *Cancer Res.* 52:6287-6291, 1992.
128. Nabel, E.G., Gordon, D., Yang, Z.-Y., Xu, L., San, H., Plautz, G.E., Wu, B.-Y., Gao, X., **Huang, L.** and Nabel, G.J. Gene transfer *in vivo* with DNA-liposome complexes: lack of autoimmunity and gonadal localization. *Human Gene Therapy* 3:649-656, 1992.
129. Park, Y.S. and **Huang, L.** Effect of chemically modified GM₁ and neoglycolipid analogs of GM₁ on liposome circulation time: evidence supporting the dysopsonin hypothesis. *Biochim. Biophys. Acta.* 1116:105-114, 1993.

130. Mori, A., Kennel, S.J. and **Huang, L.** Immunotargeting of liposomes containing lipophilic antitumor prodrugs. *Pharm. Res.* 10:507-514, 1993.
131. Plautz, G.E., Yang, Z.Y., Wu, B., Gao, X., **Huang, L.** and Nabel, G.J. Immunotherapy of malignancy by *in vivo* gene transfer into tumors. *Proc. Natl. Acad. Sci. USA.* 90:4645-4649, 1993.
132. Babbitt, B., Burtis, L., Dentinger, P., Constantinides, P., Hillis, L., McGirl, B. and **Huang, L.** Contact-dependent, immunecomplex-mediated lysis of hapten-sensitized liposomes. *Bioconjug. Chem.* 4:199-205, 1993.
133. Gao, X. and **Huang, L.** Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes. *Nucleic Acids Research* 21:2867-2872, 1993.
134. Zhou, F. and **Huang, L.** Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. *Vaccine* 11:1139-1144, 1993.
135. Nabel, G.J., Nabel, E., Yang, Z.Y., Fox, B., Plautz, G., Gao, X., **Huang, L.**, Shu, S., Gordon, D. and Chang, A.E. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. *Proc. Natl. Acad. Sci. USA* 90:11307-11311, 1993.
136. San, H., Yang, Z.-Y., Pompili, V.J., Jaffe, M.L., Plautz, G.E., Xu, L., Felgner, J.H., Wheeler, C.J., Felgner, P., Gao, X., **Huang, L.**, Gordon, D., Nabel, G.J., and Nabel, E.G. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. *Human Gene Therapy* 4:781-788, 1993.
137. Park, Y.S. and **Huang, L.** Distribution within the reticuloendothelial system of liposomes containing lipid A. *J. Drug Targeting* 1:325-330, 1993.
138. Zhou, X. and **Huang, L.** DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. *Biochim. Biophys. Acta.* 1189:195-203, 1994.
139. Zhou, F., Watkins, S.C. and **Huang, L.** Characterization and kinetics of the MHC class I-restricted presentation of a soluble antigen delivered by liposomes. *Immunobiology.* 190:35-52, 1994.
140. Litzinger, D.C., Buiting, A.M.J., van Rooijen, N., and **Huang, L.** Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly-(ethylene glycol)-containing liposomes. *Biochim. Biophys. Acta.* 1190:99-107, 1994.
141. Tari, A.M., Fuller, N., Boni, L.T., Collins, D. Rand, P. and **Huang, L.** Interactions of liposome bilayers composed of 1,2-diacyl-3-succinylglycerol with protons and divalent cations. *Biochim. Biophys. Acta.* 1192:253-262, 1994.
142. Maruyama, K., Okamoto, A., Ishida, O., Kojima, S., Suginaka, A., **Huang, L.** and Iwatsuru, M. Biodistribution and antitumor effect of adriamycin encapsulated in long-circulating liposomes containing amphipathic polyethyleneglycol or ganglioside G_{M1}. *J. Liposome Res.* 4:701-723, 1994.
143. Yao, T. Degli Esposti, S., **Huang, L.**, Aron, R., Spangenberg, A., and Zern, M. Inhibition of carbon tetrachloride-induced liver injury by liposomes containing vitamin E. *Am. J. Physiology.* 267 (Gastrointest. Liver Physiol. 30): G477-G484, 1994.

144. Hui, K.M., Sabapathy, Tr.K., Oei, A.A., Singhal, A., and **Huang, L.** Induction of alloreactive cytotoxic T lymphocytes by intra-splenic immunization with allogeneic class I major histocompatibility complex DNA and DC-chol cationic liposomes. *J. Liposome Res.* 4:1075-1090, 1994.
145. Caplen, N.J., Gao, X., Hayes, P., Elaswarapu, R., Fisher, G., Kinrade, E., Chakera, A., Schorr, J., Hughes, B., Dorin, J.R., Porteous, D.J., Alton, E.W.F.W., Geddes, D.M., Coutelle, C., Williamson, R., **Huang, L.**, and Gilchrist, C. Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. *Gene Therapy.* 1:139-147, 1994.
146. Middleton, P.G., Caplen, N.J., Gao, X., **Huang, L.**, Geddes, D.M., and Alton, E.W.F.W. Nasal application of the cationic liposome DC-chol:DOPE does not alter nasal ion transport, lung function or affect bacterial growth. *European Respiratory J.* 7:442-445, 1994.
147. Gao, X., Jaffurs, D., Robbins, P.D., and **Huang, L.** A sustained, cytoplasmic transgene expression system delivered by cationic liposomes. *Biochem. Biophys. Res. Commun.* 200:1201-1206, 1994.
148. Son, K. and **Huang, L.** Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome mediated gene transfer. *Proc. Natl. Acad. Sci. USA* 91:12669-12672, 1994.
149. Nabel, E.G., Yang, Z., Muller, D., Chang A.E., Gao, X., **Huang, L.**, Cho, K.J., Nabel, G.J. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. *Human Gene Therapy*, 5:1089-1094, 1994.
150. Sternberg, B., Sorgi, F. L., and **Huang, L.** New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. *FEBS Lett.* 356:361-366, 1994.
151. Ricordi, C., Behboo, R., Klibanov, A., Singal, A., **Huang, L.** Reversal of diabetes by intrapancreatic injection of aminoguanidine liposomes. *Transplantation Proceedings.* 26(6):3479, 1994.
152. Nabel, G.J., Nabel, E.G., Yang, Z., Fox, B.A., Plautz, G.E., Gao, X., **Huang, L.**, Shu, S., Gordon, D., Chang, A.E. *Molecular-Genetic Interventions for Cancer.* Cold Spring Harbor Symposia on Quantitative Biology, 59: 699-707, 1994
153. Zhu, Z., Hughes, K.W., **Huang, L.**, Sun, B., Liu, C., Li, Y. Expression of human α -interferon cDNA in transgenic rice plants. *Plant cell, tissue and organ culture*, 36:197-204, 1994
154. Mori, A., Kennel, S.J., Waalkes, M.v.B., Scherphof, G.L., and **Huang, L.** Characterization of organ-specific immunoliposomes for delivery of 3',5' -O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung metastasis model. *Cancer Chemother. Pharmacol.* 35:447-457, 1995.
155. Freisleben, H-J, Bormann, J., Litzinger, D.C., Lehr, F., Rudolph, P., Schatton, W., and **Huang, L.** Toxicity and biodistribution of liposomes of the main phospholipid from the archaebacterium *thermoplasma acidophilum* in mice. *J. Liposome Res.* 5 (1):215-223, 1995.
156. Maruyama, K., Takizawa, T., Yuda, T., Kennel, S. J., **Huang, L.**, and Iwatsuru, M. Targetability of novel immunoliposomes modified with amphipathic polyethyleneglycols conjugated at their distal terminals to monoclonal antibodies. *Biochim. Biophys. Acta*, 1234:74-80, 1995.

157. Caplen, N. J., Alton, Eric W.F.W., Middleton, P.G., Dorin, J. R., Stevenson, B. J., Gao, X., Durham, S. R., Jeffery, P. K., Hodson, M. E., Coutelle, C., **Huang, L.**, Porteous, D. J., Williamson, R., and Geddes, D. M. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. *Nature Medicine*, 1:39-46, 1995.
158. Farhood, H., Gao, X., Barsoum, J. and **Huang, L.** Co-delivery to mammalian cells of a transcriptional factor with cis-acting element using cationic liposomes. *Analyt. Biochem.* 225:89-93, 1995.
159. Farhood, H., Serbina, S., and **Huang, L.** The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. *Biochim. Biophys. Acta.* 1235:289-295, 1995.
160. Hofland, H., and **Huang, L.** Inhibition of human ovarian carcinoma cell proliferation by liposome-plasmid DNA complex. *Biochem. Biophys. Res. Commun.* 207 (2):492-507, 1995.
161. Briscoe, P., Caniggia, I., Graves, A., Benson, B., **Huang, L.**, Tanswell, A.K., and Freeman, B.A. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. *Am. J. Physiol.* 268 (Lung Cell Mol. Physiol. 12): L374-L380, 1995.
162. Nair, S., Buiting, A.M.J., Rouse, R., van Rooijen, N., **Huang, L.** and Rouse, B.T. Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. *International Immunology* 7 (4):679-688, 1995.
163. Yu, D., Matin, A., Xia, W., Sorgi, F., **Huang, L.**, and Hung, M.-C. Liposome-mediated E1A gene transfer as therapy for ovarian cancers that overexpress HER-2/*neu*. *Oncogene* 11:1383-1388, 1995.
164. Stern, M., Munkonge, F., Caplen, N., Sorgi, F., **Huang, L.**, Geddes, D., and Alton, E. Quantitative fluorescence measurements of chloride secretion in primary airway epithelium from CF and non-CF subjects. *Gene Therapy* 2:766-774, 1995.
165. Caplen, N.J., Kinrade, E., Sorgi, F., Gao, X., Dieter, G., Geddes, D., Coutelle, C., **Huang, L.**, Alton, E. W.F.W., and Williamson, R. *In vitro* liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE. *Gene Therapy* 2:603-613, 1995.
166. Hart, S.L., Mayall, E., Stern, M., Munkonge, F.M., Frost, A., **Huang, L.**, Vasilliou, M., Williamson, R., Alton, E.W.F.W., and Coutelle, C. The introduction of two silent mutations into a CFTR cDNA construct allows improved detection of exogenous mRNA in gene transfer experiments. *Human Molec. Genetics* 4(9):1597-1602, 1995.
167. **Huang, L.**, Farhood, H., Serbina, N., Teepe, A. G., and Barsoum, J. Endosomolytic activity of cationic liposomes enhances the delivery of human immunodeficiency virus-1 trans-activator protein (Tat) to mammalian cells. *Biochem. Biophys. Res. Commun.* 217:761-768, 1995.
168. Li, S., Khokhar, A.R., Perez-Soler, R., and **Huang, L.** Improved antitumor activity of cis-Bis-neodecanoato-trans-R,R-1,2- diaminocyclohexaneplatinum (II) entrapped in long circulating liposomes. *Oncology Res.* 7:611-617, 1995.
169. Gao, X., and **Huang, L.** Potentiation of cationic liposome mediated gene delivery by polycations. *Biochemistry* 35:1027-1036, 1996.

170. **Huang, L.**, Son, K., Gao, X., Hages, D., Yang, Y.Y., Holden, S.A., Teicher, B., Kirkwood, J., and Lazo, J.S. Efficient lipofection with cisplatin resistant human tumor cells. *Cancer Gene Therapy* 3:107-112, 1996.
171. Lee, R.J., and **Huang, L.** Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA (LPDII) for tumor cell-specific gene transfer. *J. Biol. Chem.* 271:8481-8487, 1996.
172. Mori, A., Wu, S.-P., Han, I., Khokhar, A.R., Perez-Soler, R., and **Huang, L.** *In Vivo* antitumor activity of *cis*-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) formulated in long-circulating liposomes. *Cancer Chemother. Pharmacol.* 37:435-444, 1996.
173. Bedu-Addo, F., Tang, P., Xu, Y., and **Huang, L.** Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: Implications in liposomal drug delivery. *Pharm. Res.* 13:5, 710-717, 1996.
174. Bedu-Addo, F., Tang, P., Xu, Y., and **Huang, L.** Interaction of polyethyleneglycol-phospholipid conjugates with cholesterol-phosphatidylcholine mixtures: sterically stabilized liposome formulations. *Pharm. Res.* 13:5, 718-724, 1996.
175. Yang, J.P., and **Huang, L.** Direct gene transfer to mouse melanoma by intratumor injection of free DNA. *Gene Therapy* 3:542-548, 1996.
176. Xing, X., Matin, A., Yu, D., Xia, W., Sorgi, F., **Huang, L.**, and Hung, M-C. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer. *Cancer Gene Therapy.* 3:168-174, 1996.
177. Son, K., and **Huang, L.** Factors influencing the drug sensitization of human tumor cells for *in situ* lipofection. *Gene Therapy.* 3:630-634, 1996.
178. Mori, A., Duda, E., and **Huang, L.** Recombinant human tumor necrosis factor: covalently conjugated to long-circulating liposomes. *Int. J. Pharm.* 131:57-66, 1996.
179. Bedu-Addo, F.K., and **Huang, L.** Effect of matrix lipid chain length on liposomes containing cholesterol and ganglioside GM1: Implications in drug delivery. *J. Pharm. Sci.* 85:714-719, 1996.
180. Buiting, A.M.J., Zhou, F., Bakker, J.A.J., van Rooijen, N., and **Huang, L.** Biodistribution of clodronate and liposomes used in the liposome mediated macrophage "suicide" approach. *J. Immuno. Methods.* 192:55-62, 1996.
181. Sorgi, F.L., and **Huang, L.** Large scale production of DC-Chol liposomes by microfluidization. *Int. J. of Pharmaceutics*, 144:131-139, 1996.
182. Liu, F., Yang, J.P., **Huang, L.**, and Liu, D. New cationic lipid formulations for gene transfer. *Pharm. Res.*, 13:1856-1860, 1996.
183. Liu, F., Yang, J.P., **Huang, L.**, and Liu, D. Effect of non-ionic surfactants on the formation of DNA/emulsion complex & the emulsion-mediated gene transfer. *Pharm. Res.*, 13:1642-1646, 1996.
184. Chang, J.Y., Xia, W., Shano, R., Sorgi, F., **Huang, L.** and Hung, M.-C. The tumor suppressing activity of E1A in HER-2/neu-overexpressing versus low expressing breast cancer. *Oncogene*, 14:561-568, 1997.

185. MacVinish, L.J., Gill, D.R., Hyde, S.C., Mofford, K.A., Evans, M.J., Higgins, C.F., Colledge, W.H., **Huang, L.**, Sorgi, F., Ratcliff, R., and Cuthbert, A.W. Chloride secretion in the trachea of null cystic fibrosis mice: the effects of transfection with pTtrial10-CFTR1. *J. of Physiology*, 499.3:677-687, 1997.
186. Shurin, G., Shanks, N., Nelson, L., Hoffman, G., **Huang, L.**, and Kusnecov, A.W. Hypothalamic-pituitary-adrenal activation by the bacterial superantigen staphylococcal enterotoxin B: role of macrophages and T cells. *Neuroendocrinology*, 65:18-28, 1997
187. Xing, X., Liu, V., Xia, W., Stephens, L.C., **Huang, L.**, Lopez-Berestein, G., Hung, M-C. Safety studies of the intraperitoneal injection of E1A-liposome complex in mice. *Gene Therapy*, 4:238-243, 1997.
188. Gill, D.R., Southern, K.W., Mofford, K.A., Seddon, T., **Huang, L.**, Sorgi, F., Thomson, A., McVinish, L.J., Ratcliff, R., Bilton, D., Lane, D.J., Littlewood, J.M., Webb, A.K., Middleton, P.G., Colledge, W.H., Cuthbert, A.W., Evans, M.J., Higgings.C.F., and Hyde, S.C. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. *Gene Therapy*, 4:199-209, 1997.
189. Li, S., Brisson, M., He, Y., and **Huang, L.** Delivery of PCR amplified DNA fragment into cells: a model for using synthetic genes for gene therapy. *Gene Therapy*, 4:449-454, 1997.
190. Liu, F., Qi, H., **Huang, L.**, and Liu, D. Factors controlling efficiency of cationic lipid-mediated transfection *in vivo* via intravenous administration. *Gene Therapy*, 4:517-523, 1997.
191. Ferro, W.G., Li, S., Rosenblatt, J.D., Sirianni, N., Morgan, J.E., Partridge, T.A., **Huang, L.** and Hoffman, E.P. Selection and use of ligands for receptor-mediated gene delivery to myogenic cells. *Gene Therapy*, 4:664-674, 1997.
192. Davies, J.C., Stern, M., Dewar, A., Caplen, N.J., Munkonge, F.M., Pitt, T., Sorgi, F., **Huang, L.**, Bush, A., Geddes, D.M., and Alton, E.W.F.W. CFTR gene transfer reduces the binding of pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. *Am. J. Resp. Cel. Mol. Biol.*, 16:657-663, 1997.
193. Hui, K.M., Ang, P.T., **Huang, L.** and Tay, S.K. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. *Gene Therapy*, 4:783-790, 1997.
194. Yang, K., Mu, X-S, Hayes, R.L., Qiu, Y.H., Sorgi, F.L., **Huang, L.** and Clifton, G.L. DC-chol liposome-mediated gene transfer in rat spinal cord. *Neuro Report*, 8:2355-2358, 1997.
195. Yang, J.P., **Huang, L.** Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA. *Gene Therapy*, 14:950-960, 1997.
196. Sorgi, F.L., Bhattacharya, S., and **Huang, L.** Protamine sulfate enhances lipid mediated gene transfer. *Gene Therapy*, 4:961-968, 1997.
197. Li, S., and **Huang, L.** *In vivo* gene transfer via intravenous administration of cationic lipid/protamine/DNA (LPD) complexes. *Gene Therapy*, 4:891-900, 1997.
198. He, Y. and **Huang, L.** Growth inhibition of HPV16 DNA positive mouse tumor by antisense RNA transcribed from U6 promoter. *Cancer Res.* 57, 3993-3999, 1997.

199. Goddard, CA, Ratcliff, R, Anderson, JR, Glenn, E, Brown, S, Gill, DR, Hyde, SC, MacVinish, LJ, **Huang, L**, Higgins, CF, Cuthbert, AW, Evans, MJ, Colledge, WH. A second dose of a CFTR cDNA–liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea. *Gene Therapy* 4, 1231–1236, 1997.
200. Hara, T., Tan, Y., and **Huang, L**. *In vivo* gene delivery to the liver using reconstituted chylomicron remnants as a novel non-viral vector. *Proc. Natl. Acad. Sci. USA.* 94:14547-14552, 1997. PMID: PMC25050
201. Yang, J.P. and **Huang, L**. Time-dependent maturation of cationic liposome-DNA complex for serum resistance. *Gene Therapy.* 5:380-387, 1998.
202. Goddard, C.A., Ratcliff, R., Anderson, J.R., Glenn, E., Brown, S., Gill, D.R., Hyde, MacVinish, L. J., **Huang, L**, Higgins, C.F., Cuthbert, A.W., Evans, M.J., and Colledge, W.H. A second dose of a CFTR cDNA-liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea. *Gene Therapy.* 4:1231-1236, 1997.
203. Stern, M., Caplen, N.J., Browning, J.E., Griesenbach, U., Sorgi, F., **Huang, L**, Gruenert, D.C., Marriot, C., Crystal, R.G., Geddes, D.M., and Alton, E.W.F.W. The effect of mucolytic agents on gene transfer across a CF sputum barrier *in vitro*. *Gene Therapy.* 5:91-98, 1998.
204. Stern, M., Sorgi, F., Hughes, C., Caplen, N.J., Browning, J.E., Middleton, P.G., Gruenert, D.C., Farr, S.J., **Huang, L**, Geddes, D.M. and Alton, E.W.F.W. The effect of jet nebulisation on liposome mediated gene transfer across *in vitro*. *Gene Therapy.* 5:583-593, 1998.
205. Li, S., Rizzo, M.A., Bhattacharya, S., and **Huang, L**. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. *Gene Therapy.* 5:930-937, 1998.
206. Li, S. and **Huang, L**. Targeted delivery of antisense oligodeoxynucleotides formulated in a novel lipidic vector. *J. Liposome Res.* 8:239-250, 1998.
207. Qiu, Y.H., Zhao, X., Hayes, R.L., Perez-Polo, J.R., Pike, B.R., **Huang, L**, Clifton, Gg.L., and Yang, K. Activation of phosphatidylinositol 3-kinase by brain-derived neurotrophic factor gene transfection in septo-hippocampal cultures. *J. Neurosci. Res.* 52:192-200, 1998.
208. Li, S., Deshmukh, H.M., and **Huang, L**. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. *Pharm. Res.* 15: 1540-1545, 1998.
209. He, Y., Lui, V., Barr, J., Wang, L., Shurin, M., Almonte, C., Watkins, S., and **Huang, L**. Potentiation of E7 antisense RNA induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor. *Gene Therapy.* 5:1462-1471, 1998.
210. Xing, X., Zhang, S., Chang, J.Y., Tucker, S.D., Chen, H., **Huang, L**, and Hung, M.-C. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. *Gene Therapy.* 5:1538-1544, 1998.
211. He, Y., Zeng, Q., Drenning, S., Melhem, M., Twardy, D., **Huang, L**, and Grandis, J.R.. Inhibition of human squamous cell carcinoma growth *in vivo* by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. *J. Nat. Cancer Inst.* 14: 1080-1087, 1998.

212. Brisson, M., He, Y., Li, S., Yang, J-P, and **Huang, L.** A novel T7 RNA polymerase expression vector for efficient cytoplasmic expression of target genes. *Gene Therapy.* 6: 263-270, 1999.
213. Li, S., Tseng, W.-C., Stolz, D.B., Wu, S.-P., Watkins, S.C., and **Huang, L.** Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. *Gene Therapy.* 6: 585-594, 1999.
214. Li, S., Wu, S.-P., Whitmore, M., Loeffert, E.J., Wang, L., Watkins, S.C., Pitt, B.R. and **Huang, L.** Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. *Am. J. Physiol.* 276: L796-L804, 1999.
215. Nikitin, A.Y., Juárez-Pérez, M.I., Li, S., **Huang, L.** and Lee, W.H. RB- mediated suppression of spontaneous multiple endocrine neoplasia and lung metastases in Rb^{+/-} mice. *Proc. Natl. Acad. Sci. USA.* 96: 3916-3921, 1999. PMID: PMC22395
216. Zou, L.L., **Huang, L.**, Hayes, R.L., Black, C., Qiu, Y.H., Perez-Polo, J.R., Le, W., Clifton, G.L., and Yang, K. Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications. *Gene Therapy.* 6: 994-1005, 1999.
217. Ueno, N.T., Xia, W., Tucker, S.D., Zhang, S., Lopez-Berenstein, G., **Huang, L.** and Hung, M.-C. Issues in the development of gene therapy: Preclinical Experiments in E1A Gene Delivery. *Oncology Reports* 6: 257-262, 1999.
216. Kitson, C., Angel, B., Judd, D., Rothery, S., Severs, NJ., Dewar, A., **Huang, L.**, Wadsworth, SC., Cheng, SH., Geddes, DM., and Alton, EFWF. The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. *Gene Therapy.* 6, 534-546, 1999.
217. Savva, M., Duda, E., **Huang, L.** A genetically modified recombinant tumor necrosis factor- α conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains. *Intl. J. Pharmaceutics* 184: 45-51, 1999.
218. Tan, Y., Li, S., Pitt, B., **Huang, L.** The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. *Human Gene Therapy.* 10: 2153-2161, 1999.
219. Savva, M., Torchilin, P. and **Huang, L.** Effect of grafted amphiphilic PVP-palmityl polymers on the thermotropic phase behavior of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine bilayer. *J. Colloid Interf. Sci.* 217: 166-171, 1999.
220. Savva, M., Torchilin, P., **Huang, L.** Effect of poly(vinylpyrrolidone) on the thermal phase transition of 1,2 dipalmitoyl1-sn-glycero-3-phosphocholine bilayer. *J. Colloid Interf. Sci.* 217: 160-165, 1999.
221. Whitmore, M., Li, S. and **Huang, L.** LPD lipopolyplex initiates a potent cytokine response and inhibits pulmonary metastatic tumor growth. *Gene Therapy,* 6:1867-1875, 1999.
222. Savva, M., and **Huang, L.** Effect of PEG homopolymer and grafted amphiphilic PEG-palmityl on the thermotropic phase behavior of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine bilayer. *J. Liposome Res.* 9(3), 357-365, 1999.

223. Chesnoy, S. and **Huang, L.** DNA condensed by polycations and lipids for gene transfer. *S.T.P. Pharma Sci.* 9:5-12-1999.
224. Brisson, M., Tseng, WC, Almonte, C., Watkins, S., **Huang, L.** Subcellular trafficking of the cytoplasmic expression system. *Human Gene Therapy.* 10:2601-2613, 1999.
225. Li, S., Tan, Y., Viroonchatapan, E., Pitt, B. R. and **Huang, L.** Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. *Am. Physiol: Lung Cell Mol. Physiol.* 278: L504-L511, 2000.
226. Li, B., Li, S., Tan, Y., Stolz, D.B., Watkins, S., Block, L.H. and **Huang, L.** Lyophilization of Cationic Lipid-Protamine-DNA (LPD) Complexes. *J. Pharm. Sci.* 89(3): 355-364, 2000.
227. He, Y., Pimenov, A. A., Nayak, J., Plowey, J., Falo, L., **Huang, L.** Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. *Human Gene Therapy.* 11(4): 547-554, 2000.
228. Xing, X., Wang, S-C, Zou, Y., Xia, W., Shao, R., Kwong, K.Y., Yu, Z., Zhang, S., Miller, S., **Huang, L.** and Hung, M-C. The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. *Nature Med.* 6(2): 189-195, 2000.
229. Liang, K., Hoffman, E.P., and **Huang, L.** Targeted delivery of plasmid DNA to myogenic cells via transferrin conjugated peptide nucleic acid (PNA). *Molecular Therapy.* 3: 236-243, 2000.
230. Leone, P. Janson, C.G., Bilianuk, L., Wang, Z., Sorgi, F., **Huang, L.**, Matalon, R., Kaul, R., Zheng, Z., Freese, A., McPhee, S.W., Mee, E., During, M.J. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. *Ann Neurol.* 48:27-38, 2000.
231. Grandis, J.R., Drenning, S.D., Zeng, Q., Watkins, S.C., Melhem, M.F., Endo, S., Johnson, D.E., **Huang, L.**, He, Y-K and Kim, J.D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. *Proc. Natl. Acad. Sci. USA* 97: 4227-4232, 2000. PMID: PMC18206
232. Hyde, S.C., Southern, K.W., Gileadi, U., Fitzjohn, E.M., Mofford, K.A., Waddell, B.E., Gooi, H.C., Goddard, C.A., Hannavy, K., Smyth, S.E., Egan, J.J., Sorgi, F.L., **Huang, L.**, Cuthbert, A.W., Evans, M.J., Colledge, W.H., Higgins, C.F., Webb, A.K., and Gill, D.R. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. *Gene Therapy,* 7: 1156-1165, 2000.
233. Endo, S., Zeng, Q., Burke, N.A., He, Y-K, Melhem., M.F., Watkins, S.F., Lango, M.N., Drenning, S.D., **Huang, L.**, and Grandis, J.R. TGF- α antisense gene therapy inhibits head and neck squamous cell carcinoma growth *in vivo.* *Gene Therapy,* 7: 1906-1914, 2000.
234. Rogy, M., Reinisch, W., Beinhauer, B., Pokieser, P., **Huang, L.** Transfer of Interleukin-4 and Interleukin-10 in patients with severe inflammatory bowel disease of the rectum. *Human Gene Therapy.* 11:1731-1741, 2000.
235. Griesenbach, U, Scheid, P, Hillery, E, de Martin, R, **Huang, L**, Geddes DM, Alton EW. Anti-inflammatory gene therapy directed at the airway epithelium. *Gene Therapy* 7:306-13, 2000.

236. Han, Y.Y., **Huang, L.**, Jackson, E.K., Dubey, R.K., Gillepsie, D.G., and Carcillo, J.A. Liposomal ATP or NAD⁺ protects human endothelial cells from energy failure in a cell culture model of sepsis. *Research communications in molecular pathology and pharmacology*, 110:107-116, 2000.
237. Hofman, C. R., Dileo, J. P., Li, Z., Li, S., **Huang, L.** Efficient *in vivo* gene transfer by PCR amplified fragment with reduced inflammatory activity. *Gene Therapy*. 8: 71-74, 2001.
238. Lui, V. W. Y., He, Y., Goyal, K. and **Huang, L.** Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. *Molecular Therapy*. 3: 169-177, 2001.
239. Wu, X., He, Y., Falo, L. D., Hui, K. M., and **Huang, L.** Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding a Flt3L-TRAIL fusion protein. *Molecular Therapy*. 3: 368-374, 2001.
240. Yang, J., Chen, S., **Huang, L.**, Michalopoulos, G. and Liu, Y. Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth. *Hepatology*. 33: 848-859, 2001. PMID: PMC 1821076
241. Tan, Y., Liu, F., Li, Z., Li, S. and **Huang, L.** Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. *Molecular Therapy*. 3: 673-682, 2001.
242. Lui, V. W. Y., Falo, L. and **Huang, L.** Systemic production of IL-12 naked DNA mediated gene transfer and attenuation of transgene expression *in vivo*. *J. Gene Med.* 3: 384-393, 2001.
243. Liu, F., Nishikawa, M., Clemens, P.R. and **Huang, L.** Transfer of full-length Dmd to the diaphragm muscle of Dmd^{mdx/mdx} mice through systemic administration of plasmid DNA. *Molecular Therapy*. 4: 45-51, 2001.
244. Chesnoy, S., Durand, D., Doucet, J., Stolz, D.B. and **Huang, L.** Improved DNA/Emulsion complex stabilized by polyethylene-glycol conjugated phospholipid. *Pharm. Res.* 18: 1480-1484, 2001.
245. Liu, F. and **Huang, L.** Improving plasmid DNA-mediated liver gene transfer by prolonging its retention in the hepatic vasculature. *J. Gene Med.* 3: 569-576, 2001.
246. Whitmore, M., Li, S., Falo, Jr., L. and **Huang, L.** Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. *Cancer Immunology and Immunotherapy*. 50: 503-514, 2001.
247. Han, Y., **Huang, L.**, Jackson, E., Dubey, R., Gillepsie, G., and Carcillo, J. Liposomal ATP or NAD protects human endothelial cells from energy failure in a cell culture model of sepsis. *Research Communications in Molecular Pathology and Pharmacology*. 110: 107-116, 2001.
248. Hortobagyi, G., Ueno, N., Xia, W., Zhang, S., Wolf, J., Putnam, J., Weiden, P., Willey, J., Carey, M., Branham, D., Payne, J., Tucker, S., Bartholomeusz, C., Kilbourn, R., De Jager, R., Sneige, N., Katz, R., Anklesaria, P., Ibrahim, N., Murray, J., Theriault, R., Valero, V., Gershenson, D., Bevers, M., **Huang, L.**, Lopez-Berestein G., Hung M. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biological effects: a phase I clinical trial. *J Clin Oncol* 19:3422-3433, 2001.

249. Fox, E., Griesenbach, U., Rogers, D.F., **Huang, L.**, Li, S., Booy, B., Jeffery, P.K., Geddes, D.M., Alton, E.W.F.W. Successful oligodeoxynucleotide transfer to the airway epithelium following intravenous delivery. *Thorax*, 56:2, 2001.
250. Lui, V. W. Y., He, Y., Falo, L. and **Huang, L.** Systemic administration of naked DNA encoding IL-12 for the treatment of HPV-DNA positive tumor. *Human Gene Therapy*. 13: 177-185, 2002.
251. Chesnoy, S. and **Huang, L.** Enhanced cutaneous gene delivery following intradermal injection of naked DNA in a high ionic strength solution. *Molecular Therapy*. 1: 57-62, 2002.
252. Liu, F. and **Huang, L.** A syringe electrode device for simultaneous injection of DNA and electrotransfer. *Molecular Therapy*. 5: 323-328, 2002.
253. Liu, F. and **Huang, L.** Electric gene transfer to the liver following systemic administration of plasmid DNA. *Gene Therapy*. 9: 1116-1119, 2002. This paper was highlighted by Nature.com on August 6, 2002.
254. Liu, F. and **Huang, L.** Non-invasive gene delivery to the liver by mechanical massage. *Hepatology*. 35: 1314-1319, 2002.
255. Ma, Z., Zhang, J., Alber, S., Dileo, J., Negishi, Y., Stolz, D., Watkins, S., **Huang, L.**, Pitt, B., and Li, S. Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. *Am. J. of Respiratory Cell and Molecular Biology*. 27: 151-159, 2002.
256. Ueno, NT., Bartholomeusz, C., Xia, W., Anklesaria, P., Bruckheimer EM., Mebel, E. Paul, R., Li, S., Yo, G., **Huang, L.** and Hung, MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. *Cancer Research*. 62: 6712-6716, 2002.
257. Tan, Y., Zhang, J. and **Huang, L.** Co-delivery of NF-KB decoy-related oligodeoxynucleotide improves LPD-mediated systemic gene transfer. *Molecular Therapy*. 6: 804-812, 2002.
258. Sturlan, S., Beinhauer, B.G., Oberhuber, G., **Huang, L.**, Aasen, A.O., Rogy, M.A. *In vivo* gene transfer of murine interleukin-4 inhibits colon-26-mediated cancer cachexia in mice. *Anticancer Research*, 22: 2547-2554, 2002.
259. Yuan, X., Ma, Z., Zhou, W., Niidome, T., Alber, S., **Huang, L.**, Watkins, S., and Li, S. Lipid-mediated delivery of peptide nucleic acids to pulmonary endothelium. *Biochemical and Biophysical Research Communications*. 302(1):6-11, 2003. PMID:12593839
260. Chuang, Y-C., Chancellor, M. B., Seki, S., Yoshimura, N., Tyagi, P., **Huang, L.**, Lavelle, J.P., De Groat, W.C., Fraser, M.O. Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. *Urology*. 61:664-670, 2003.
261. Chesnoy, S., Lee, P., and **Huang, L.** Intradermal injection of transforming growth factor- β 1 gene enhances wound healing in genetically diabetic mice. *Pharmaceutical Research*. 20: 345-350, 2003.
262. Fraser, M., Chancellor, M., Tyagi, P., Yokoyama, T., Yoshimura, N., **Huang, L.**, De Groat, W., Chuang, Y. Intravesical liposome administration- a novel treatment for the hyperactive bladder in the rat. *Urology*. 61: 656-663, 2003.

263. Dileo, J., Miller, T., Chesnoy, S., and **Huang, L.** Gene transfer to sub-dermal tissues via a new design of gene gun. *Human Gene Therapy*. 14: 79-87, 2003.
264. Li, Z., Ning, W., Wang, J., Choi, A., Lee, P-Y, Tyagi, P., and **Huang, L.** Controlled gene delivery system based on thermo-sensitive biodegradable hydrogel. *Pharmaceutical Research*. 20: 884-888, 2003.
265. Zhang JL., Wilson A., Ma Z., Tang ZL., Satoh E., Mazda O., **Huang L.**, Pitt B., Li S. Prolonged gene expression in mouse lung endothelial cells following transfection with Epstein-Bar virus-based episomal plasmid. *Gene Therapy*. 10:822-826, 2003
266. Dileo, J., Banerjee, R., Whitmore, M., Nayak, J., Falo, L., and **Huang, L.** LPD mediated antigen delivery to antigen presenting cells results in enhanced anti-tumor immune responses. *Molecular Therapy*. 7: 640-648, 2003.
267. Lee, P.-Y., Li, Z., and **Huang L.** Thermosensitive hydrogel as a TGF- β 1 gene delivery vehicle enhances diabetic wound healing. *Pharmaceutical Research*. 20: 1995-2000, 2003.
268. Sturlan, S., Schneeberger, A., Fang, M., Beinhauer, B.G., Luhrs, P., Kutil, R., Wessner, B., **Huang, L.**, Aasen, A.O., Rogy, M.A. Intraperitoneal administration of pMP6/liposome complexes inhibits the growth of co-localized colon-26 adenocarcinoma cells by inducing a tumor-specific immune response. *Anticancer Research*, 23: 4843-4851, 2003.
269. Tyagi, P., Chancellor, M.B., Li, Z., De Groat, W., Yoshimura, N., Fraser, M.O., and **Huang, L.** Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. *J. of Urology*. 171: 483-489, 2004.
270. Liu, F., Lei, J., Vollmer, R., and **Huang, L.** Mechanism of liver gene transfer by mechanical massage. *Molecular Therapy*, 9: 452-457, 2004.
271. Tyagi, P., Li, Z., Chancellor, M., De Groat, W., Yoshimura, N., and **Huang, L.** Sustained intravesical drug delivery using thermosensitive hydrogel. *Pharmaceutical Research*, 21: 832-837, 2004.
272. Cui, Z., Han, S-J, **Huang, L.** Coating of mannan on LPD nanoparticles containing HPV E7 peptide significantly enhanced immunity against HPV-Positive tumor. *Pharmaceutical Research*, 21:1018-1025, 2004
273. Stabile, L.P., Lyker, J.S., **Huang, L.** and Siegfried, J.M. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. *Gene Therapy*. 11: 325-335, 2004.
274. Lee, P-Y; Chesnoy, S., and **Huang, L.** Electroporatic delivery of TGF-B1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. *J. of Investigative Dermatology*. 123: 791-798. 2004.
275. Liang, K.W., Nishikawa, M., Liu, F., Sun, B., Ye, Q., **Huang, L.** Restoration of dystrophin expression in mdx mice by intravascular injection of naked DNA containing full-length dystrophin cDNA. *Gene Therapy*. 11: 901-908, 2004.
276. Li, Z. and **Huang, L.** Sustained delivery and expression of plasmid DNA based on biodegradable polyester, poly (D, L-lactide-co-4-hydroxy-L-proline). *J. of Controlled Release*. 98:437-446, 2004.

277. Banerjee, R., Tyagi, P., Li, S., and **Huang, L.** Anisamide-Targeted Stealth Liposomes: A Potent Carrier for Targeting Doxorubicin to Human Prostate Cancer Cells. *International J. of Cancer.* 112: 693-700, 2004.
278. Liu, F., Shollenberger, L.M., and **Huang, L.** Non-immunostimulatory nonviral vectors. *FASEB J.* 18:1779-81, 2004.
279. Hyndman, L., Lemoine, J.L., **Huang, L.**, Porteous, D.J., Boyd, A.C., and Nan, X. HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. *J. of Controlled Release.* 99: 435-444, 2004.
280. Cui, Z., Han, S-J, Vangasseri, D-P, and **Huang, L.** The immunostimulation mechanism of LPD nanoparticles. *Molecular Pharmaceutics.* 2: 22-28, 2005
281. Cui, ZR. and **Huang, L.** Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer. *Cancer Immunol. Immunother.* 54: 1180-1190, 2005.
282. Lemoine, J. and **Huang, L.** Mechanism of efficient transfection of the nasal airway epithelium by hypotonic shock. *Gene Therapy,* 12: 1275-1282, 2005.
283. Wilson, A., Zhou, W., Champion, H., Alber, S., Tang, Z-L, Kennel, S., Watkins, S., **Huang, L.**, Pitt, B., and Li, S. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. *Molecular Therapy,* 12: 510-518, 2005.
284. Zhang, J., Liu, F., Conwell, C., Tan, Y. and **Huang, L.** Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. *Molecular Therapy,* 13:429-437, 2006.
285. Liu, F., Heston, S. Shollenberger, L. M., Sun, B., Mickle, M., Lowell, M., and **Huang, L.** Mechanism of *in vivo* DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved. *J. Gene Med.* 8:353-361, 2006.
286. Mu, Y., Zhang, J., Zhang, S., Toma, D., Re:n, S., **Huang, L.** Yaramus, M., Baum, A., Venkataramanan, R., and Xie, W. Traditional Chinese medicines Wu Wei Zi (*Schisandra chinensis Baill*) and Gan Cao (*Glycyrrhiza uralensis Fisch*) activate PXR and increase Warfarin clearance in rats. *J. Pharmacol. Expt. Therap.* 316:1369-1377, 2006.
287. Tyagi, P., Banerjee, R., Basu, S., Yoshimura, N., Chancellor, M., **Huang, L.** Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. *Molecular Pharmaceutics.* 3(4):398-406, 2006.
288. Vangasseri, D. Cui, Z.R. Chen, W.H. Hokey, D.A., Falo, L.D. and **Huang, L.** Immunostimulation of dendritic cells by cationic liposomes. *Molecular Membrane Biology* 23(5): 385-395, 2006.
289. Holder. E., Greisenbach, U., Li. S., **Huang. L.**, Rogers, D., Jeffery, P., Geddes, D.M., Alton, E.W. Intravenously administered oligonucleotides can be delivered to conducting airway epithelium via the bronchial circulation. *Gene Therapy.* 13(23):1628-38, 2006.
290. Li, S.D., **Huang, L.** Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. *Molecular Pharmaceutics.* 3(5): 579-588, 2006

291. Olton, D., Li, J., Wilson, M.B., Rogers, T., Close, J., **Huang, L.**, Kumta, P.N., and Sfeir, C. Nanostructured Calcium Phosphates (NanoCaPs) for Non-Viral Gene Delivery: Influence of the Synthesis Parameters on Transfection Efficiency. *Biomaterials*. 28: 1267 – 1279, 2007.
292. Lee, P.Y., Cobain, E., Huard, J., and **Huang, L.** Thermosensitive Hydrogel PEG-PLGA-PEG Enhances the Engraftment of Muscle-Derived Stem Cells and Promotes Healing in Diabetic Wound. *Molecular Therapy*. 15(6): 1189 – 1194, 2007.
293. Liu, F., Conwell, C.C., Yuan, X., Shollenberger, L.M., and **Huang, L.** Novel Non-viral Vectors Target Cellular Signaling Pathways: Regulated Gene Expression and Reduced Toxicity. *J. Pharmacol. Expt. Therap.* 321:777 – 783, 2007.
294. Liu, F., Shollenberger, L.M., Conwell, C.C., Yuan, X., and **Huang, L.** Mechanism of Naked DNA Clearance After Intravenous Injection. *J. Gene Med.* 9:613 – 619, 2007.
295. Yan, W., Chen, W.C. and **Huang, L.** Mechanism of Adjuvant Activity of Cationic Liposome: Phosphorylation of a Map Kinase, ERK and Induction of Chemokines. *Molecular Immunology*. 44: 3672 -3681, 2007.
296. Chen, W., Yan, W., and **Huang, L.** A Simple but Effective Cancer Vaccine Consisting of an Antigen and a Cationic Lipid. *Cancer Immunology Immunotherapy*. 57:517 – 530, 2008.
297. Tyagi, P., Chancellor, M., Yoshimura, N., and **Huang, L.** Activity of Different Phospholipids in Attenuating Hyperactivity in Bladder Irritation. *BJU International*. 101:627 – 632, 2007
298. Li, S-D., Chen, Y-C., Hackett, M.J. and **Huang, L.** Tumor Targeted Delivery of siRNA by Self-assembled Nanoparticles. *Molecular Therapy*. 16(1):163 – 169, 2008. (PMCID: PMC2739987)
299. Conwell, C.C., Liu, F., and **Huang, L.** Several Serum Proteins Significantly Decrease Inflammatory Response to Lipid Based Nonviral Vectors. *Molecular Therapy*. 16:370 – 377, 2008.
300. Li, S-D., and **Huang, L.** Efficient Gene Silencing in Metastatic Tumor by siRNA Formulated in Surface-modified Nanoparticles. *Journal of Controlled Release*. 126:77 – 84, 2008. (PMCID: PMC2692667)
301. Li, S-D., Chono, S. and **Huang, L.** Efficient Oncogene Silencing and Metastasis Inhibition via Systemic Delivery of siRNA. *Molecular Therapy*. 16 (5):942 – 946, 2008. (PMCID: PMC2778045)
302. Chen, W. and **Huang, L.** Induction of Cytotoxic T-lymphocytes and Anti-tumor Activity by a Liposomal Lipopeptide Vaccine. *Molecular Pharmaceutics*. 5(3):464 – 471, 2008. (PMCID: PMC2690700)
303. Yan, W., Chen, W., and **Huang, L.** Reactive Oxygen Species Play a Central Role in the Activity of Cationic Liposome Based Cancer Vaccine. *Journal of Controlled Release*. 130: 22 – 28, 2008. PMID: 18554742.
304. Chono, S., Li, S-D., Conwell, C.C., and **Huang, L.** An Efficient and Low Immunostimulatory Nanoparticle Formulation for Systemic siRNA Delivery to the Tumor. *Journal of Controlled Release*. 131: 64 – 69, 2008. (PMCID: PMC2585496)

305. Toyokawa, H., Nakao, A., Bailey, R.J., Nalesnik, M.A., Kaizu, T., Lemoine, J.L., Ikeda, A., Tomiyama, A., Papworth, G.D., **Huang, L.**, Demetris, A.J., Starzl, T.E., Murase, N. Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation. *Liver Transplantation*, 14:346-357, 2008. (PMCID: PMC3022430)
306. Yan, W., and **Huang, L.** The Effects of Salt on the Physiochemical Properties and Immunogenicity of Protein Based Vaccine Formulated in Cationic Liposome. *International Journal of Pharmaceutics*. 368:56-62, 2009. (PMCID: PMC2841293)
307. Chen, Y., Sen J., Bathula, S., Yang, Q., Fittipaldi, R., and **Huang, L.** Novel Cationic Lipid That Delivers siRNA and Enhances Therapeutic Effect in Lung Cancer Cells. *Molecular Pharmaceutics*. 6:696-705, 2009. (PMCID: PMC2763490)
308. Li, S-D, **Huang, L.** Nanoparticles Evading the Reticuloendothelial System: Role of the Supported Bilayer. *Biochim. Biophys. Acta – Biomembranes*. 1788:2259 – 2266, 2009 (PMCID: PMC2757503)
309. Li, J., Chen, Y-C., Tseng, Y-C., Mozumdar, S., and **Huang, L.** Biodegradable Calcium Phosphate Nanoparticle with Lipid Coating for Systemic siRNA Delivery. *Journal of Controlled Release*. 142:416-421, 2010. (PMCID: PMC2833237)
310. Chen, Y., Wu, J.J., and **Huang, L.** Nanoparticles Targeted with NGR Motif Deliver c-Myc siRNA and Doxorubicin for Anticancer Therapy. *Molecular Therapy* 18(4): 828 – 834, 2010. (PMCID: PMC2862540)
311. Liu, F., Frick, A., Yuan, X., and **Huang, L.** Dysopsonin Activity of Serum DNA-Binding Proteins Favorable for Gene Delivery. *J. Pharm. Expt. Ther.* 332:500-504, 2010. Published on October 28, 2009 as DOI:10.1124/jpet.109.159541 (PMCID: PMC2812122)
312. Deng, J., **Huang, L.**, and Liu, F. Understanding the Structure and Stability of Paclitaxel Nanocrystals. *International Journal of Pharmaceutics*. 390:242-249, 2010, Epub on Feb 16, 2010. (PMCID: PMC3685190)
313. Liu, F., Park, JY, Zhang, Y., Conwell, C., Liu, Y., Bathula, S., and **Huang, L.** Targeted Cancer Therapy with Novel High Drug-loading Nanocrystals. *Journal of Pharmaceutical Sciences*. 99:3542-3551, 2010.
314. Deng, J., **Huang, L.**, and Liu, F. Extraction Issues of Paclitaxel in Nanocrystals. *Journal of Biomedical Nanotechnology*. 6:198-201, 2010.
315. Liu, Y., and **Huang, L.** Designer Lipids Advance Systemic siRNA Delivery. *Molecular Therapy* 18(4): 669 – 670, 2010. (PMCID: PMC2862526)
316. Liu, Y., **Huang, L.**, and Liu, F. Paclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer. *Molecular Pharmaceutics*. 7:863-869, 2010. (PMCID: PMC3577056)
317. Chen, Y., Bathula, R., Li, J., and **Huang, L.** Multifunctional Nanoparticles Delivering siRNA and Doxorubicin Overcome Drug Resistance in Cancer. *Journal of Biological Chemistry*. 285(29):22639-50, 2010. (PMCID: PMC2903346)
318. Nakagawa, O., Ming, X., **Huang, L.**, and Juliano, R.L. Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small Molecule Ligands. *Journal of American Chemical Society*. 132(26):8848-8849, 2010. (PMCID: PMC2901626)

319. Chen, Y., Zhu, X., Zhang, X., Liu, B., and **Huang, L.** Nanoparticles Modified with Tumor-targeted scFv Deliver siRNA and miRNA for Metastasis Therapy. *Molecular Therapy*. 18:1650-1656, 2010. (PMCID: PMC2956922)
320. Chen, Y., Bathula, S. R., Yang, Q., and **Huang, L.** Targeted Nanoparticles Deliver siRNA to Melanoma. *Journal of Investigative Dermatology*. 130(12):2790-2798, 2010. This paper has been featured in a Commentary: "Paying "particle" attention to novel melanoma treatment strategies", Weiss, M.B. and Aplin, A.E., *Journal of Investigative Dermatology*. 130(12):2769-2771, 2010. It has also been selected by Faculty of 1000 as the top 2% of published articles in biology and medicine.
321. Yan, W., Chen, W.C., Liu, Z. and **Huang, L.** Bryostatin-I: A Dendritic Cell Stimulator for Chemokines Induction and a Promising Adjuvant for a Peptide Based Cancer Vaccine. *Cytokine*. 52:238-244, 2010. PMID: 20869878.
322. Vasievich, E. A., Chen, W.C. and **Huang, L.** Enantiospecific Adjuvant Activity of Cationic Lipid DOTAP in Cancer Vaccine. *Cancer Immunology and Immunotherapy*. 60(5):629-38, 2011. [Epub, Jan 26, 2011]. PMID: 21267720. PMCID: PMC5514367.
323. Bauman, J.A., Li, S.D., Yang, A., **Huang, L.** and Kole, R. Anti-Tumor Activity of Splice-Switching Oligonucleotides. *Nucleic Acid Research*, 38(22): 8348–8356, 2010. Epub 2010 Aug 18. PMCID: PMC3001088.
324. Kim, S.K. and **Huang, L.** Nanoparticle Delivery of a Peptide Targeting EGFR Signaling. *J. Controlled Release*, 157:279–286, 2012. Epub 2011 August 17. NIHMS320076. (PMCID: PMC3229664)
325. Li, J., Yang, Y. and **Huang, L.** Calcium Phosphate Nanoparticles with an Asymmetric Lipid Bilayer Coating for siRNA Delivery to The Tumor. *J. Controlled Release* 158: 108-114, 2012. (PMCID: PMC3288896)
326. Yang, Y., Li, J., Liu, F. and **Huang, L.** Systemic Delivery of siRNA via LCP Nanoparticle Efficiently Inhibits Lung Metastasis. *Molecular Therapy*, 20:609-615, 2012. Epub 2011 December 20 (NIHMS338649) (PMCID: PMC3293613)
327. Vasievich, E.A., Ramishetti, S., Zhang, Y. and **Huang, L.** Trp2 Peptide Vaccine Adjuvanted with (R)-DOTAP Inhibits Tumor Growth in an Advanced Melanoma Model. *Molecular Pharmaceutics*, 9:261-268, 2012. Epub 2011 December 28 (NIHMS346819) (PMCID: PMC3273554)
328. Kim, S. K., Foote, M. B. and **Huang, L.** The Targeted Intracellular Delivery of Cytochrome-C Protein to Tumors Using Lipid-Apolipoprotein Nanoparticles. *Biomaterials*, 33(15): 3959-3966, 2012. Epub 2012 February 26. (PMCID: PMC3307951)
329. Yang, Y., Hu, Y., Wang, Y., Li, J., Liu, F. and **Huang, L.** Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-small Cell Lung Cancer. *Molecular Pharmaceutics*. 9:2280–2289, 2012. Epub 2012 June 22. (PMCID: PMC3484223)
330. Liu, Y., Tseng, Y.-C. and **Huang, L.** Biodistribution Studies of Nanoparticles Using Fluorescence Imaging: A Qualitative or Quantitative Method? *Pharmaceutical Research*. 12:3273-3277, 2012. Epub 2012 July 18. (PMCID: PMC3584332)

331. Kim, S.K., Foote, M.B. and **Huang, L.** Targeted Delivery of EV peptide to Tumor Cell Cytoplasm Using Lipid Coated Calcium Carbonate Nanoparticles. *Cancer Letters*. 334:311-318, 2013. ePublication 2012 July 14. (PMCID: PMC3496799)
332. Lara, H., Wang, Y.H., Beltran, A. S., Juarez-Moreno, K., Yuan, X.N., Kato, S., Leisewitz, A. V., Cuello-Fredes, M., Licea, A. F., Connolly, D. C., **Huang, L.** and Blancafort, P. Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors. *J. Biol. Chem.* 287(35):29873-29886, 2012. doi: 10.1074/jbc.M112.360768. Epub 2012 Jul 10. (PMCID: PMC3436144)
333. Wang, Y. H., Su, H. H., Yang, Y., Hu, Y. X., Zhang, L., Blancafort, P. and **Huang, L.** Systemic Delivery of Modified mRNA Encoding Herpes Simplex Virus 1 Thymidine Kinase for Targeted Cancer Gene Therapy. *Molecular Therapy*. 21(2):358-67, 2013. doi: 10.1038/mt.2012.250. Epub 2012 Dec 11. (PMCID: PMC3594035)
334. Zhang, Y. Kim, W. Y., and **Huang, L.** Systemic Delivery of Gemcitabine Triphosphate via LCP Nanoparticles for NSCLC and Pancreatic Cancer Therapy. *Biomaterials*, 34:3447-3458, 2013. Doi:10.1016/j.biomaterials.2013.01.063. ePub 2013 Feb 06. (PMCID: PMC3600638)
335. Yan, Y., Krishnakumar, S., Yu, H., Ramishetti, S., Deng, L. W, Wang, S., **Huang, L.**, and Huang, D. Nickel(II) Dithiocarbamate Complexes Containing Sulforhodamine B as Fluorescent Probes for Selective Detection of Nitrogen Dioxide. *Journal of the American Chemical Society*. 135(14):5312-5315, 2013. doi: 10.1021/ja401555y. Epub 2013 Mar 29.
336. Hu, Y.X., Haynes, M.T., Wang, Y.H., Liu, F. and **Huang, L.** A Highly Efficient Synthetic Vector: Non-Hydrodynamic Delivery of DNA to Hepatocyte Nuclei In Vivo. *ACS Nano*. 7:5376-5384, 2013. doi: 10.1021/nn4012384. Epub 2013 May 10. (PMCID: PMC3718078)
337. Zhang, Y. Schwerbrock, N.M.J., Rogers, A., Kim, W. and **Huang, L.** Co-Delivery of VEGF siRNA and Gemcitabine Monophosphate in a Single Nanoparticle Formulation for Effective Treatment of NSCLC. *Mol. Therapy*. 21(8):1559-1569, 2013. doi: 10.1038/mt.2013. Epub 2013 Jun 18. (PMCID: PMC3734668)
338. Wang, Y.H., Xu, Z.H., Guo, S.T., Zhang, L., Sharma, A., Robertson, G.P. and **Huang, L.** Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis. *Molecular Therapy*. 21(10):1919-1929, 2013. doi: 10.1038/mt.2013.135. Epub 2013 Jun 18. (PMCID: PMC3808133)
339. Yao, J., Zhang, Y., Ramishetti, S. Wang, Y.H. and **Huang, L.** Turning An Antiviral into An Anticancer Drug: Nanoparticle Delivery of Acyclovir Monophosphate. *J. Controlled Release*. 170(3):414-420, 2013. doi: 10.1016/j.jconrel.2013.06.009. Epub 2013 Jun 18. NIHMS495137 (PMCID: PMC3742590)
340. Zhang, Y., Peng, L., Mumper, R.J. and **Huang, L.** Combinational Delivery of c-Myc siRNA And Nucleoside Analogues in A Single, Synthetic Nanocarrier for Targeted Cancer Therapy. *Biomaterials*. 34:8459-8468, 2013. Epub 2013 Aug 8. (PMCID: PMC3926217)
341. Wang, Y.H., Zhang, L. Guo, S.T., Hatefi, A. and **Huang, L.** Incorporation of Histone Derived Recombinant Protein for Enhanced Disassembly of Core-Membrane Structured Liposomal Nanoparticles for Efficient siRNA Delivery. *J. Controlled Release*. 172:179-189, 2013. Epub 2013 Aug 23.

342. Xu, Z.H., Ramishetti S., Tseng, Y.-C., Guo S.T., Wang Y.H., and **Huang, L.** Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. *J. Controlled Release*. 172:259-265, 2013. Epub 2013 Sep 1. PMID: 24004885.
343. Guo, S.T., Wang, Y.H., Miao, L., Xu, Z.H., Lin, C.M., Zhang, Y. and **Huang, L.** Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy. *ACS Nano*, 7: 9896-9904, 2013. Epub 2013 Oct 1. (PMCID:PMC3906679)
344. Tseng, Y.-C., Yang, A. and **Huang, L.** How Does the Cell Overcome LCP Nanoparticle-Induced Calcium Toxicity? *Molecular Pharmaceutics*. 10:4391-4395, 2013. Epub 2013 Oct 1. (PMCID: PMC3946490)
345. Guo, S.T., Miao, L., Wang, Y.H. and **Huang, L.** Unmodified Drug Used as a Material to Construct Nanoparticles: Delivery of Cisplatin for Enhanced Anti-Cancer Therapy. *J. Controlled Release*, 174:137-142, 2014. Epub 2013 Nov 23. (PMCID: PMC3946998)
346. Liu, Y., Hu, Y.X. and **Huang, L.** Influence of Polyethylene Glycol Density and Surface Lipid on Pharmacokinetics and Biodistribution of LCP Nanoparticles. *Biomaterials*, 35:3027-3034, 2014. Epub 2014 Jan 2. (PMCID: PMC3926205)
347. Tseng, Y.-C., Xu, Z. Guley, K., Yuan, H. and **Huang, L.** Lipid-Calcium Phosphate Nanoparticles for Delivery to the Lymphatic System and SPECT/CT Imaging of Lymph Node Metastases. *Biomaterials*, 35:4688-4698. 2014. Epub 2014 Mar 6. (PMCID: PMC4004378)
348. Xu, Z.H., Wang, Y.H., Zhang, L. and **Huang, L.** Nanoparticle-Delivered TGF- β siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment. *ACS Nano*, 8(4):3636-3645, 2014. Epub 2014 Mar 1. (PMCID: PMC4004320)
349. Zhang, J., Miao, L., Guo, S.T., Zhang, Y., Zhang, L., Satterlee, A., Kim, W.Y., and **Huang, L.** Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. *J. Controlled Release*, 182:90-96, 2014. Epub 2014 Mar 15. (PMCID: PMC4009696)
350. Guo, S.T., Lin, C.M., Xu, Z.H., Miao, L., Wang, Y.H., **Huang, L.** Co-Delivery of Cisplatin and Rapamycin for Enhanced Anticancer Therapy through Synergistic Effects and Microenvironment Modulation. *ACS Nano*, 8(5):4996-5009, 2014. Epub 2014 Apr 14. (PMCID: PMC4046782)
351. Zhao, Y.N., Qureshi, F., Zhang, S.B., Cui, S.H., Wang, B., Chen, H.Y., Lv, H.T., Zhang, S.F. and **Huang, L.** Novel gemini cationic lipids with carbamate groups for gene delivery. *J. Mater. Chem. B*, 2:2920-2928, 2014. Epub 2014 Mar 10. (PMCID: PMC4100725).
352. Guo, S.T., Wang, Y., Miao, L., Xu, Z. Lin, C.H. and **Huang, L.** Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy. *Biomaterials*, 35(26):7647-7653, 2014. Epub 2014 Jun 8. (PMCID: PMC4076841)
353. Miao, L., Guo, S.T., Zhang, J., Kim, W.Y. and **Huang, L.** Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. *Advanced Functional Materials*, 24(42):6601-6611, 2014. Epub 22 Aug 2014, (PMCID:PMC4225819).

354. Schuck, R.N., Zha, W., Edin, M.L., Gruzdev, A., Vendrov, K.C., Miller, T.M., Xu, Z., Lih, F.B., DeGraff, L.M., Tomer, K.B., Jones, M., Makowski, L., **Huang, L.**, Poloyac, S.M., Zeldin, D.C. and Lee, C.R. The Cytochrome P450 Epoxigenase Pathway Regulates The Hepatic Inflammatory Response in Fatty Liver Disease. *PLOS One*, 9(10):e110162, 2014.
355. Sha, H., Zou, Z., Xin, K., Bian, X., Cai, X., Lu, W., Chen, J., Chen, G., **Huang, L.**, Blair, A.M., Cao, P. and Liu, B., Tumor-Penetrating Peptide Fused EGFR Single-domain Antibody Enhances Cancer Drug Penetration into 3D Multicellular Spheroids and Facilitates Effective Gastric Cancer Therapy. *Journal of Controlled Release*, 200:188-200, 2015. PMID: PMC5008032.
356. Chen, W.H., Lecaros, R.L.G., Tseng, Y.C., **Huang, L.** and Hsu, Y.C. Nanoparticle Delivery of HIF1 α siRNA Combined with Photodynamic Therapy as a Potential Treatment Strategy for Head-and-Neck Cancer. *Cancer Lett.* 359(1):65-74, 2015. doi: 10.1016/j.canlet.2014.12.052. Epub 2015 Jan 14. PMID: 25596376. PMID: PMC5010227.
357. Zhao, Y., Zhang, S., Zhang, Y., Cui, S., Chen, H., Zhi, D., Zhen, Y., Zhang, S. and **Huang, L.** Tri-peptide cationic lipids for gene delivery. *J Mater Chem B Mater Biol Med.* 3(1):119-126, 2015. PMID: PMC4285367.
358. Zhao, Y. Huo, M., Xu, Z. Wang, Y. and **Huang, L.** Nanoparticle Delivery of CDDO-Me Remodels the Tumor Microenvironment and Enhances Vaccine Therapy for Melanoma. *Biomaterials*, 68:54-66, 2015. PMID: PMC4551104.
359. Tang, J., Li, L., Howard, C.B., Mahler, S.M., **Huang, L.** and Xu, Z.P. Preparation of Optimized Lipid-Coated Calcium Phosphate Nanoparticles to Enhance In Vitro Gene Delivery to Breast Cancer Cells. *J. Mater. Chem. B*, 3: 6805–6812, 2015. PMID: PMC4869335.
360. Miao, L. Wang, Y. Xiong, Y., Lin, C.M., Chen, N. Zhang, L. Kim, W. and **Huang, L.** Nanoparticle Modulation of the Tumor Microenvironment Enhances Therapeutic Efficacy of Nanoformulated Cisplatin. *Journal of Controlled Release*, 217:27-41, 2015. PMID: PMC4623876.
361. Lu, Y., Miao, L., Wang, Y., Xu, Z., Zhao, Y., Shen, Y., Xiang, G. and **Huang, L.** Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. *Molecular Therapy*, 24(2):364-374, 2015. Epub 2015 Sep 3, PMID: PMC4817807.
362. Satterlee, A.B., Yuan, H. and **Huang, L.** A Radio-Theranostic Nanoparticle with High Specific Drug Loading for Cancer Therapy and Imaging. *Journal of Controlled Release*, 217:170-182, 2015. PMID: 26341695, PMID: PMC4670036.
363. Lecaros, R.L.G., **Huang, L.**, Lee, T.C., and Hsu, Y.-C. Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment. *Molecular Therapy*, 24(1):106-116, 2015. Sep 16. Epub ahead of print. PMID: PMC4754546.
364. Srinivas, R., Satterlee, A, Wang, Y., Zhang, Y., Wang, Y., and **Huang, L.** Theranostic Etoposide Phosphate/Indium Nanoparticles for Cancer Therapy and Imaging. *Nanoscale*, 7:18542-18551, 2015. Epub 2015 Oct 22. PMID: PMC4670036.

365. Au, K.M., Satterlee, A., Min, Y., Tian, X., Kim, Y.S., Caster, J.M., Zhang, L., Zhang, T., **Huang, L.**, and Wang, A.Z., Folate-Targeted pH-Responsive Calcium Zoledronate Nanoscale Metal-Organic Frameworks: Turning A Bone Antiresorptive Agent into an Anticancer Therapeutics. *Biomaterials*, 82:178-93, 2016. Epub 2015 Dec 20. PMID: PMC4728024.
366. Zhao, Y., Wang, W., Guo, S., Wang, Y., Miao, L, Xiong, Y. and **Huang, L.**, PolyMetformin Polymer Combines Carrier and Anti-Cancer Activities for in vivo siRNA delivery. *Nature Communications*, 7:11822, 2016. PMID: PMC4897747.
367. Li, Y., Wu, Y., **Huang, L.**, Miao, L. Zhou, J. Satterlee, A.B. and Yao, J. Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy. *Journal of Controlled Release*, 228:107-119, 2016. Epub 2016 Mar 3. PMID: 26941036.
368. Lu, Y., Wang, Y., Miao, L., Haynes, M., Xiang, G. and **Huang, L.** Exploiting In Situ Antigen Generation and Immune Modulation to Enhance Chemotherapy Response in Advanced Melanoma: A Combination Nanomedicine Approach. *Cancer Lett.*, 379(1):32-38, 2016. Epub 2016 May 25. PMID: 27235608.
369. Luo, C. Miao, L., Zhao, Y., Musetti, S., Wang, Y. Shi, K. and **Huang, L.** A Novel Cationic Lipid with Intrinsic Antitumor Activity to Facilitate Gene Therapy of TRAIL DNA. *Biomaterials*, 102:239-248, 2016. Epub 2016 Jun 16. PMID: PMC5512171.
370. Luo, C., Sun, J., Liu, D., Sun, B., Miao, L., Musetti, S., Li, J., Han, X., Du, Y., Li, L., **Huang, L.** and He, Z. Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy. *Nano Letters*, 16:5401-5408, 2016. Epub 2016 Aug 8.
371. Goodwin, T.J., Zhou, Y., Musetti, S.N., Liu, R. and **Huang, L.** Local and Transient Gene Expression Primes the Liver to Resist Cancer Metastasis. *Science Translational Medicine*, 8(364):364ra153, 2016. PMID: 27831902. PMID: PMC5512420.
372. Haynes, M. and **Huang, L.** Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. *ACS Applied Materials & Interfaces*, 8:24361-24367, 2016. PMID: PMC5512567.
373. Miao, L., Newby, J., Lin, C., Zhang, L., Xu, F., Kim, W.Y., Forest, M.G., Lai, S.K., Milowsky, M.I., Wobker, S.E. and **Huang, L.** The Binding Site Barrier Elicited by Tumor Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. *ACS Nano*, 10:9243-9258, 2016. Published online 24 September 2016. PMID: PMC5515694.
374. Qiu, N., Liu, X., Zhong, Y., Zhou, Z., Piao, Y., Miao, L., Zhang, Q., Tang, J., **Huang, L.** and Shen, Y. Esterase-Activated Charge-Reversal Polymer for Fibroblast-Exempt Cancer Gene Therapy. *Advanced Materials*, 28(48):10613-10622, 2016. DOI: 10.1002/adma.201603095, 2016.
375. Luo, C., Sun, J., Sun, B., Liu, D., Miao, L. Goodwin, T.J., **Huang, L.** and He, Z. Facile Fabrication of Tumor Redox-Sensitive Nanoassemblies of Small-Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine. *Small*, 12(46):6353-6362, 2016. Published online 30 September 2016. PMID: PMC5206766.

376. Xiong, Y., Zhao, Y., Miao, L., Lin, C.M. and **Huang, L.** Co-Delivery of Polymeric Metformin and Cisplatin by Self-Assembled Core-Membrane Nanoparticles to Treat Non-Small Cell Lung Cancer. *Journal of Controlled Release*, 244: 63–73, 2016. Published online 10 November 2016. PMID: PMC5515375.
377. Goodwin, T.J. and **Huang, L.** On the article “Findings questioning the involvement of Sigma-1 receptor in the uptake of anisamide-decorated particles” [*J. Control. Release* 224 (2016) 229–238] Letter to the Editor 1 (September 14, 2016). *Journal of Controlled Release*, 243:382-385, 2016.
378. Miao, L., Liu, Q., Lin, C.M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W.Y. and **Huang, L.** Targeting Tumor-associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors: *In situ* Generation of Tumor Suppressive Fibroblasts. *Cancer Research*, 77(3); 719–731, 2017. PMID: PMC5290135.
379. Huo, M., Zhao, Y., Satterlee, A.B., Wang, Y., Xu, Y. and **Huang, L.** Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. *Journal of Controlled Release*, 245:81-94, 2017. Published online 15 November 2016. PMID: PMC5222779.
380. Satterlee, A.B., Rojas, J.D., Dayton, P.A. and **Huang, L.** Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy. *Theranostics*, 7:253-269, 2017. PMID: PMC5197062.
381. Cheng, L. Wang, Y. and **Huang, L.** Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-Inflammatory Microenvironment in the Lymph Node. *Molecular Therapy*, 25(7):1665-1675, 2017. doi: 10.1016/j.ymthe.2017.02.007. Published online March 8, 2017. PMID: PMC5498801.
382. Shi, K., Zhao, Y., Miao, L., Satterlee, A.B., Haynes, M.T., Luo, C., Musetti, S. and **Huang, L.** Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition. *Molecular Therapy*, 25(7):1567-1579, 2017. doi: 10.1016/j.ymthe.2017.02.008. Published online March 5, 2017. PMID: PMC5498803.
383. Satterlee, A.B., Attayek, P., Midkiff, B. and **Huang, L.** A Dosimetric Model for the Heterogeneous Delivery of Radioactive Nanoparticles In Vivo: A Feasibility Study. *Radiation Oncology*, 12:54, 2017. DOI 10.1186/s13014-017-0794-z. PMID: PMC5356254.
384. Hu, K., Miao, L., Goodwin, T.J, Li, J., Liu, Q. and **Huang, L.** Quercetin Remodels the Tumor Microenvironment to Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles. *ACS Nano*, 11(5):4916-4925, 2017. DOI: 10.1021/acsnano.7b01522. Published online April 21, 2017. PMID: PMC5961944.
385. Goodwin, T.J. and **Huang, L.** Investigation of Phosphorylated Adjuvants Co-encapsulated with a Model Cancer Peptide Antigen for the Treatment of Colorectal Cancer and Liver Metastasis. *Vaccine*, 35:2550-2557, 2017. DOI: 10.1016/j.vaccine.2017.03.067. Published online April 3, 2017. PMID: PMC5448460.
386. Goodwin, T.J., Shen, L., Hu, M., Li, J., Feng, R., Dorosheva, O. Liu, R. and **Huang, L.** Liver Specific Gene Immunotherapies Resolve Immune Suppressive Ectopic Lymphoid Structures in Microniche of Liver Metastases, Prolonging Survival. *Biomaterials*, 141:260-271, 2017. Epub 2017 Jul 6. PMID: PMC5557391

387. Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C., Goodwin, T., Dorosheva, O., Liu, R., **Huang, L.** Transient and Local Expression of Chemokine and Immune Checkpoint Traps to Treat Pancreatic Cancer. *ACS Nano*, 11: 8690–8706, 2017. DOI: 10.1021/acsnano.7b01786. PMID: PMC5961942.
388. Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A.W.H., Wong, J., Lai, P.B.S., Goodwin, T., Liu, R., **Huang, L.**, Chen, Z., Chow, K.-L., To, K.-F. and Cheng, A.S.L. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. *GUT*, 67(5):931-944, 2018. DOI: 10.1136/gutjnl-2017-314032; Epub September 22, 2017. PMID: PMC5961939.
389. Liu, Q., Zhu, H., Liu, Y., Musetti, S. and **Huang, L.** BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. *Cancer Immunology, Immunotherapy*, 67(2), 299-310, 2018. doi: 10.1007/s00262-017-2079-7; ePub November 1 2017. PMID: PMC5801101.
390. Liu, L., Wang, Y., Miao, L., Liu, Q., Musetti, S., Li, J. and **Huang, L.** Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. *Molecular Therapy*, 26(1):45-55, 2018. Epub 2017 Dec 5. PMID: PMC5763160.
391. Ye, Y., Wang, C., Zhang, X., Hu, Q., Zhang, Y., Liu, Q., Wen, D., Milligan, J., Bellotti, A., **Huang, L.**, Gianpietro, D. and Gu, Z. A Melanin-mediated Cancer Immunotherapy Patch. *Science Immunology*, 10 Nov 2017: Vol. 2, Issue 17, eaan5692; DOI: 10.1126/sciimmunol.aan5692.
392. Wang, Y., Zhang, L., Xu, Z., Miao, L. and **Huang, L.** mRNA Vaccine with Antigen-Specific Check Point Blockade Induces an Enhanced Immune Response Against Established Melanoma. *Molecular Therapy*, 26(2):420-434, 2018. DOI: 10.1016/j.ymthe.2017.11.009, Epub November 21 2017. PMID: PMC5835019.
393. Liu, Q., Zhu, H., Tiruthani, K., Shen, L., Chen, F., Gao, K., Zhang, X., Hou, L., Wang, D., Liu, R. and **Huang, L.** Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene-Mutant Melanoma. *ACS Nano*, 12(2):1250-1261, 2018. doi: 10.1021/acsnano.7b07384. Epub 2018 Jan 31. PMID: PMC5834397.
394. Tang, J., Howard, C.B., Mahler, S.M., Thurecht, K.T., **Huang, L.**, and Xu, Z.P. Enhanced Delivery of siRNA to Triple Negative Breast Cancer in Vitro and in Vivo through Functionalizing Lipid-coated Calcium Phosphate Nanoparticles with Dual Target Ligands. *Nanoscale*, 10(9):4258-4266, 2018. doi: 10.1039/c7nr08644j. Epub 23 Jan 2018.
395. Hou, L., Liu, Q., Shen, L., Liu, Y., Zhang, X., Chen, F., and **Huang, L.** Nano-delivery of Fraxinellone Remodels Tumor Microenvironment and Facilitates Therapeutic Vaccination in Desmoplastic BRAF-mutant Melanoma. *Theranostics*, 2018, 8(14): 3781-3796. doi:10.7150/thno.24821. PMID: PMC6071534.
396. Song, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T.J., Li, J., Dorosheva, O., Liu, T., Liu, R. and **Huang, L.** Synergistic and Low Adverse Effect Cancer Immunotherapy by Immunogenic Chemotherapy and Locally Expressed PD-L1 Trap. *Nature Communications*, 9(1):2237, 2018. doi: 10.1038/s41467-018-04605-x. PMID: PMC5993831.
397. Wang, Y., Song, W., Hu, M., An, S., Xu, L., Li, J., Kinghorn, M.A., Liu, R. and **Huang, L.** Nanoparticle-mediated HMGA1 Silencing Promotes Lymphocyte Infiltration and Boosts Checkpoint Blockade Immunotherapy for Cancer. *Advanced Functional Materials*, 2018, 1802847. DOI: 10.1002/adfm.201802847.

398. Liu, Q., Chen, F., Hou, L., Shen, L., Zhang, X., Wang, D. and **Huang, L.** Nanocarrier-Mediated Chemo-Immuno Therapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma. *ACS Nano*, 12(8):7812-7825, 2018. doi: 10.1021/acsnano.8b01890. PMID: PMC6115293.
399. Shen, L., Li, J., Liu, Q., Song, W., Zhang, X., Tiruthani, K., Hu, H., Das, M., Goodwin, T.J., Liu, R. and **Huang, L.** Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers. *ACS Nano*, 12:9830-9841, 2018. doi: 10.1021/acsnano.8b00967. 2018 Sep 25 ePub ahead of print.
400. Sun, H., Yang, W., Tian, Y., Zeng, X., Zhou, J., Mok, M.T.S., Tang, W., Feng, Y., Xu, L., Chan, A.W.H., Tong, J.H., Cheung, Y.-S., Lai, P.B.S., Wang, H.K.S., Tsang, S.-W., Chow, K.-L., Hu, M., Liu, R. **Huang, L.**, Yang, B., Yang, P., To, K.-F., Sung, J.J.Y., Wong, G.L.H., Wong, V.W.S., and Cheng, A.S.L. An Inflammatory-CCRK Circuitry Drives mTORC1-dependent Metabolic and Immunosuppressive Reprogramming in Obesity-associated Hepatocellular Carcinoma. *Nature Communications*, 6;9(1):5214, 2018. PMID: PMC6283830
401. Song, W., Tiruthani, K., Wang, Y., Shen, L., Hu, M., Dorosheva, O., Qiu, K., Kinghorn, K.A., Liu, R., and **Huang, L.** Trapping Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis. *Advanced Materials*, 2018 Nov 2:e1805007. doi: 10.1002/adma.201805007. [Epub ahead of print]. PMID: PMC6580426.
402. Cheng, N., Watkins-Schulz, R., Junkins, R.D., David, C.N., Johnson, B.M., Montgomery, S.A., Peine, K.J., Darr, D.B., Yuan, H., McKinnon, K.P., Liu, Q., Miao, L., **Huang, L.**, Bachelder, E.M., Ainslie, K.M. and Ting, J.P.Y. Nanoparticle-incorporated STING activator as an immunotherapeutic for PD-L1 resistant triple-negative breast cancer. *JCI Insight*. 2018;3(22):e120638. <https://doi.org/10.1172/jci.insight.120638>.
403. Das, M., Shen, L., Liu, Q., Goodwin, T.J. and **Huang, L.** Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer. *Molecular Therapy*, 27:507-517, 2019. doi: 10.1016/j.ymthe.2018.11.012. [Epub ahead of print], PMID: PMC30545600.
404. Chen, Y., Song, W., Shen, L., Qiu, N., Hu, M., Liu, Y., Liu, Q. and **Huang, L.** Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumor. *ACS Nano*, 13(2):1751-1763, 2019. DOI: 10.1021/acsnano.8b07830. Jan 14 2019 [Epub ahead of print].
405. An, S., Tiruthani, K., Wang, Y., Xu, L., Hu, M., Li, J., Song, W., Jiang, H., Sun, J., Liu, R. and **Huang, L.** Locally Trapping the C-C Chemokine Receptor Type 7 by Gene Delivery Nanoparticle Inhibits Lymphatic Metastasis Prior to Tumor Resection. *Small*, 2019 Mar;15(9):e1805182. doi: 10.1002/sml.201805182. Epub 2019 Jan 28. PMID: PMC6878664.
406. Tang, J., Li, B., Howard, C.B., Mahler, S.M., Thurecht, K.J., Wu, Y., **Huang, L.** and Xu Z.P. Multifunctional lipid-coated calcium phosphate nanoplateforms for complete inhibition of large triple negative breast cancer via targeted combined therapy. *Biomaterials*, 2019 Sep;216:119232. doi: 10.1016/j.biomaterials.2019.119232. Epub 2019 May 31.
407. Wang, M., Zhai, Y., Ye, H., Lv, Q., Sun, B., Luo, C., Jiang, Q., Zhang, H., Xu, Y., Jing, Y., **Huang, L.**, Sun, J. and He, Z. Ultrahigh Co-loading Capacity and Stimuli-responsive Release Based on Cascade Reaction of Self-destructive Polymer for Improved Chemo-photodynamic Therapy. *ACS Nano*, 13(6):7010-7023, 2019.

408. Song, W., Liu, R. and **Huang, L.** Response to Comment on “Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis” *Advanced Materials*, 2019, 1902569. DOI: 10.1002/adma.201902569.
409. Hu, M., Wang, Y., Xu, L., An, S., Tang, Y., Zhou, X., Li, J., Liu, R. and **Huang, L.** Relaxin Gene Delivery Mitigates Liver Metastasis and Synergizes with Check Point Therapy. *Nature Communications*, 2019 Jul 5, 10(1):2993. doi: 10.1038/s41467-019-10893-8. PMCID: PMC6611764
410. Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufès C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, **Huang L**, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. On the issue of transparency and reproducibility in nanomedicine. *Nature Nanotechnology*. 2019 Jul;14(7):629-635. doi: 10.1038/s41565-019-0496-9. PMCID: PMC6939883.
411. Zhang, X., Shen, L., Liu, Q. Hou, L. and **Huang, L.** Inhibiting PI3 Kinase- γ in Both Myeloid and Plasma Cells Remodels the Suppressive Tumor Microenvironment in Desmoplastic Tumors. *Journal of Controlled Release*, 309: 173-180, 2019. <https://doi.org/10.1016/j.jconrel.2019.07.039>. PMCID: PMC6815713.
412. Zhang, J., Shen, L., Li, X., Song, W., Liu, Y. and **Huang, L.** Nanoformulated Codelivery of Quercetin and Alantolactone Promotes an Antitumor Response through Synergistic Immunogenic Cell Death for Microsatellite-Stable Colorectal Cancer. *ACS Nano*, 13(11):12511-12524, 2019. doi: 10.1021/acsnano.9b02875.
413. Gusti-Ngurah-Putu, E.-P., **Huang, L.** and Hsu, Y.-C. Effective Combined Photodynamic Therapy with Lipid Platinum Chloride Nanoparticles Therapies of Oral Squamous Carcinoma Tumor Inhibition. *Journal of Clinical Medicine*, 8(12). pii: E2112, 2019. doi: 10.3390/jcm8122112. PMCID: PMC6947167.
414. Hu, M., Zhou, X., Wang, Y., Guan, K. and **Huang, L.** Relaxin-FOLFOX-IL-12 Triple Combination Therapy Engages Memory Response and Achieves Long-term Survival in Colorectal Cancer Liver Metastasis. *Journal of Controlled Release*, 319:213-221, 2019. doi: 10.1016/j.jconrel.2019.12.053.
415. Zhu, H., Liu, Q., Miao, L., Musetti, S. Huo, M. and **Huang, L.** Remodeling Fibrotic Tumor Microenvironment of Desmoplastic Melanoma to Facilitate Vaccine Immunotherapy. *Nanoscale*, 12:3400-3410, 2020. DOI: 10.1039/c9nr09610h.
416. Xu, H., Hu, M., Liu, M., An, S., Guan, K., Wang, M., Li, L., Zhang, J., Li, J. and **Huang, L.** Nano-Puerarin Regulates Tumor Microenvironment and Facilitates Chemo- and Immunotherapy in Murine Triple Negative Breast Cancer Model. *Biomaterials*, 235:119769, 2020. DOI: 10.1016/j.biomaterials.2020.119769. PMCID: PMC31986348.
417. Yu, Z., Guo, J., Hu, M., Gao, Y. and **Huang L.** Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma. *ACS Nano*, 14: 4816-4828, 2020. doi.org/10.1021/acsnano.0c00708.

418. Guo, J., Yu, Z., Das, M. and **Huang, L.**, Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis. *ACS Nano*, 14: 5075-5089, 2020. doi.org/10.1021/acsnano.0c01676.
419. Liu, Y., Qiu, N., Shen, L., Liu, Q., Zhang, J., Cheng, Y.-Y., Lee, K.H. and **Huang, L.** Nanocarrier-Mediated Immunogenic Chemotherapy for Triple Negative Breast Cancer. *Journal of Controlled Release*, 323:431-441, 2020. DOI: 10.1016/j.jconrel.2020.04.040
420. Das, M., Li, J., Bao, M. and **Huang, L.** Nano delivery of gemcitabine derivative as a therapeutic strategy in a desmoplastic KRAS mutant pancreatic cancer. *AAPS Journal*, 22, 88, 2020. DOI: 10.1208/s12248-020-00467-8.
421. Das, M., Zhou, X., Liu, Y., Das, A., Vincent, B.G., Li, J., Liu, R. and **Huang, L.** Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. *Translational Oncology*, 13: 100856, 2020. doi.org/10.1016/j.tranon.2020.100856.
422. Xiong, Y., Song, W., Shen, L., Wang, Y., Zhang, J., Hu, M., Liu, Y., Li, J., Liu, R. and **Huang, L.** Oral Metformin and Polymetformin Reprogram Immunosuppressive Microenvironment and Boost Immune Checkpoint Inhibitor Therapy in Colorectal Cancer. *Advanced Therapeutics*, 2020, 2000168. doi: 10.1002/adtp.202000168.
423. Harrison, E.B., Porrello, A., Bowman, B.M., Belanger, A.R., Yacovone, G., Azam, S.H., Windham, I.A., Ghosh, S.K., Wang, M., Mckenzie, N., Waugh, T.A., Van Swearingen, A.E.D., Cohen, S.M., Allen, D.G., Goodwin, T.J., Mascenik, T., Bear, J.E., Cohen, S., Randell, S.H., Massion, P.P., Major, M.B., **Huang, L.** and Pecot, C.V. A circle RNA regulatory axis promotes lung squamous metastasis via CDR1 regulation of Golgi trafficking. *Cancer Research*, 80(22):4972-4985, 2020. PMID: PMC7669576
424. Ji, G., Ma, L., Yao, H., Ma, S., Si, X., Wang, Y., Bao, X., Ma, L., Chen, F., Ma, C., **Huang, L.**, Fang, X. and Song, W. Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. *Acta Pharmaceutica Sinica B*, 10:2171-2182, 2020.
425. Hu, M., Wang, Y., Liu, Z., Yu, Z., Guan, K., Liu, M., Wang, M., Tan, J. and **Huang, L.** Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis. *Nature Nanotechnology*, 16(4):466-477, 2021. <https://doi.org/10.1038/s41565-020-00836-6>. This manuscript was commented by Fallowfield, J.A. and Ramachandran, P. A relaxin-based nanotherapy for liver fibrosis. *News & Views, Nature Nanotechnology*, <https://doi.org/10.1038/s41565-020-00832-w>, 2021.
426. Qiu, N., Liu, Y., Liu, Q., Chen, Y., Shen, L., Hu, M., Zhou, X., Shen, Y., Gao, J. and **Huang, L.** Celastrol Nanoemulsion Induces Immunogenicity and Downregulates PD-L1 to Boost Abscopal Effect in Melanoma Therapy. *Biomaterials*, 269, Feb 2021, 120604. DOI: 10.1016/j.biomaterials.2020.120604. PMC8601126. Corrigendum published in *Biomaterials* 277 (2021) 121121. DOI: 10.1016/j.biomaterials.2021.121121.
427. Guo, J., Yu, Z., Sun, D., Zou, Y., Liu, Y. and **Huang, L.** Two Nanoformulations Induce Reactive Oxygen Species and Immunogenetic Cell Death for Synergistic Chemo-Immunotherapy Eradicating Colorectal Cancer and Hepatocellular Carcinoma. *Molecular Cancer*, 20:10, 2021. <https://doi.org/10.1186/s12943-020-01297-0>
428. Liu, Y., Tiruthani, K., Wang, M., Zhou, X., Qiu, N., Xiong, Y., Pecot, C.V., Liu, R. and **Huang, L.** Tumor-targeted Gene Therapy with Lipid Nanoparticles Inhibits Tumor-Associated Adipocytes and Remodels the

Immunosuppressive Tumor Microenvironment in Triple-Negative Breast Cancer. *Nanoscale Horizons*, 6, 319 – 329, 2021. DOI: 10.1039/d0nh00588f. published on February 15, 2021.

429. Zhou, X., Liu, Y., Hu, M., Wang, M., Liu, X. and **Huang, L.** Relaxin Gene Delivery Modulates Macrophages to Resolve Cancer Fibrosis and Synergizes with Immune Checkpoint Blockade Therapy. *Science Advances*, 2021; 7:eabb6596, online publication on 17 February 2021. doi: 10.1126/sciadv.abb6596.
430. Musetti, S. N. and **Huang, L.** Tinagl1 gene therapy suppresses growth and remodels the microenvironment of triple negative breast cancer. *Molecular Pharmaceutics*, 18(5):2032-2038, 2021. Epub 2021 Apr 20. <https://pubs.acs.org/action/showCitFormats?doi=10.1021/acs.molpharmaceut.1c00008&ref=pdf>
431. Xi, Y., Li, Y., Xu, P., Li, S., Liu, Z., Tung, H.-C., Cai, X., Wang, J., Huang, H., Wang, M., Xu, M., Ren, S., Li, S., Zhang, M., Lee, Y.J., **Huang, L.**, Yang, D. He, J., Huang, Z., and Xie, W. The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1. *Science Translational Medicine*. 7(36):eabg9241, 2021. doi: 10.1126/sciadv.abg9241. Epub 2021 Sep 1, 2021. PMID: PMC8442864.
432. Ji, G., Si, X., Dong, S., Xu, Y., Li, M., Yang, B., Tang, Z., Fang, X., **Huang, L.**, Song, W., and Chen, X., Manipulating Liver Bile Acid Signaling by Nano-delivery of Bile Acid Receptor Modulators for Liver Cancer Immunotherapy. *Nano Letters*, 21, 16:6781–6791, 2021. doi.org/10.1021/acs.nanolett.1c01360.
433. Yeh C.-H., Chen, J. Zheng G., **Huang L.**, and Y.-C. Hsu, Novel Pyropheophorbide Phosphatidic Acids Photosensitizer Combined EGFR siRNA Gene Therapy for Head and Neck Cancer Treatment. *Pharmaceutics*, 13(9):1435, 2021. doi: 10.3390/pharmaceutics13091435.
434. Sendi, H., Yazdimamaghani, M., Hu, M., Sultanpuram, N., Wang, J., Moody, A.S., McCabe, E., Zhang, J., Graboski, A., Li, L., Rojas, J.D., Dayton, P.A., **Huang, L.** and Wang, A.Z. Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis. *Cancer Research*, 82(1):105-113, 2022. DOI: 10.1158/0008-5472.CAN-21-2269.
435. Yu, Z., Guo, J. Liu, Y. Wang, M., Liu, Z., Gao, Y. and **Huang, L.** Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. *Journal of Nanobiotechnology*, 20:9, 2022. <https://doi.org/10.1186/s12951-021-01205-8>.
436. Guo, J. and **Huang, L.** Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy. *Nature Protocols*, 2022. <https://doi.org/10.1038/s41596-022-00698-3>
437. Shen, L., Li, J., Liu, Q., Das, M., Song, W., Zhang, X., Tiruthani, K., Dorosheva, O., Hu, H., Lai, S., Liu, R. and **Huang, L.** Nano-trapping CXCL13 Reduces Regulatory B cells in Tumor Microenvironment and Inhibits Tumor Growth. *Journal of Controlled Release*, 343:303-313, 2022. doi: 10.1016/j.jconrel.2022.01.039.
438. Wang, Y., Sun, C., **Huang, L.**, Wang, X., Liu, M., Wang, L., Sun, S., Xu, H., Ma, G., Zhang, L., Li, L., Liu, Y., Zeng, J. and Liu, H. Magnolol-loaded Cholesteryl Biguanide Conjugate Hydrochloride Nanoparticles for Triple-negative Breast Cancer Therapy. *International Journal of Pharmaceutics*, 615, 121509, 2022.
439. Liu, X., Zhou, J., Wu, H., Chen, S., Tang, W., Duan, L. Wang, Y., McCabe, E., Hu, M., Yu, Z., Liu, H., Choi, C.H.J., Sung, J.J., **Huang, L.**, Liu, R. and Cheng, A.S. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma. *Molecular Therapy*, S1525-0016(22)00566-4. 2022. doi: 10.1016/j.ymthe.2022.09.012.

Clinical Protocols:

1. Nabel, G.J., Chang, A., Nabel, E.G., Plautz, G., Fox, B.A., **Huang, L.** and Shu, S. Immunotherapy of malignancy by *in vivo* gene transfer into tumors. *Human Gene Therapy*, 3:399-410, 1992.

Books Authored or Edited:

1. **Huang, L.**, Hung, M.C., Wagner, E. Nonviral Vectors for Gene Therapy. Academic Press, 1999.
2. **Huang, L.**, Hung, M.C., Wagner, E. Nonviral Vectors for Gene Therapy. 2nd ed., Part I, *Advances in Genetics*, Vol. 53, Elsevier Academic Press, 2005.
3. **Huang, L.**, Hung, M.C., Wagner, E. Nonviral Vectors for Gene Therapy, 2nd ed., Part II, *Advances in Genetics*, Vol. 54, Elsevier Academic Press, 2005.
4. **Huang, L.**, Liu, D. and Wagner, E. Nonviral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer. *Advances in Genetics*, Vol. 88, Elsevier Academic Press, 2014.
5. **Huang, L.**, Liu, D. and Wagner, E. Nonviral Vectors for Gene Therapy: Physical Methods and Medical Translation. *Advances in Genetics*, Vol. 89, Elsevier Academic Press, 2014.

Reviews, Book Chapters and Conference Proceedings:

1. **Huang, L.** Liposome-cell interactions *in vitro*. In: *The Liposomes*, Ed. Ostro, M., Marcel Dekker, chap. 3, pp. 87-124, 1983.
2. **Huang, L.**, Huang, A. and Kennel, S.J. Coupling of antibodies with liposomes. In: *Liposome Technology*, Vol. 3., Ed. Gregoriadis, G., CRC Press, Inc., chap. 4, pp. 51-62, 1984.
3. Huang, A., Kennel, S.J. and **Huang, L.** Preparation of immunoliposomes. In: *Investigation of Membrane-Located Receptors*. Eds. Reid, E., Cook, G.M.W. and Morr'e, D.J. Plenum Press, pp. 351-355, 1984.
4. **Huang, L.** Liposomes as a new biotechnology: preparation and properties of liposomes. In: *Proceedings of the 1984 Symposium on Genetic Engineering and Biotechnology*, Eds. Wu, R., Lin, E. and Kung, S.D. State Science and Technology Commission of the People's Republic of China, Beijing, pp. 447-454, 1984.
5. **Huang, L.** Liposome-cell interactions *in vitro* and *in vivo*. In: *Proceedings of the 1984 Symposium on Genetic Engineering and Biotechnology*, Eds. Wu, R., Lin, E. and Kung, S.D., State Science and Technology Commission of the People's Republic of China, Beijing, pp. 455-462, 1984.
6. **Huang, L.** Liposomes as diagnostic reagents and as vehicles for intracellular delivery of nucleic acids and proteins. In: *Proceedings of the 1984 Symposium on Genetic Engineering and Biotechnology*, Eds. Wu, R., Lin, E. and Kung, S.D. State Science and Technology Commission of the People's Republic of China, Beijing, pp. 463-473, 1984.
7. **Huang, L.** Liposomes as Drug Carriers. In: *Proceedings of the 1984 Symposium on Genetic Engineering and Biotechnology*, Eds. Wu, R., Lin, E. and Kung, S.D. State Science and Technology Commission of the People's Republic of China, Beijing, pp. 474-480, 1984.

8. Sullivan, S.M., Connor, J. and **Huang, L.** Immunoliposomes: preparation, properties and applications. *Medicinal Research Reviews*, Vol. 6, 171-195, 1986.
9. Kabalka, G., Buonocore, E., Hubner, K., **Huang, L.**, Moss, T. and Norley, N. Gadolinium labeled liposomes as contrast agents for magnetic resonance imaging. In: *Contrast Agents in Magnetic Resonance Imaging*, Eds. Runge, V.M., Claussen, C. and James, A.E. Excerpta Medica Publ., pp. 88-91, 1986.
10. Connor, J., Sullivan, S.M. and **Huang, L.** Monoclonal antibody and liposomes. In: *Monoclonal Antibodies in Pharmacology*, a volume of *International Encyclopedia of Pharmacology and Therapeutics*, Eds. Fraser, C.M. and Venter, J.C. Pergamon Press, also published in *Pharmacology and Therapeutics* 28:341-365, 1985.
11. **Huang, L.**, Connor, J. and Wang, C.-Y. pH-sensitive immunoliposomes. In: *Drug and Enzyme Targeting* (volume 149 of *Methods in Enzymology*), Eds. Green, R. and Widder, K.J. Academic Press, chap. 8, pp. 88-99, 1987.
12. Connor, J. and **Huang, L.** Acid induced fusion of liposomes. In: *Cell Fusion*, Ed. Sowers, A.E. Plenum Publ. Co., chap. 13, pp. 285-299, 1988.
13. Collins, D., Norley, S., Rouse, B. and **Huang, L.** Liposomes as carriers for antitumor and antiviral drugs: pH-sensitive immunoliposomes and sustained release immunoliposomes. In: *Liposomes as Drug Carriers: Recent Trends and Progress*, Ed. Gregoriadis, G., Wiley, chap. 55, pp. 761-770, 1988.
14. Ho, R.J.Y. and **Huang, L.** Immunoliposome assays: perspectives, progress and potential. In: *Liposomes as Drug Carriers: Recent Trends and Progress*, Ed. Gregoriadis, G., Wiley, chap. 38, pp. 527-547, 1988.
15. Collins, D. and **Huang, L.** Drug delivery by immunoliposomes. In: *Molecular Mechanisms of Membrane Fusion*, Ed. Ohki, S., et al., Plenum Publishing Corp., pp. 149-161, 1988.
16. Wright, S. and **Huang, L.** Antibody directed liposomes as drug delivery vehicles, *Advanced Drug Delivery Reviews* 3:343-389, 1989.
17. Holmberg, E. and **Huang, L.** pH-sensitive and target sensitive immunoliposomes for drug targeting. In: *Liposomes in the Therapy of Infectious Diseases and Cancer*, Eds. Lopez-Berestein, G. and Fidler, I. Allen R. Liss, Inc., pp. 25-34, 1989.
18. **Huang, L.** and Zhou, X. Cytoplasmic delivery of DNA by pH-sensitive immunoliposomes. In: *Proceedings of ILRAD Workshop on Protein Traffic in Parasites and Mammalian Cells*, pp. 81-86, 1989.
19. Brynestad, K., Babbitt, B., **Huang, L.** and Rouse, B.T. Liposomal peptide as a subunit vaccine. In: *Therapeutic Peptides and Proteins: Formulation, Delivery, and Targeting*, Eds. Marshak, D. and Liu, D. Cold Spring Harbor Laboratory, pp. 99-106, 1990.
20. Rouse, B.T., Kennel, S.J. and **Huang, L.** Drug delivery by immunoliposomes. In: *Proceedings of ILRAD Workshop on Chemotherapy of Trypanosomiasis*, pp. 119-122, 1990.
21. Maruyama, K., Kennel, S.J. and **Huang, L.** Liposomal drug delivery system, *Polymer Preprints* 31:159-160, 1990.

22. Maruyama, K., Kennel, S.J. and **Huang, L.** The target binding and retention of Stealth immunoliposomes. *J. Pharmacobio-Dyn.*, 14, s-32, 1991.
23. **Huang, L.**, Reddy, R., Nair, S., Zhou, F. and Rouse, B.T. Liposomal delivery of soluble protein antigens for class I MHC mediated antigen presentation. In: 41st Forum in Immunology, ed. van Rooijen, N., *Research In Immunology* 143:192-196, 1992.
24. Zhou, X. and **Huang, L.** Targeted delivery of DNA by liposomes and polymers. In: Proceedings of 5th International Symposium on Recent Advances in Drug Delivery Systems. *J. Controlled Release* 19:269-274, 1992.
25. Mori, A. and **Huang, L.** Immunoliposome targeting in a mouse model: optimization and therapeutic application. In: *Liposome Technology*, Vol. 3, 2nd edition, Ed. Gregoriadis, G. CRC Press, chap. 10, pp 153-162, 1992.
26. Tari, A., Zhou, F. and **Huang, L.** Two types of pH-sensitive immunoliposome. In: *Liposome Technology*, Vol. 3, 2nd edition, Ed. Gregoriadis, G. CRC Press, chap. 19, pp. 289-300, 1992.
27. Pinnaduwage, P. and **Huang, L.** Target sensitive liposome for potential therapeutic applications. In: *Liposome Technology*, Vol. 3, 2nd edition, Ed. Gregoriadis, G. CRC Press, chap. 18, pp. 277-287, 1992.
28. Litzinger, D.C. and **Huang, L.** Phosphatidylethanolamine liposomes: drug delivery, gene transfer, and immunodiagnostic applications. In: *Biomembrane Reviews, Biochim. Biophys. Acta.* 1113:201-227, 1992.
29. Mori, A. and **Huang, L.** "Ninja liposomes" avoiding reticuloendothelial system: development and application. Proceedings of First Shizuoka Drug Delivery System Symposium, University of Shizuoka, Japan. *Progress in Drug Delivery Systems* 1:1-8, 1992.
30. Pitt, B.R. and **Huang, L.** Targeted drug delivery to the lung. *Contemp. Int. Med.* 4:81-92, 1992.
31. Mori, A., Liu, D. and **Huang, L.** Novel immunoliposome targeting system avoiding reticuloendothelial cell interactions. In: *Drug Targeting And Delivery: Concepts In: Dosage Form Design*, ed. Junginger, H. E., Ellis Horwood Publishers, pp. 26-42, 1992.
32. Scherphof, G.L., Maruyama, K., van Borssum Waalkes, M., Hoekstra, D., Damen, J., Kennel, S.J. and **Huang, L.** Lipid flow phenomena between liposomes, lipoproteins and cell membranes: applications in drug delivery. In: *Liposome Dematics*, eds. Braun-Falco, Korting and Maibach, Springer Verlag, pp. 11-19, 1992.
33. Klibanov, A.L. and **Huang, L.** Long-circulating liposomes: development and perspectives. *J. Liposome Res.* 2:321-334, 1992.
34. **Huang, L.** Stealth liposomesTM, Ninja liposomes or cryptosomes: are they really sterically stabilized liposomes? *J. Liposome Res.* 2:451-454, 1992.
35. **Huang, L.** and Zhou, F. Liposome and immunoliposome mediated delivery of proteins and peptides. In: *Targeting of Drugs 3: The Challenge of Peptides and Proteins*, eds. Gregoriadis, G., Allison, A.C. and Poste, G. NATO Advance Study Institute Series, Plenum., pp. 45-50, 1992.

36. Gao, X. and **Huang, L.** Cationic liposomes and polymers for gene transfer. *J. Liposome Res.* 3:17-30, 1993.
37. Hofland, H. and **Huang, L.** Delivery of nucleic acid pharmaceuticals with liposomes. In: *Recent Advances in Pharmaceutical and Industrial Biotechnology*, Ed. Duchene, D. Proceedings of 6th International Pharmaceutical Technology Symposium, Ankara, Turkey, pp. 99-109, 1993.
38. Son, K. and **Huang, L.** Liposomes for gene transfer. In proceedings of 53rd INSERM Workshop on "Transfer of genes and antisense oligonucleotides: physiological and therapeutic applications", Le VJsinet, France, 1993.
39. Torchilin, V.P., Zhou, F. and **Huang, L.** pH-sensitive liposomes. *J. Liposome Res.* 3:201-255, 1993.
40. Liu, D. and **Huang, L.** Immunoliposome targeting to pulmonary endothelium. In: *Drug Delivery Series*, Vol. 2, Eds. Florence, A.T. and Gregoriadis, G. pp.111-124, 1993.
41. **Huang, L.**, Klibanov, A.L., Mori, A. and Gao, X. Targeted delivery of drugs and DNA with liposomes. Proceedings of conference on "Liposomes as biomimetics", Rome, Italy, June 23-26, 1993. *J. Liposome Res.* 3:505-515, 1993.
42. Singhal, A. and **Huang, L.** Gene transfer in mammalian cells using liposomes as carriers. In: *Gene Therapeutics: Methods and Application of Direct Gene Transfer*, Ed. Wolff, J.A., Birkhauser, pp. 118-142, 1994.
43. Zhou, F. and **Huang, L.** Liposome-mediated cytoplasmic delivery of proteins: an effective means to access the MHC class I-restricted antigen presentation pathway. *ImmunoMethods* 4:229-235, 1994.
44. Singhal, A. and **Huang, L.** Direct gene transfer by liposomes. Proceeding of The Liposome Conference In St. Petersburg: *New Concepts, Perspectives and Clinical Applications.* *J. Liposome Res.* 4:289-299, 1994.
45. Liu, D. and **Huang, L.** Interaction of pH-sensitive liposomes with blood components. Proceedings of The Liposome Conference In St. Petersburg: *New Concepts, Perspectives and Clinical Applications.* *J. Liposome Res.* 4:121-141, 1994.
46. Maruyama, K., Unezaki, S., Yuda, T. Ishida, O., Takahashi, N., Suginaka, A., **Huang, L.** and Iwatsuru, M. Enhanced delivery and antitumor effect of doxorubicin encapsulated in long-circulating liposomes. Proceedings of The Liposome Conference in St. Petersburg: *New Concepts, Perspectives and Clinical Applications.* *J. Liposome Res.* 4:143-165, 1994.
47. **Huang, L.** Target-sensitive liposomes. *J. Liposome Res.* 4:397-412, 1994.
48. **Huang, L.** and Sorgi, F.L. Comments: Forum on "Liposomes in controlled release". *J. Liposome Res.* 4:439-440, 1994.
49. Farhood, H., Gao, X., Son, K., Yang, Y.Y., Lazo, J.S., and **Huang, L.** Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. In: *Annals of the New York Academy of Sciences*, eds. Brian E. Huber and John S. Vol. 716, pp 23-35, 1994.

50. Nabel, G.J., Nabel, E.G., Yang, Z., Fox, B.A., Plautz, G.E., Gao, X., **Huang, L.**, Shu, S., Gordon, D., and Chang, A.E. Molecular genetic interventions for cancer. In: *Molecular Genetics of Cancer*. Cold Spring Harbor Laboratory Press, Vol. LIX pp 699-707, 1994.
51. Singhal, A., and **Huang, L.** DC-chol liposomes as DNA carriers for gene therapy. In: *Gene Therapy: From Basic Research To The Clinic*, Ed. Kam M. Hui, World Scientific Publishing Co. Pte. Ltd., pp 107-129, 1994.
52. Son, K. and **Huang, L.** Liposomal DNA delivery. In: *Trends and Future Perspectives in Peptides and Protein Drug Delivery*, Eds. Lee, V.H.L., Hashida, M. and Mizushima, Y. pp. 321-336, 1995.
53. Hung, M.C., Matin, A., Zhang, Y., Xing, X., Sorgi, F., **Huang, L.** and Yu, D. HER-2/neu: targeting gene therapy. *Gene* 159:65-71, 1995.
54. Zhou, F., and **Huang, L.** Delivery of protein antigen to major histocompatibility complex class-I-restricted antigen presentation pathway. *Journal of Drug Targeting* 3:91-109, 1995.
55. Mori, A., and **Huang, L.** Targeted immunoliposomes: potential role in the delivery of cytotoxic drugs. *Clin. Immunother.*, 3 (3): 227-240, 1995.
56. Goyal, K. and **Huang, L.** Gene therapy using DC-Chol liposomes. *J. Liposome Res.* 5 (1):49-60, 1995.
57. Gao, X., and **Huang, L.** Cationic liposome mediated gene transfer. *Gene Therapy*, 2:710-722, 1995.
58. Bedu-Addo, F., and **Huang, L.** Interaction of PEG-phospholipid conjugates with phospholipid: Implications in liposomal drug delivery. *Advanced Drug Delivery Reviews*, 16:235-247, 1995.
59. Yao, T., **Huang, L.** and Zern, M.A. The use of liposomes in the therapy of liver disease. *Advanced Drug Delivery Reviews* 17:239-246, 1995.
60. Farhood, H., and **Huang, L.** Delivery of DNA, RNA, and proteins by cationic liposomes. In: *Non-medical Use of Liposomes*, Eds. Barenholz, Y. and Lasic, D., CRC Press, Incorporated, pp 31-42, 1996.
61. Li, S., Gao, X., Son, K., Sorgi, F. and **Huang, L.** DC-Chol lipid system in gene transfer. *J. of Controlled Release* 39:373-381, 1996.
62. Lee, R.J. and **Huang, L.** Gene transfer by liposome-entrapped polycation-condensed DNA-LPDI and LPDII. *Conference Proceedings, Artificial Self-Assembling Systems for Gene Delivery*, American Chemical Society, Washington, D.C., eds. Felgner, Heller, Lehn, Behr and Szoka, Jr. chap. 16, pp 169-176, 1996.
63. Li, S., and **Huang, L.** Lipidic supramolecular assemblies for gene transfer. *J. Liposome Research* 6:589-608, 1996.
64. Li, S. and **Huang, L.** Targeted delivery of antisense oligodeoxynucleotides by LPD II. *J. Liposome Research*, 7:63-76, 1997.
65. Deshmukh, H.M., and **Huang, L.** Liposome and polylysine mediated gene transfer. *New J. of Chemistry*, 21:113-124, 1997.

66. Hara, T., Liu, F., Liu, D., and **Huang, L.** Emulsion formulations as a vector for gene delivery *in vitro* and *in vivo*. *Advanced Drug Delivery Reviews* 24:265-271, 1997.
67. Son, K., Sorgi, F., Gao, X., **Huang, L.** Cationic liposome-mediated gene transfer to tumor cells *in vitro* and *in vivo*. In: *Methods in Molecular Medicine, Gene Therapy Protocols*; Ed. Robbins, P. Humana Press, chap. 23, pp. 329-337, 1997.
68. Lee, R.J., and **Huang, L.** Lipidic vector systems for gene transfer. *Critical Reviews in Therapeutic Drug Carrier Systems*, 14(2) 173-206, 1997.
69. Li, S., and **Huang, L.** Protamine sulfate provides enhanced and reproducible intravenous gene transfer by cationic liposome/DNA complex. *J. Liposome Res.*, 7:207-219, 1997.
70. Sorgi, F. L., and **Huang, L.** Drug delivery applications of liposomes containing non-bilayer forming phospholipids. In: *Lipid Polymorphs and Membrane Properties*. In: *Current Topics in Membranes*, Volume 44. Ed. Epand, R. Academic Press Inc. chpt. 12, pp. 449-475, 1997.
71. Lee, R., and **Huang, L.** pH-sensitive liposome-mediated macromolecule delivery into the cytoplasm of cultured cells. In: *Cells: A Laboratory Manual*, Eds. Spector, D., Goldman, R., and Lein-Wand, L., Cold Spring Harbor Laboratory Press, Vol. 2, chpt. 87, pp 87.1 - 87.9, 1997.
72. Lee, R., and **Huang, L.** Delivery of DNA into mammalian cells using cationic liposomes. In: *Cells: A Laboratory Manual*, Eds. Spector, D., Goldman, R., and Lein-Wand, L., Cold Spring Harbor Laboratory Press, Vol. 2, chpt. 87, pp87.1 - 87.9,1997.
73. Hofland, H.E.J., and **Huang, L.** Formulation and delivery of nucleic acids. In: *Handbook of Experimental Pharmacology: Novel Therapeutics from Modern Biotechnology*, Volume 137. eds. Oxender, D.L. and Post, L.E., Springer-Verlag, chpt.8, pp. 165-192, 1998.
74. Brisson, M., and **Huang, L.** Improved gene delivery formulations and expression systems for enhanced transfection efficiency. 4th International Symposium on Bioorganic Chemistry. In: *Pure & Appl. Chem.*70 (1):83-88, 1998.
75. Li, S., and **Huang, L.** Functional pleomorphism of liposomal gene delivery vectors: lipoplex and lipopolyplex. In: *Liposomes: Rational Design*, Ed. Janoff, A. Marcel Dekker, Inc., Chpt. 4, pp.89-124, 1999.
76. Yang, J.P., and **Huang, L.** Novel supramolecular assemblies for gene delivery. In: *Self-Assembling Complexes for Gene Delivery: from Chemistry to Clinical Trial.*, Ed. Kabanov, A., John Wiley Publishing. chpt 6, pp 117-134. 1998.
77. Bhattacharya, S. and **Huang, L.** Cationic liposome-DNA complexes in gene therapy, In: *Medical Applications of Liposome*, Eds. Lasic, D.D. and Papahadjopoulos, D., Elsevier Press, chpt 5.3, pp. 371-394, 1998.
78. Tseng, W.C. and **Huang, L.** Liposome based gene therapy. *Pharm. Sci. & Tech. Today*. 1 (5): 206-213, 1998.

79. Chesnoy, S. and **Huang, L.** DNA condensed by polycations and lipids for gene transfer. *S.T.P. Pharma Sciences*. 9: 5-12, 1999.
80. Brisson, M. and **Huang, L.** Liposomes: conquering the nuclear barrier. *Current Opinion in Molecular Therapeutics*. 1(2): 140-146, 1999.
81. **Huang, L.** and Viroonchatapan, E. Introduction: Nonviral Vectors for Gene Therapy. Ed. **Huang, L.**, Hung, M.C., Wagner, E. Academic Press, chpt 1, pp. 4-17, 1999.
82. Li, S., and **Huang, L.** Novel Lipidic Vectors for Gene Transfer: Nonviral Vectors for Gene Therapy, ed. **Huang, L.**, Hung, M.C., Wagner, E. Academic Press, chpt 13, pp. 290-306, 1999.
83. Li, S. and **Huang, L.** Nonviral Gene Therapy: Promises and Challenges, *Millennium Review, Gene Therapy* 7: 31-34, 2000.
84. Chesnoy S, **Huang, L.** Structure and function of lipid-DNA complexes for gene delivery. *Annu. Rev. Biophys. Biomol. Struct.* 29:27-47, 2000.
85. Liu, F., Liang, K., **Huang, L.** Gene transfer to Skeletal Muscles via Systemic Administration of Plasmid DNA. *Molecular Interventions*. 1: 168-172, 2001.
86. Liang, K. W. and **Huang, L.** New Lipid/DNA Complexes for Gene Delivery. In: *Polymeric Biomaterials: 2nd edition*, Ed. Dumitriu, S., Marcel Dekker, pp. 929-958, 2002.
87. Dileo, J. and **Huang, L.** Liposome Mediated Gene Therapy for Cancer. *Encyclopedia of Cancer*, pp. 31-37, 2002.
88. Tan, Y., Whitmore, M., Li, S., Frederik, P., and **Huang, L.** LPD Nanoparticles as a Novel Non-Viral Vector for Efficient Gene Delivery. Ed. Morgan, J.R. *Gene Therapy Protocols*, 2nd edition, Humana Press, Inc. chpt. 6, pp. 73-82, 2002.
89. Nishikawa, M. and **Huang, L.** Nonviral Vectors in the New Millennium. *Human Gene Therapy*. 12: 861-870, 2001.
90. Lui, V. and **Huang, L.** Non-Viral Approaches for Cancer Gene Therapy. *Pharmaceutical Gene Delivery Systems*, Marcel Dekker, Inc. 131: 279-319, 2003.
91. Liu, F. and **Huang, L.** Development of non-viral vectors for systemic gene delivery. *Journal of Controlled Release*. 78: 259-266, 2002.
92. Li, S., Ma, Z., Tan, Y., Liu, F., Dileo, J. and **Huang, L.** Targeted Gene Delivery via Lipidic Vectors. In: *Vector Targeting for Therapeutic Gene Delivery*, Eds. Curiel, D. and Douglas, J., John Wiley & Sons, Inc. Chpt. 2. pp. 17-32, 2002.
93. Tan, Y. and **Huang, L.** Overcoming the Inflammatory Toxicity of Cationic Gene Vectors. *Journal of Drug Targeting*. 2: 153-60, 2002.
94. Liang, K., Liu, F. and **Huang, L.** Targeted gene delivery: the role of peptide nucleic acid. *Letters in Peptide Science*. 7: 161-167, 2004.

95. Niidome, T. and **Huang, L.** Gene therapy progress and prospects: Non-viral vectors. *Gene Therapy*. 9: 1647-1652, 2002.
96. Nishikawa, M., **Huang, L.**, and Hashida, M. Dystrophin gene transfer for Duchenne Muscular Dystrophy. *Gene & Medicine*. 6 (3): 389-394, 2002. (In Japanese).
97. Dileo, J., Banerjee, R., Whitmore, M., Nayak, J., Falo, L., **Huang, L.** Lipid-Protamine-DNA-Mediated antigen delivery to antigen-presenting cells resulting in enhanced anti-tumor immune responses. *Molecular Therapy*. 7(5): 650-648, 2003.
98. Banerjee, R. and **Huang, L.** Gene Therapy with Plasmid DNA. *Burger's Medicinal Chemistry and Drug Delivery 6th Edition*. Ed. Abraham, D.J. John Wiley & Sons, Inc. Vol. 4 Chapter 13. pp. 651-677, 2003.
99. Zhang, J., Li, S., and **Huang, L.** Cationic liposome-protamine-DNA complexes for gene delivery, *Methods in Enzymology*. Ed. Düzgünes, N. Elsevier Academic Press. V. 373 Liposomes Part C, pp. 332-341, 2003.
100. Conwell, C. C. and **Huang, L.** Recent progress in nonviral gene delivery. *Non-viral gene therapy: gene design and deliver*. Eds. Taira, K. and Kataoka K. Springer-Verlag Tokyo Inc. Chapter 1. pp 3-10, 2005.
101. Zhang, J-S., Liu, F., and **Huang, L.** Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. *Advanced Drug Delivery Reviews*. pp. 689-962, 2005.
102. Chen, W.S.C. and **Huang, L.** Non-viral Vector as Vaccine Carrier. In "Non-Viral Vectors for Gene therapy" 2nd ed., Eds. Huang, L., Huang, M.C. and Wagner, E. *Advances In Genetics*, Vol. 54: 316-338. Elsevier Inc. chapter 13, pp. 315-337, 2005.
103. Conwell, C.C. and **Huang, L.** Recent Advances in non-viral gene delivery. In "Non-Viral Vectors for Gene Therapy" 2nd ed., Eds. Huang, L., Huang, M.C. and Wagner, E., *Advances In Genetics*, Vol. 53. Elsevier Inc. Chapter 1, pp. 3-18, 2005.
104. Vangsseri, D., Han S-J., and **Huang, L.** Lipid-Protamine-DNA-Mediated Antigen Delivery. *Current Drug Delivery*. Bentham Science Publishers. 2(4): 401-406, 2005.
105. Liang, K.W., Liu, F., and **Huang, L.** Targeted Gene Delivery: The Role of Peptide Nucleic Acid. In "Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules", Eds. Janson, C. G., During, M. J. *Medical Intelligence Unit*. Landes Bioscience. Chapter 3, pp. 30-37, 2006.
106. Banerjee, R and **Huang, L.** Vector System: Plasmid DNA. In "Encyclopedia of Molecular Cell Biology and Molecular Medicine 2nd Edition." Ed. Meyers, R.A. Wiley-VCH Verlag GmbH & Co KgaA, Weinheim, Germany pp. 287 – 329, 2006.
107. Tyagi, P., Wu, P.C., Chancellor, M., Yoshimura, N., **Huang L.** Recent Advances in Intravesical Drug/Gene Delivery. *Molecular Pharmaceutics*. 3:369-379, 2006. (PMCID: PMC2504416)
108. Li, S., **Huang, L.** Gene Therapy Progress and Prospects: Non-viral Gene Therapy by Systemic Delivery. *Gene Therapy*. 13(18):1313-1319, 2006.

109. Tyagi, P., Tyagi, S., Kaufman, J., **Huang, L.**, and de Miguel, F. Local Drug Delivery to Bladder Using Technology Innovations. *Urol Clin N Am* 33:529-530, 2006.
110. Li, S-D., Li, S., and **Huang, L.** Lipoplex and LPD Nanoparticles for In Vivo Gene Delivery. In “Gene Transfer. Delivery and Expression of DNA and RNA”, Eds, Friedman, T and Rossi J. Cold Spring Harbor Laboratory Press. Chapter 39, pp 433 – 438, 2006.
111. Li, S-D. and **Huang, L.** Surface-Modified LPD Nanoparticles for Tumor Targeting. In “Oligonucleotide Therapeutics”. *Annual of the New York Academy of Sciences* 1082: 1 – 8, 2006.
112. Shollenberger, L. M. and **Huang, L.** Liposome-Polycation-DNA: A Nonviral Gene Vector Turned into a Potent Vaccine Carrier. In “Liposome Technology: Entrapment of Drugs and Other Materials into Liposomes” 3rd Edition. Ed, Gregoriadis, G. Informa Healthcare USA, Inc. pp 245 – 252, 2007.
113. Lee, P.-Y. and **Huang, L.** Non-viral vector systems. In Dr. Beverly Teicher’s Series “Gene Therapy for Cancer”; Eds. Hunt, K. K. Vorburger, S.A and Swisher, S.G. Humana Press Inc. pp.157-170, 2007.
114. Yan, W. and **Huang, L.** Recent Advance in Liposome-based Nanoparticles for Antigen Delivery. *Polymer Reviews*. 47:329 – 344, 2007.
115. Li, S-D., and **Huang, L.** Non-viral is superior to viral gene delivery. *Journal of Controlled Release*. 123: 181-183, 2007.
116. Li, S-D., and **Huang, L.** Pharmacokinetics and Biodistribution of Nanoparticles. *Molecular Pharmaceutics* 5(4): 496 – 504, 2008.
117. Chen, Y., and **Huang, L.** Tumor Targeted Delivery of siRNA by Non-Viral Vector: Safe and Effective Cancer Therapy. *Expert Opin. Drug Deliv.* 5 (12):1301-1311, 2008. PMID: PMC5515368.
118. Gao, K. and **Huang, L.** Non-viral Methods for siRNA Delivery. *Molecular Pharmaceutics*. 6: 651-658, 2009. (PMCID: PMC2692493)
119. Li, S-D, and **Huang, L.** Targeted Delivery of siRNA by Nonviral Vectors: Lessons learned from recent advances. *Current Opinion in Investigational Drugs* 9(12): 1317 – 1323, 2008.
120. Tseng, Y-C., Mozumdar, S. and **Huang, L.** Lipid-based Systemic Delivery of siRNA. *Advanced Drug Delivery Reviews*. 61(9):721 – 731, 2009.
121. Bathula, S. R, and **Huang, L.** Gene Therapy with Plasmid DNA. In “Burgers Medicinal Chemistry, Drug Discovery and Development.” John Wiley & Sons. 2010.
122. Vasievich, E.A., and **Huang, L.** Chemical Vectors for Delivery of Nucleic Acid-Based Drugs. In “Delivery Technologies for Biopharmaceuticals. Peptides, Proteins, Nucleic Acids and Vaccines.” Eds, Jorgensen, L., Nielsen, H.M.. John Wiley & Sons. Pp 69 – 92, 2009.
123. Tseng, Y.C. and **Huang, L.** Self-Assembled Lipid Nanomedicines for siRNA Tumor Targeting. *J Biomed Nanotechnol.* 5(4): 351–363, 2009. PMID: PMC5512419

124. Li, S.D. and **Huang, L.** Stealth Nanoparticles: High Density but Sheddable PEG Is a Key for Tumor Targeting. *Journal of Controlled Release*. 145(3):178-81, 2010. ePublication on Mar 23, 2010.
125. Li, J. and **Huang, L.** Targeted Delivery of RNAi Therapeutics for Cancer Therapy. *Nanomedicine*, 5(10), 1483–1486, 2010.
126. Sheng, W.Y. and **Huang, L.** Cancer Immunotherapy and Nanomedicine. *Pharm. Res.* 28(2):200-14, 2011. Published on line September 4, 2010.
127. Liu, F., Park, JY, Zhang, Y, Conwell, C, Liu, Y, Bathula, SR, **Huang, L.** Targeted cancer therapy with novel high drug-loading nanocrystals. *J. Pharm. Sci.*, 99(8):3542-3551, 2010.
128. Zhang, Y. and **Huang, L.** RNA Drug Delivery Approaches. A chapter in “Drug Deliver in Oncology: From Research Concept to Cancer Therapy”, Volume 3, Eds. Kratz, F., Senter, P. and Steinhagen, H. Wiley-VCH, 2011.
129. Vasievich E.A. and **Huang L.** The suppressive tumor microenvironment: a challenge in cancer immunotherapy. *Mol. Pharm.* 8(3):635-41, 2011. Epub 2011 May 5. PMID: PMC5514373.
130. **Huang, L.** and Liu, Y. In Vivo Delivery of RNAi with Lipid-Based Nanoparticles. *Annu. Rev. Biomed. Eng.* 13:507-530. 2011. ePublication on May 31, 2011.
131. Guo, S. and **Huang, L.** Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy. *Journal of Nanomaterials*, Special issue “Nanostructures for Medicine and Pharmaceuticals,” 2011. JNM/742895.
132. Guo, X. and **Huang, L.** Recent Advances in Non-viral Vectors for Gene Delivery. *Accounts of Chemical Research*. 45(7):971-979, 2012, ePublication on August 26, 2011. PMID: PMC3240701
133. Wang, Y.H. and **Huang, L.** Multifunctional Theranostic Nanoparticles for Brain Tumors. A commentary. *Molecular Therapy*, 20:10-11, 2012.
134. Watson, D.S., Endsley, A.N. and **Huang, L.** Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. *Vaccine*, 30(13):2256–2272, 2012. ePublication on February 2, 2012. PMID: PMC3296885.
135. Zhang, Y., Satterlee, A. and **Huang, L.** In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles? *Molecular Therapy*. 20(7):1298-1304, 2012. doi: 10.1038/mt.2012.79. Epub 2012 Apr 24. PMID: PMC3392980.
136. Ramishetti S. and **Huang, L.** Intelligent Design of Multifunctional Lipid-Coated Nanoparticles Platforms for Cancer Therapy. *Therapeutic Delivery*, 3:1429-1445, 2012. PubMed ID NIHMS437888. PMID: PMC3584330.
137. Zhang S. B., Zhi D. F., and **Huang, L.** Lipid-Based Vectors for siRNA Delivery. *Journal of Drug Targeting*, 20(9): 724-735, 2012. PMID: PMC5006685.

138. Xu, Z. H. and **Huang, L.** Chemical Vectors for Gene Delivery. In "Gene therapy: technologies and applications", ed. by Duc Hong Le, Ryuichi Morishita and Hironori Nakagami, Future Medicine, Future Science Group (FSG), Chapter 3, page 34-45, 2013.
139. Wang, Y. and **Huang, L.** Lipid Nanoparticles for the Delivery of Nucleic Acids. In: "Nanoparticulate Drug Delivery Systems: Strategies, Technologies, and Applications". ed. by Yoon Yeo, p51-80. John Wiley & Sons, 2013.
140. Satterlee, A.B., **Huang, L.** (2014). Cancer Therapy with RNAi delivered by Nonviral Membrane/Core Nanoparticles. In "Cancer Gene Therapy by Viral and Non-viral Vectors" (pp.). Hoboken, New Jersey. John Wiley & Sons, Inc.
141. Asai, T. and **Huang, L.** Nanoparticle-mediated RNA interference for cancer therapy. In "RNA Interference - Pathways to Advanced Therapeutics". Ed: Andrew Miller & Luc Jasmin. Springer. In press. 2013.
142. Gao, K. and **Huang, L.** Achieving efficient RNAi therapy: progress and challenges. *Acta Pharmaceutica Sinica B.* 3(4):213–225, 2013.
143. Haynes, M.T. and **Huang, L.** Hepatic RNA Interference: Delivery by Synthetic Vectors. *Drug Delivery and Translational Research*, 4(1):61-73, 2014. published on line May 24, 2013. PMID: PMC3963286.
144. Yao, J., Fan, Y., Li, Y.K. and **Huang, L.** Strategies on the nuclear-targeted delivery of genes. *J. Drug Target.* 21:926-939, 2013, Aug 22. Epub ahead of print. PMID: 23964565. PMID: PMC5006680.
145. Wang, Y., Xu, Z. and **Huang, L.** Reply to "On the Mechanism and Benefit of siRNA-mediated Targeting of CD47 in Cancer". *Mol. Ther.* 21(10):1812-1813, 2013. doi: 10.1038/mt.2013.206.
146. Wang, Y. and **Huang L.** A window onto siRNA delivery. *Nat. Biotechnol.* 31(7):611-612. 2013. doi: 10.1038/nbt.2634. PMID: 23839146.
147. Guo, S.T. and **Huang, L.** Nanoparticles Containing Insoluble Drug for Cancer Therapy. *Biotechnology Advances*, 32(4):778-88, 2014. Epub 2013 Oct 18. PMID: PMC3980181.
148. Guo, S.T., Miao, L. and **Huang, L.** Lipid Coated Calcium Phosphate Nanoparticles for Drug Delivery. *Acta Biophysica Sinica*, 11:823-830, 2013. (Chinese with English abstract)
149. Chen, Y., Gao, D.Y. and **Huang, L.** In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. *Advanced Drug Delivery Reviews*, 81:128-141, 2015. Epub 2014 May 22. PMID: PMC5009470.
150. Zhang, J., Li, X. and **Huang, L.** Non-viral nanocarriers for siRNA delivery in breast cancer. *J. Controlled Release*, 190:440-450, 2014. Epub 2014 May 27. PMID: PMC4142098.
151. Goodwin, T. and **Huang, L.** Nonviral Vectors: We Have Come a Long Way. In "Non-viral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer" ed. Huang, L., Liu, D. and Wagner, E. Chapter 1, pp 1-12, 2014, *Advances in Genetics*, Volume 88, Elsevier Academic Press. PMID: PMC5006058.

152. Zhao, Y. and **Huang, L.** Lipid Nanoparticles for Gene Delivery. In “Non-viral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer” ed. Huang, L., Liu, D. and Wagner, E. Chapter 2, pp 13-36, 2014, *Advances in Genetics*, Volume 88, Elsevier Academic Press. PMID: PMC5006671.
153. Wang, Y. and **Huang, L.** Composite Nanoparticles for Gene Delivery. In “Non-viral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer” ed. Huang, L., Liu, D. and Wagner, E. Chapter 5, pp 111-137, 2014, *Advances in Genetics*, Volume 88, Elsevier Academic Press. PMID: PMC5009467.
154. Hayes, M.T. and **Huang, L.** Lipid-Coated Calcium Phosphate Nanoparticles for Nonviral Gene Therapy. In “Non-viral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer” ed. Huang, L., Liu, D. and Wagner, E. Chapter 7, pp 206-229, 2014, *Advances in Genetics*, Volume 88, Elsevier Academic Press.
155. Lin, G. Zhang, H. and **Huang, L.** Smart polymeric nanoparticles for cancer gene delivery. *Molecular Pharmaceutics*, 12:314-321, 2015.
156. Wang, Y., Miao, L., Satterlee, A. and **Huang, L.** Delivery of Oligonucleotides with Lipid Nanoparticles. *Advanced Drug Delivery Review*, 87:68-80, 2015. PMID: PMC4539950.
157. Miao, L. and **Huang, L.** Exploring the Tumor Microenvironment with Nanoparticles. *Cancer Treatment and Research*, 166, pp 193-226, 2015. Published as a chapter in “Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer”, ed. C.A. Mirkin et al, Springer International Publishing Switzerland. PMID: PMC5010228.
158. Miao, L., Lin, C.M. and **Huang, L.** Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. *Journal of Controlled Release*, 219:192-204, 2015. Epub 2015 Aug 12. PMID: PMC4656082.
159. Satterlee, A.B. and **Huang, L.** Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform. *Theranostics*, 6(7):918-929, 2016. PMID: PMC4876619.
160. Putra, G.N.P.E., **Huang, L.** and Hsu, Y.-C. Cisplatin Encapsulated Nanoparticle as a Therapeutic Agent for Anticancer Treatment. *Proc. SPIE 9709, Biophotonics and Immune Responses XI, 97090T* (March 9, 2016); doi:10.1117/12.2214695.
161. **Huang, L.** and Miao, L. Pieter Cullis: An Outstanding Lipid Biophysicist, Drug Delivery Scientist, Educator and Entrepreneur. *Journal of Drug Targeting*, 24(9):762-764, 2016. DOI: 10.3109/1061186X.2016.1172590, 2016.
162. Liu, Y. and **Huang, L.** Lipid-coated Cisplatin Nanoparticles for Insoluble Drug Loading. In “Liposome-Based Drug Delivery Systems”, Chapter 7, ed. Wan-Liang Lu and Xian-Rong Qi, Springer Nature, 2017.
163. Song, W., Musetti, S.N. and **Huang, L.** Nanomaterials for Cancer Immunotherapy, *Biomaterials*, 148:16-30, 2017. PMID: PMC5762124.
164. Zhang, Q. and **Huang, L.** Preface: Nanoformulations for combination or cascade anticancer therapy. *Advanced Drug Delivery Reviews*, 115:1-2, 2017.
165. Miao, L., Guo, S. Lin, C.M., Liu, Q. and **Huang, L.** Nanoformulations for combination or cascade anticancer therapy. *Advanced Drug Delivery Reviews*, 115:3-22, 2017. PMID: PMC5591780.

166. Asai, T., **Huang, L.** and Oku, N. Nanoparticle-mediated RNA interference for cancer therapy. *Biomedical Applications of Functionalized Nanomaterials*, 1st Edition, chapter 17, 521-540 Elsevier (2018)
167. Liu, Q., Das, M., Liu, Y. and **Huang, L.** Targeted Drug Delivery to Melanoma. *Advanced Drug Delivery Reviews*, 127:208-221, 2018. doi: 10.1016/j.addr.2017.09.016. [Epub ahead of print].
168. Hu, M. and **Huang, L.** Nanomaterial Manipulation of Immune Microenvironment in The Diseased Liver. *Advanced Functional Materials*, 2018, 1805760. DOI: 10.1002/adfm.201805760.
169. Musetti, S. and **Huang, L.** Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy, *ACS Nano*, 12, 11740–11755, 2018.
170. Das, M., Musetti, S. and **Huang, L.** RNA interference-based cancer drugs: The roadblocks, and the ‘delivery’ of the promise. *Nucleic Acid Therapeutics*, 29(2):61-66, 2019. ePub 18 Dec 2018, <https://doi.org/10.1089/nat.2018.0762>
171. Das, M. and **Huang, L.** Liposomal nanostructures for drug delivery in gastrointestinal cancers. *Journal of Pharmacology and Experimental Therapeutics*, 370(3):647-656. 2019, ePublished on December 12, 2018 as DOI: 10.1124/jpet.118.254797. PMID: PMC30541917.
172. Liu, M., Song, W. and **Huang, L.** Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy. *Cancer Letters*, 448:31-39, 2019. doi: 10.1016/j.canlet.2019.01.032. [Epub ahead of print]
173. Qi, C., Musetti, S., Fu, L.-H. Zhu, Y.-J. and **Huang, L.** Biomolecules-Assisted Green Synthesis of Nanostructured Calcium Phosphates and Their Biomedical Applications. *Chemical Society Reviews*, 48(10):2698-2737, 2019. doi: 10.1039/c8cs00489g.
174. Song, W., Anselmo, A.C. and **Huang, L.** Nanotechnology Intervention of Microbiome for Cancer Therapy, *Nature Nanotechnology*, 14(12):1093-1103, 2019. doi: 10.1038/s41565-019-0589-5.
175. Zhang, Y. and **Huang, L.** Liposomal Delivery System, in "Nanoparticles for Biomedical Applications", Ed. Eun Ji Chung, Lorraine Leon, Carlos Rinaldi. Chapter 10, p. 145-152, Elsevier, 2020. doi.org/10.1016/B978-0-12-816662-8.00010-2.
176. Liu, Y., Guo, J. and **Huang, L.** Modulation of Tumor Microenvironment for Immunotherapy: Focus on Nanomaterial-Based Strategies. *Theranostics*, 10:3099-3117, 2020. doi: 10.7150/thno.42998
177. Chen, R., **Huang, L.** and Hu, K. Natural products remodel cancer-associated fibroblasts in desmoplastic tumors. *Acta Pharmaceutica Sinica B*, 10:, 2020. doi.org/10.1016/j.apsb.2020.04.005.
178. Guo, J. and **Huang, L.** Membrane-Core Nanoparticles for Cancer Nanomedicine. *Advanced Drug Delivery Reviews*, 156:23-39, 2020. doi: 10.1016/j.addr.2020.05.005.
179. Zhang, J., Li, X., and **Huang, L.** Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment. *Advanced Drug Delivery Reviews*, 154-155: 245-273, 2020. doi: 10.1016/j.addr.2020.05.006.

180. Yang, Y., Guo, J. and **Huang, L.** Tackling TAMs for Cancer Immunotherapy: It's Nano Time! Trends in Pharmacological Sciences, 41(10):701-714, 2020. doi: 10.1016/j.tips.2020.08.003. PMID: PMC7652091.
181. Zhou, X., Liu, X. and **Huang, L.** Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Advanced Functional Materials, 2020, 2006220. doi.org/10.1002/adfm.202006220.
182. Huang, D., Sun, L., **Huang, L.** and Chen Y. Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. Journal of Personalized Medicine, 11:124, 2021. <https://doi.org/10.3390/jpm11020124>.
183. Miao, L., Zhang, Y. and **Huang, L.** mRNA Vaccine for Cancer Immunotherapy. Molecular Cancer, 20:41, 2021. <https://doi.org/10.1186/s12943-021-01335-5>.
184. Xu, H., Wu, T. and **Huang, L.** Therapeutic and Delivery Strategies of Phytoconstituents for Renal Fibrosis. Advanced Drug Delivery Reviews, 177:113911, 2021. <https://doi.org/10.1016/j.addr.2021.113911>
185. Hu, M. and **Huang, L.** Strategies Targeting Tumor Immune and Stromal Microenvironment and Their Clinical Relevance. Advanced Drug Delivery Reviews, 183:114137, 2022. doi: 10.1016/j.addr.2022.114137.
186. Guo, J. and **Huang, L.** Nanodelivery of cGAS-STING Activators for Tumor Immunotherapy. Trends in Pharmacological Sciences, September 08, 2022. <https://doi.org/10.1016/j.tips.2022.08.006>.
187. Han, S., Chen, X., and **Huang, L.** The tumor therapeutic potential of long non-coding RNA delivery and targeting. Acta Pharmaceutica Sinica B, in press, 2022. <https://doi.org/10.1016/j.apsb.2022.12.005>, Available online 13 December 2022
188. Zhang, J., **Huang, L.**, Ge, G., and Hu, K. Emerging Epigenetic-based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment. Advanced Science, 2023, 2206169. DOI: 10.1002/advs.202206169.
189. Guo, J., Zou, Y. and **Huang, L.** Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy. Small Methods, <https://doi.org/10.1002/smt.202201307>, 2023.

Editorials:

1. **Huang, L.** Journal of Liposome Research: A Journal Born Again. J. Liposome Res. 2(2), iii, 1992.
2. **Huang, L.** Forum on "Liposomes in controlled release". J. Liposome Res. 4:327-330, 1994.
3. Felgner, P.L., Barenholz, Y., Behr, J.P., Cheng, S.H., Cullis, P., **Huang, L.**, Jessee, J.A., Seymour, L., Szoka, F., Thierry, A.R., Wagner, E. and Wu, G. Nomenclature for synthetic gene delivery system. Human Gene Therapy, 8:511-512, 1997.
4. Li, S., and **Huang, L.** Liposomal gene delivery: a complex package. News and Views, Nature Biotechnology, 15:620-621, 1997.

5. **Huang, L.** and Li, S. Introduction to Forum on “Intravenous delivery of genes”, J. Liposome Res.,7 (2-3) vii-xii, 1997.
6. **Huang, L.** Introduction to Forum on “Liposomal Oligonucleotides” J. Liposome Res., 7 (1):vii-xi, 1997.
7. **Huang, L.** “To target or not to target: That is the question” Introduction to Forum on “Liposome Targeting in Animal Models.” J. Liposome Research. 7 (4) ix-xii, 1997.
8. **Huang, L.** “Journal of Liposome Research (1991-1997).” Editorial. J. Liposome Res. 7(4) vii-viii, 1997.

Patents:

1. **Huang, L.** and Ho, R.J.-Y. Immunoliposome Assay - Methods and Products. Continuation In Part. Application filed 1986, Serial No. 816,817.
2. **Huang, L.** Homogeneous Liposome-Based Signal Amplification Method for Assays Involving Enzymes. Application filed 1987, Serial No. 072,463.
3. **Huang, L.** Solid Core Liposomes, 1987. Patent No. 4,833,166, issued May 23, 1989.
4. **Huang, L.** and Ho, R.J.-Y. Immunoliposome Assay - Methods and Products. Patent No. 4,708,933, issued Nov. 24,1987 and Canadian Patent No. 1,264,662, 1984. Patent issued January 23, 1990.
5. **Huang, L.** Target-Specific Cytotoxic Liposomes, 1987. Patent No. 4,925,661, issued May 15, 1990.
6. **Huang, L.** Target-Sensitive Immunoliposomes - Preparation and Characterization, 1987. Patent No. 4,957,735, issued September 18, 1990.
7. **Huang, L.** and Liu, D. Blood-Stable, Cholesterol-Free Liposomes. Application filed 1989, Serial No. 07/298,452. U.S. Patent No. 5,043,164, issued August 27, 1991.
8. **Huang, L.** and Connor, J. Fused Liposome and Acid Induced Method for Liposome Fusion. Patent No. 4,789,633, 1984. Patent issued December 6, 1988. Continuation In Part U.S. Patent No. 5,283,122, issued February 1, 1994.
9. Epand, R., Bottega, R. and **Huang, L.** Method for Delivery Nucleic Acids Into Cells. Application filed 1991, Serial No. 07/751/873. U.S. Patent No. 5,283,185, issued February 1, 1994.
10. Sorgi, F., and **Huang, L.** A dry powder formulation for gene therapy. Application filed March, 1995.
11. **Huang, L.**, Robbins, P., Jaffurs, D., Brisson, M., Li, S. and Yang, J.P. A cytoplasmic gene expression system, which utilizes a prokaryotic RNA polymerase autogene. Application filed April, 1996.
12. **Huang, L.** and Hara, T. Emulsion formulations and their use as vehicles for the delivery of hydrophilic biologically active molecules to cells. Application filed July, 1996.

13. Zern, M., **Huang, L.** and Yao, T. Treatment of Disease States Induced by Oxidative Stress. Application filed 1993, Serial No. 08/000,275. U.S. Patent No. 5,637,315, issued June 10, 1997.
14. **Huang, L.**, and Gao, X. Stable lipid-comprising drug delivery complexes and methods for their production. U.S. Patent No. 5,795,587, issued August 18, 1998
15. Lee, R., and **Huang, L.** Novel lipidic vector for nucleic acid delivery. US Patent No. 5,908,777, issued June 1, 1999.
16. **Huang, L.** and Hara, T. Emulsion formulations for hydrophilic active agents. US patent number 6,890,557. Patent issued May 10, 2005.
17. Liu, F. and **Huang, L.** Method for transforming diaphragm muscle cells. US patent serial number 09/696,691. Application filed October 25, 2000.
18. Liu, D., Liu, F., Yang, J.P. and **Huang, L.** Emulsions and micellar formulations for DNA mediated gene transfer. US Patent No. 6,120,794, issued September 19, 2000.
19. **Huang, L.** and Deshmukh, H. Cationic cholesteryl derivatives containing cyclic polar groups. US patent No. 6,258,792 issued July 10, 2001.
20. **Huang, L.** and Epanand, R. Stable aqueous dispersions including cationic lipids. US patent serial number 6,361,791 issued March 26, 2002.
21. Banerjee, R., Li, S., Li, S., **Huang, L.** Targeting Anti-Cancer Drugs via Sigma Receptor. Application filed February 27, 2002.
22. **Huang, L.**, Epanand, R.M., and Bottega, R. Cationic Amphiphiles of Cholesterol. US patent serial number 6,509,032. Issued January 21, 2003.
23. **Huang, L.**, Cationic cholesteryl derivatives containing cyclic polar groups. US patent serial number 6,583,131. Issued June 24, 2003.
24. **Huang, L.**, Emulsion and micellar formulations for the delivery of biologically active substances to cells. US patent serial number 6,586,003. Issued July 1, 2003.
25. **Huang, L.**, Emulsion formulations for hydrophilic active agents. US patent serial number 6,610,321. Issued August 26, 2003.
26. **Huang, L.**, Cationic cholesteryl derivatives containing cyclic polar groups. US patent serial number 6,927,213. Issued August 9, 2005.
27. **Huang, L.**, Application of lipid vehicles and use for drug delivery. US patent serial number 7,063,860. Issued June 20, 2006.
28. **Huang, L.**, Chen, W. Antigen delivery compositions and methods of use. US patent serial number 7,303,881. Issued December 4, 2007.

29. **Huang, L.** Chen, Y., Sen, J., Bathula, S.R. Methods and compositions comprising novel cationic lipids. (UNC Case # 08-0038) PCT patent application filed May 19, 2008.
- US Patent Application 61/054,328
PCT/US2009/042476
 - Exclusive licensed to Steel Heritage Bioscience on April 6, 2022
30. **Huang, L.** Chono, S., Li, S.D., Hackett, M., Kim, S.K. and Tseng, Y.C. Methods and compositions for the delivery of bioactive compounds. PCT/US2009/042485 filed 5/19/2008.
31. **Huang, L.** and Li, J. Biodegradable Delivery System complexes for the delivery of bioactive compounds. (UNC case 09-0134)
- 61/230,783 filed 8/3/2009 Huang, Li
 - 61/258,028 filed 11/4/2009 Huang, Li
 - PCT/US2010/044209 8/3/2010 Huang, Li
 - US patent (US 9,937,128 B2) issued. Date of Patent: Apr. 10, 2018, Huang, Li
 - US patent (US 10,624,852 B2) issued on April 21, 2020
 - Exclusive licensed to Steel Heritage Bioscience, April 6, 2022
32. Chancellor, M., Tyagi, P., Fraser, M. O., Chuang, Y. C., Hsein, K., de Groat, W. C., **Huang, L.** and Yoshimura, N. “Sphingomyelin liposomes for the treatment of hyperactive bladder disorders”, US patent serial number 8,110,217 B2. Issued February 7, 2012.
33. **Huang, L.**, Guo, S.T. and Ramishetti, S. “Lipid Coated Nanoparticles Containing Agents Having Low Aqueous and Lipid Solubilities and Methods Thereof”. (UNC case 13-0023):
- 61/706,454 filed 9/27/2012 in US, Huang, Guo and Ramishetti
 - PCT/US2013/061985 filed 9/26/2013 international, Huang, Guo and Ramishetti
34. **Huang, L.**, Guo, S.T. and Miao, L. “Polymer Nanoparticles Containing Multiple Agents and Methods Thereof” (UNC case 14-0033):
- US Provisional patent application (61/894,171) filed October 22, 2013. Huang, Guo and Miao
 - PCT/US2015/031052 filed 4/21/2016, Huang, Guo and Miao.
35. **Huang, L.**, Zhao, Y., Guo, S.T. and Shi, K. “Polymeric Metformin and Its Use As a Therapeutic Agent and As a Delivery Vehicle” (UNC case 15-0060)
- US Provisional patent application (62/129,276) filed March 6, 2015. Huang, Zhao, Guo and Shi
 - PCT patent application (#PCT/US2016/020921) filed September 15, 2016. Huang, Zhao, Guo and Shi
36. **Huang, L.**, Goodwin, T.J. and Liu, R. “Methods and Compositions for Reducing Metastases” (UNC case 16-0041)
- US Provisional patent application (62/232,169) filed September 24, 2015. Huang, Goodwin and Liu
 - PCT patent application (# PCT/US2016/051966) filed September 15, 2016. Huang, Goodwin, Miao and Liu
 - US patent (15/763,065) filed March 23, 2018. Notice of Allowance, May 20, 2021
37. **Huang, L.**, Huo, M. “Combination Therapy for Melanoma” (UNC case 16-0056)
- US Provisional patent application (62/259,860) filed: November 25, 2015. Huang and Huo
 - Abandoned.

38. **Huang, L.** and Liu, Q. “BRAF peptide vaccine” (UNC case 17-0102)

- US Provisional patent application (62/558,515)
 - Abandoned.
39. **Huang, Leaf**, Yi-Chih Hsu, Gang Zheng, Chia-Hsien Yeh “Nucleic Acid, Medical Nanoparticle Group and Medicine Combination”
- Patent issued, I607766, December 11, 2017, Republic of China (Taiwan)
40. **Huang, Leaf**; Shen, Limei; Li, Jingjing; Liu, Rihe “CXCL13 Traps and Their Uses to Modulate Tumor Microenvironments” (UNC case 18-0095)
- US Provisional patent application (62/650,734) filed: March 30, 2018.
41. **Huang, Leaf**; Liu, Qi; Chen, Fengqian “Nanocarrier-mediated Chemo-immuno Therapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma” (UNC case 18-0125)
- US Provisional patent application (62/660,446) filed April 20, 2018.
42. **Huang, Leaf** and Hu, Mengying “Targeting Hepatic Stellate Cells to Treat Liver Fibrosis and Metastasis” (UNC2-37191/US-1/PRO)
- US Provisional Patent application (62/757,407) “Methods for treating or slowing the progression of liver fibrosis and liver metastasis”, filed Nov 08, 2018.
 - Application abandoned Nov 08, 2019.
43. **Huang, Leaf** and Xu, Huan “Nano-Puerarin Regulates Tumor Microenvironment and Facilitates Chemo- and Immunotherapy in Murine Triple Negative Breast Cancer Model”
- US provisional patent application (62/837,538) filed on April 23, 2019.
 - PCT/US2020/029453 was filed on April 23, 2020.
44. **Huang, Leaf**, Zhang, Jing and Shen, Limei “Nano co-delivery of quercetin and alantolactone promotes anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer”, (UNC 19-0065)
- US provisional patent application (62/837,536) filed on April 23, 2019.
 - PCT/US2020/029448 was filed on April 23, 2020.
45. **Huang, Leaf** and Chen, Yanzuo, “Methods to dilate tumor vessels”, (UNC 19-0076)
- US Provisional Application (62/790,581) filed Jan 10, 2019.
46. **Huang, Leaf** and Guo, Jianfeng, “Nano FOLFOX for cancer therapy”, (UNC 20-0002)
- Report of Invention filed June 29, 2019.
 - PCT/US2020/055424 filed on October 13, 2020
 - Licensed to Steel Heritage Bioscience on April 6, 2022
47. **Huang, Leaf** and Yu, Zhuo, “Hepatocellular Carcinoma Therapy Based on Immunogenic Cell Death”. (UNC 20-0003)
- Report of Invention filed July 1, 2019.
48. **Huang, Leaf** and Li, Jun, “Nanoparticle Delivery of Nucleoside Phosphate Against COVID-19 Infection”. (UNC 20-0121)
- Report of Invention filed March 18, 2020.

49. **Huang, Leaf** and Wang, Menglin, “Liposomal Antibiotics Induces Anticancer Immunity by Killing the Tumor Associated Bacteria” (UNC 21-0148)
- Report of Invention filed June 28, 2021.
 - “Compositions and Methods for Inducing Anticancer Immunity”, US Provisional Application filed Jun 13, 2022.
 - Under license negotiation with Stemirna Therapeutics since October 2022.
50. **Huang, Leaf** and Yu, Zhuo, “Method to reopen the closed liver fenestrae for drug delivery” (UNC 22-0052)
- Report of Invention filed November 11, 2021.
 - US Provisional patent “METHODS OF USING 3-HYDROXY-3-METHYLGLUTARYL COA REDUCTASE INHIBITORS TO TREAT DISORDERS, DISEASES AND/OR CONDITIONS OF THE LIVER” Filed on December 21, 2021. Application number 63292062.
 - Abandoned Dec 21, 2022.
51. **Huang, L.** and Cheng, Yung-Yi, “A new approach for treating liver fibrosis” (UNC 22-0085)
- Report of Invention filed Feb 11, 2022.

Abstracts

Dr. Huang also authored or co-authored more than 274 meeting abstracts since 1973.

GRANT FUNDING

Current Funding for Huang Lab:

<u>Total Direct Cost/y</u>	<u>Years Inclusive</u>	<u>Grant Number and Title</u>	<u>Source</u>
\$50,000	Ongoing	Fred Eshelman Distinguished Professorship	Eshelman School of Pharmacy

GRANT PROPOSALS PENDING

<u>Total Direct Cost</u>	<u>Title</u>	<u>Source</u>
--------------------------	--------------	---------------